Mitochondrial DNA gene expression and consequences of its loss in mammals by Miranda Vergara, Maria del Pilar
  
Mitochondrial DNA gene expression  
 and consequences of its loss in mammals  
 
 
 
 
 
Inaugural-Dissertation 
zur 
Erlangung des Doktorgrades 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Universität zu Köln  
 
 
vorgelegt von 
MARIA DEL PILAR MIRANDA VERGARA 
aus Bogotá, Kolumbien 
 
 
 
Köln, Deutschland  
2018 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Berichterstatter: 
Prof. Dr. Nils-Göran Larsson 
Prof. Dr. Aleksandra Trifunovic 
 
 
Tag der mündlichen Prüfung: 04.09.2018 
  
   
  
 
 
 
 
 
 
 
 
 
 
“The only way to find out what will happen when a complex system is disturbed is to disturb 
the system, not merely to observe it passively" 
 – paraphrasing George Box (Mosteller & Tukey 1977) 
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ZUSAMMENFASSUNG 
 
Mitochondrien sind intrazelluläre Organellen, die verschiedene essenzielle Funktionen haben 
wie die Produktion des Hauptanteils zellulärer Energie in Form von Adenosintriphosphat (ATP) 
durch die oxidative Phosphorylierung (OXPHOS). Mitochondriale Fehlfunktionen treten bei 
schweren metabolischen Erberkrankungen mit breitem klinischen Spektrum auf, sowie in 
verschiedenen altersbedingten Erkrankungen, und wurden außerdem mit dem Altersprozess 
assoziiert. Die mitochondriale Biogenese hängt von der Exprimierung zweier zellulärer 
Genome ab. Während das mitochondriale Genom (mtDNA) für ein paar wenige essentielle 
Untereinheiten des OXPHOS Systems, sowie für Transfer- und Ribosomalen-RNAs die zur 
Translation dieser Untereinheiten in den Mitochondrien notwendig sind, kodiert, ist der Großteil 
der mitochondrialen Proteine nuklear kodiert (nDNA). Die Mechanismen, die die Expression 
der mtDNA regulieren, sind größtenteils unbekannt, und wie Störungen dieser Prozesse zu 
einem pathogenen Erscheinungsbild führen, ist nur unzureichend verstanden.  
 
Das erste Ziel dieser Doktorarbeit war es zu untersuchen welche in vivo Rolle die 
mitochondriale RNA Polymerase (POLRMT) in der Regulation der Exprimierung der mtDNA 
spielt. Um die Funktion von POLRMT und Spleißvarianten des Polrmt Gens in Säugern zu 
analysieren, haben wir transgene Mausmodelle mit verschiedenen Gendosierungen von 
Polrmt hergestellt und charakterisiert. Zu diesen Polrmt Modellen zählten ein homozygoter 
Ganzkörperknockout sowie ein gewebespezifischer Knockout in Herz- und Skelettmuskel, ein 
heterozygoter Knockout, und einen überexprimierenden Mausstamm. Unsere Studien 
ergeben, dass Polrmt nur für ein mitochondriales Protein, POLRMT, kodiert, und dass keine 
andere RNA Polymerase seine Funktion ersetzen kann. Wir zeigen dass POLRMT zwei 
essenzielle Rollen in Säuger-Mitochondrien hat, i) sie ist die einzige RNA Polymerase die die 
mtDNA transkribiert, und ii) sie synthetisiert die für die Replikation der mtDNA essentiellen 
RNA Primer. Desweiteren deuten unsere Daten darauf hin, dass POLRMT Teil eines 
Prozesses ist, der durch einen promoterspezifischen Transkriptionsstart den Wechsel 
zwischen mtDNA Replikation und Transkription koordiniert. Abschließend zeigen wir, dass 
POLRMT der limitierende Faktor für den Transkriptionsstart ist, und dass POLRMT regelmäßig 
zum Transkriptionsstart an die Promotoren bindet, wohingegen die Synthese von fast 
genomlanger mitochondrialer RNA (mt-RNA) auf der Ebene der Elongation reguliert ist. 
  
Das zweite Ziel dieser Dissertation war es die zellulären Konsequenzen defekter Gen-
Expression der mtDNA und fortschreitender OXPHOS Fehlfunktion zu erforschen. In einer 
systematischen Studie haben wir das mitochondriale Proteom (Mitoproteom) und das 
komplette zelluläre Transkriptom vom Herz von fünf Knockout Mausstämmen von denen jeder 
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defekt für einen essenziellen Faktor für die Regulation der mtDNA Gen-Expression ist, 
miteinander verglichen. Desweiteren haben wir Veränderungen des Mitoproteoms während 
der postnatalen Entwicklung des Mausherzens untersucht und Unterschiede im Mitoproteom 
in einem Mausstamm mit fortschreitender OXPHOS Fehlfunktion verfolgt. 
Überraschenderweise haben wir entdeckt, dass eine Minderung des intra-mitochondrialen 
Coenzym Q (Q) Biosynthesestoffwechsels mit fortschreitender OXPHOS Fehlfunktion einher 
geht.  Weiter haben wir gefunden, dass die zelluläre Stressreaktion sehr früh während der 
fortschreitender OXPHOS Fehlfunktion aktiviert wird, wahrscheinlich durch die 
Transkriptionsfaktoren myc Protoonkogen Protein (MYC) und zyklischer AMP-abhängiger 
Transkriptionsfaktor ATF4 (ATF4). Diese zelluläre Antwort umfasst eine Erhöhung der Enzyme 
des mitochondrialen Kohlenstoffkreislaufes (1C), der Prolinsynthese und der mitochondrialen 
Proteasen und Chaperone.  
 
Schlussfolgernd lässt sich sagen, dass die hier präsentierte Arbeit fundamentale 
Mechanismen der Regulation der mtDNA Gen-Exprimierung in vivo identifiziert hat, und 
primäre und sekundäre Konsequenzen defekter Expression der mtDNA genau festlegt. Diese 
Arbeit ist nicht nur von außerordentlich wichtiger Bedeutung für unser Verständnis der 
Funktion dieses essentiellen Organells, sondern hat außerdem neue Mechanismen, die in 
mitochondrialen Krankheitsbildern eine Rolle spielen, identifiziert, was für die Diagnose von 
Patienten und zukünftigen Behandlungsstrategien bedeutend ist. 
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ABSTRACT 
 
Mitochondria are intracellular organelles that fulfil multiple essential functions, including the 
generation of the vast majority of the cellular energy currency adenosine triphosphate (ATP) 
via the oxidative phosphorylation (OXPHOS) system. Mitochondrial dysfunction is found in 
severe inherited metabolic disorders with a broad clinical spectrum, in several common age-
related diseases, and has been associated with the ageing process itself. Mitochondrial 
biogenesis depends on the expression of two cellular genomes. While the mitochondrial 
genome (mtDNA) encodes a few essential subunits of the OXPHOS system and the transfer 
and ribosomal RNAs required to translate these subunits in mitochondria, most mitochondrial 
proteins are encoded in the nuclear genome (nDNA). The mechanisms regulating the 
expression of mtDNA are still largely unknown and how disrupting this process leads to 
pathogenic phenotypes is poorly understood.  
 
The first aim of this thesis was to elucidate the in vivo function of the mitochondrial RNA 
polymerase (POLRMT) in the regulation mtDNA gene expression. We generated and 
characterized transgenic mouse models with varying gene dosage of Polrmt to investigate the 
role of POLRMT and the splice variants of the Polrmt gene in mammals. These Polrmt models 
included a whole-body knockout, a heart and skeletal muscle knockout, a heterozygous 
knockout, and an overexpressing mouse strain. Our findings reveal that Polrmt only codes for 
a mitochondrial isoform, POLRMT, and that no other RNA polymerase can replace its function. 
We show that POLRMT has two essential roles in mammalian mitochondria, i) it is the only 
RNA polymerase transcribing mtDNA, and ii) it synthesizes the RNA primers required for 
mtDNA replication. Moreover, our data suggests that POLRMT is part of a mechanism 
involving promoter-specific transcription initiation that coordinates the switch between mtDNA 
replication and transcription. Finally, we show that POLRMT is the limiting factor for 
transcription initiation and that it is frequently loading at the promoters to initiate transcription, 
whereas productive near-genome length mitochondrial RNA (mt-RNA) synthesis is regulated 
at the elongation level.  
 
The second aim of this thesis was to investigate the cellular consequences of disrupting 
mtDNA gene expression and the progression of OXPHOS deficiency. We performed a 
systematic comparison of the mitoproteome and total cellular transcriptome from heart of five 
knockout mouse models, each deficient in an essential factor acting at a specific level of gene 
expression regulation. We also studied the mitoproteome changes during normal post-natal 
development in mouse heart and followed proteome changes in a model with progressive 
OXPHOS deficiency in the heart. Surprisingly, we found a decline in the intra-mitochondrial Q 
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biosynthesis pathway that correlates with the progressive OXPHOS deficiency. Furthermore, 
we found that cellular stress responses, likely mediated by the myc proto-oncogene protein 
(MYC) and the cyclic AMP-dependent transcription factor ATF4 (ATF4) transcription factors, 
are activated very early in the progression of OXPHOS deficiency. These cellular responses 
include the upregulation of enzymes of the mitochondrial one-carbon (1C) pathway, proline 
synthesis, and mitochondrial proteases and chaperones.  
 
In conclusion, the work presented in this thesis has identified fundamental mechanisms 
of regulation of mtDNA gene expression in vivo and pinpointed primary and secondary 
consequences of impaired expression of mtDNA. This work has not only important implications 
for our understanding of the function of this essential organelle but it has also identified novel 
mechanisms involved in mitochondrial pathology that can be relevant for patient diagnosis and 
future treatment strategies.  
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1. INTRODUCTION 
 
1.1. Mitochondrial origin  
 
According to the endosymbiotic theory, mitochondria are derived from a proteobacterium that 
was engulfed by an archaeon more than 1.45 billion years ago (Martin & Mentel 2010). This 
fusion event created the eukaryotic cell. The genome of the engulfed proteobacterium was 
drastically reduced and the proteobacterium became an integrated organelle – the 
mitochondrion – that provided the energetic capacity to evolve and express the complex 
genomes giving rise to the different eukaryotic groups (Lane & Martin 2010). Thus, all 
eukaryotic organisms studied to date contain an organelle of mitochondrial origin or have 
secondarily lost this organelle during evolution (Karnkowska et al. 2016). Although it is widely 
accepted that the precursor of mitochondria had the capacity to convert energy from different 
sources into ATP (Zimorski et al. 2014), the precise characteristics of mitochondria in the last 
eukaryotic common ancestor are still a matter of debate. However, several events for the 
establishment of an integrated organelle must have already occurred: (1) a substantial 
reduction of the bacterial genome either by gene transfer to the nucleus or loss of redundant 
and unnecessary genes, (2) the establishment of substrate transport and protein import 
systems that allowed the biogenesis of the organelle and integration of metabolic reactions 
with the host organism, and (3) the development of mechanisms for mitochondrial segregation 
during cell division (Roger et al. 2017). Mitochondria often have diversified functions in different 
eukaryotic cell types and organisms. Mitochondria and related organelles derived from the 
mitochondrial ancestor have been classified into five types based on their energy metabolism: 
aerobic mitochondria, anaerobic mitochondria, hydrogen producing mitochondria, mitosomes, 
and hydrogenosomes (Müller et al. 2012). Despite the drastic differences in terms of function 
and composition between these different mitochondrion-related organelles, they all conserve 
mitochondrial marker proteins like the ones required for iron sulphur (FeS) cluster biosynthesis 
(Tovar et al. 2003) and some components of the protein import machinery that can be traced 
back to their ancestral origin (Zimorski et al. 2014). As a remnant from their endosymbiotic 
origin, mitochondria are surrounded by a double membrane and, remarkably, all aerobic 
mitochondria have retained a small mtDNA (Stewart & Larsson 2014).  
 
1.2. Mitochondrial functions in mammals 
 
Mitochondria fulfil several functions that are essential for the eukaryotic cell. Mammals contain 
aerobic mitochondria that harvest electrons from carbon sources and uses the released energy 
to pump protons necessary for driving ATP synthesis via the OXPHOS system (Nelson & Cox 
2009). The mammalian OXPHOS system comprises five multiprotein complexes (I-V) localized 
in the inner mitochondrial membrane (IMM) (Figure 1.1). Complexes I (reduced nicotinamide 
adenine dinucleotide (NADH):ubiquinone oxidoreductase), III (ubiquinol-cytochrome c 
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oxidoreductase), and IV (cytochrome c oxidase) catalyse electron transfer from NADH to 
oxygen and translocate protons to the intermembrane space. The difference in proton 
concentration between the mitochondrial matrix (MM) and the intermembrane space (IMS) 
provides the proton-motive force that is harvested by complex V (F1F0-ATP synthase) to 
convert adenosine diphosphate (ADP) into ATP. Electrons from complex I are transferred to 
complex III by ubiquinone (coenzyme Q; Q) and from complex III to IV by cytochrome c 
(Milenkovic et al. 2017). NADH is regenerated during oxidoreduction (redox) reactions and one 
of the main sources is the tricarboxylic acid (TCA) cycle where reduction of NAD+ is coupled 
to the oxidation of carbon sources to carbon dioxide (Nelson & Cox 2009). The enzymes of the 
TCA cycle are localized in the MM except for the succinate dehydrogenase or OXPHOS 
complex II that is partly embedded in the IMM and transfers electrons from reduced flavin 
adenine dinucleotide (FADH2) to the electron carrier Q (Mourier & Larsson 2011). 
 
Figure 1.1 | Mitochondrial 
compartments and OXPHOS 
system 
A) Scheme of mitochondrial 
compartments, OXPHOS 
complexes, and mtDNA. (B) Scheme 
of the OXPHOS system. Dotted line 
represents the electron flow. Yellow 
represents nDNA-encoded OXPHOS 
subunits and blue represents 
mtDNA-encoded subunits. 
Abbreviations not described in the 
figure in alphabetic order: ADP, 
adenosine diphosphate; ATP, 
adenosine triphosphate; CI - V, 
OXPHOS complexes I-V; CytC, 
Cytochrome C; FADH2 and FAD, 
reduced and oxidized flavine adenine 
dinucleotide; H+, hydrogen protons; 
H2O, water; NADH and NAD+, 
reduced and oxidized nicotinamide 
adenine dinucleotide; O2, oxygen; 
OXPHOS, oxidative phosphorylation; 
Q, coenzyme Q. Modified from 
Mourier et al. 2011.  
 
 
 
 
 
 
 
 
Carbohydrates, lipids, and amino acids are the three carbon sources mammalian cells 
can use and their metabolism converges in the TCA cycle. Carbohydrates are metabolized via 
glycolysis to pyruvate that is imported into mitochondria and converted to acetyl-coenzyme A 
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(CoA). Fatty acids are activated in the cytosol to acyl-CoA esters, imported into mitochondria, 
and oxidized through several cycles of b-oxidation (FAO) which result in the generation of 
acetyl-CoA, NADH, and FADH2 (Houten et al. 2016). Several reactions required for amino acid 
degradation occur in mitochondria and their intermediate products can enter the TCA cycle as 
acetyl-CoA, a-ketoglutarate, or succinate (Guda et al. 2007). The use of the different carbon 
sources in mammals depend on the tissue and metabolic state. For example, brain and nerve 
tissue rely mainly on glucose or ketone body oxidation; heart, skeletal muscle, and kidney 
mainly use FAO; and enterocytes use energy derived from glutamine oxidation (Vusse & 
Reneman 1995). Importantly, many of the metabolites, redox cofactors, and ATP generated in 
these pathways are used to synthesise new macromolecules including non-essential amino 
acids, carbohydrates, lipids, secondary metabolites, and nucleic acids. Thus, the central 
carbon metabolism ensures the conversion of energy sources into ATP, redox power, and 
precursor metabolites required for biosynthesis (Nielsen 2017). 
 
Biosynthesis of Q, FeS clusters, and heme groups partially take place in mitochondria 
and these compounds are necessary to support OXPHOS. Q is synthesised in the IMM by 
attaching a tail formed of several isoprenoid units derived from the cytosolic mevalonate 
pathway to a 4-hydroxybenzoate head, which is subsequently modified by carboxylation, 
hydroxylation, and methylation reactions (Stefely & Pagliarini 2017). In addition to its role in 
electron transfer, Q is suggested to be a ubiquitous lipid antioxidant present in all cellular 
membranes (Wang & Hekimi 2016). FeS clusters are co-factors for several enzymes in the 
cell, including mitochondrial enzymes of the OXPHOS complexes I-III, TCA cycle and FAO,  
as well as nuclear enzymes required for DNA replication and repair (Stehling & Lill 2013). 
Heme groups are also iron-containing essential co-factors. Haemoglobin and myoglobin, for 
example, use heme-groups to transport oxygen, and cytochrome c is an electron shuttle in 
OXPHOS (Kranz et al. 2009; Levi & Rovida 2009). Importantly, cytochrome c release to the 
cytosol is a determining step for the activation of the intrinsic pathway of apoptosis (Galluzzi 
et al. 2016).  
 
 The aforementioned introduction to mitochondrial functions is far from being complete 
but illustrates the high degree of connectivity and coordination between metabolic reactions 
and the central role of mitochondria in these processes. Thus, proper mitochondrial biogenesis 
and function is fundamental to sustain mammalian life. 
 
1.3. Dual genetic control of mitochondrial biogenesis 
 
It is estimated that mammalian mitochondria contain 1000 to 1500 proteins (Pagliarini et al. 
2008) from which half of the proteins are core mitochondrial components present in all 
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mammalian cells whereas the other half are expressed in a tissue-specific manner (Calvo & 
Mootha 2010).The endeavour of defining the mitoproteome has advanced steadily in recent 
years but a significant proportion of proteins is still of unknown function in mitochondria 
(Pagliarini & Rutter 2013). 
 
Mammalian mtDNA encodes only thirteen essential proteins of the OXPHOS 
complexes I, III, IV, and V. All of the remaining mitochondrial proteins are encoded in the 
nucleus, translated in the cytosol, and imported into mitochondria (Figure 1.2) (Gustafsson et 
al. 2016). It is estimated that one quarter of the mitoproteome is dedicated to maintain and 
express mtDNA (Gonczarowska-Jorge et al. 2017). Furthermore, in mouse, whole-body 
knockout of different nDNA-encoded proteins involved in mtDNA gene expression lead to 
embryonic lethality, whereas conditional knockout in heart and skeletal muscle lead to 
cardiomyopathies and premature death caused by severe mitochondrial dysfunction (Cámara 
et al. 2011; Larsson et al. 1998; Metodiev et al. 2009; Milenkovic et al. 2013; Ruzzenente et 
al. 2012; Park et al. 2007). These findings highlight the importance of a concerted expression 
of both genomes for the mammalian organism.  
 
 
Figure 1.2 | Dual genetic origin of the OXPHOS system 
OXPHOS complexes are encoded in two cellular genomes, nDNA and mtDNA. mtDNA encodes 13 subunits of 
OXPHOS complexes I, III, IV and V that are translated in the mitoribosomes. All other mitochondrial proteins are 
encoded in the nucleus, translated in the cytosol and imported into mitochondria where they are assembled together 
with the mtDNA-encoded subunits. Abbreviations in alphabetic order: mtDNA, mitochondrial DNA, nDNA, nuclear 
DNA; OXPHOS, oxidative phosphorylation. Modified from Larsson 2010. 
 
In terms of energy balance, the maintenance of such an elaborate machinery to 
express only a few mtDNA-encoded proteins seems counterintuitive and, therefore, different 
hypotheses have been proposed to explain why mtDNA is still maintained. The first one argues 
that the process of genome reduction, that accompanied the integration of mitochondria as a 
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cellular organelle, is still ongoing and, eventually, mtDNA will disappear. The strongest 
evidence supporting this hypothesis is that the mitochondrial related organelles, 
hydrogenosomes and mitosomes, do not have mtDNA (Burki 2016; Palmer 1997). However, 
until now, there is a perfect correlation between maintaining mtDNA and the capacity to 
perform aerobic respiration. All aerobic mitochondria appear to have retained genes coding for 
OXPHOS components, at least mt-Co1, mt-Co3, and mt-Cytb, as well as genes required for 
mitochondrial translation (Stewart & Larsson 2014). The conservation of such a specific set of 
mitochondrial genes has been interpreted in two opposite but not mutually exclusive ways. On 
the one hand, it has been proposed that the complete transfer of these genes to the nucleus 
is limited by selection constraints. Examples of these constraints are incompatibility in gene 
expression due to differences in codon usage between nDNA and mtDNA or problems in 
targeting and importing these proteins into mitochondria due to their high hydrophobicity 
(Björkholm et al. 2015). The transfer to the nucleus of many of the genes that were once 
encoded in the genome of the proteobacterium argues that both problems can potentially be 
circumvented. On the other hand, the co-localization for redox regulation hypothesis postulates 
that maintaining genes of electron transport chains in the mitochondrial compartment allows 
rapid regulation of organelle-specific gene expression in response to redox states (Allen 2017). 
 
1.4. Nuclear regulation of mitochondrial biogenesis and stress responses 
 
1.4.1. Mitochondrial biogenesis 
 
Mitochondrial biogenesis is induced in response to developmental and physiological stimuli. 
To exemplify, cardiomyocytes are the cells with the highest volume density of mitochondria, 
which provide the energetic reserve capacity that the heart requires (Goffart et al. 2004). The 
development and maturation of the cardiac mitochondrial system occur largely during the 
perinatal stages, processes that include a major increase in mitochondrial biogenesis at birth 
(Piquereau et al. 2010). This increase corresponds to a shift in metabolism from glycolysis to 
FAO and OXPHOS as mammals adapt to changes in oxygen availability (Finck et al. 2002). 
Other external stimuli like changes in environmental temperature, exercise, caloric intake, and 
hormones have also been reported to induce mitochondrial biogenesis (Ryan & Hoogenraad 
2007). Furthermore, an increase in mitochondrial mass is a common finding in patients with 
mitochondrial diseases and transgenic mouse models with mitochondrial dysfunction 
(Kauppila et al. 2017). Thus, under pathologic or stress conditions, retrograde signalling from 
the mitochondria to the nucleus activates cellular responses to loss of mitochondrial function 
that lead to mitochondrial biogenesis. 
 
Several transcription factors acting on the nuclear genome have been implicated in the 
regulation of expression of mitochondrial proteins in mammals. The nuclear respiratory factors 
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NRF1 and GABPA (also known as NRF2) function as positive regulators of transcription of 
nDNA-encoded mitochondrial genes. Binding sites for both transcription factors have been 
identified in upstream sequences of several mitochondrial genes including genes encoding 
OXPHOS proteins (Kelly & Scarpulla 2004). In line with this, knockout of Nrf1 and Gabpa in 
mouse is embryonic lethal with a clear mitochondrial phenotype (Huo and Scarpulla 2001; 
Ristevski et al. 2004; Yang et al. 2014). Members of the nuclear receptor super family that 
include the peroxisome proliferated-activated receptors (PPARs) and the estrogen-related 
receptors (ERRs) regulate the expression of enzymes involved in mitochondrial metabolism 
(Scarpulla et al. 2012). Finally, several targets of MYC are genes encoding mitochondrial 
proteins and it has been suggested that this transcription factor coordinates mitochondrial 
biogenesis during cell cycle and pathologic stress (Ahuja et al. 2010; Morrish & Hockenbery 
2014). 
 
The peroxisome-proliferator-activated receptor coactivators (PGC1a, PGC1b, and 
PPRC1) have been found to interact with NRF1, GABPA, PPARs and ERRs and, therefore, 
have the potential to induce most aspects involved in mitochondrial biogenesis (Scarpulla et 
al. 2012). Furthermore, several signalling pathways like the mechanistic target of rapamycin 
(mTOR) and cyclic adenosine monophosphate (AMP)-activated protein kinase (AMPK) that 
are activated by changes in the cellular metabolic state (e.g. amino-acid concentrations, 
ADP/ATP or NAD+/NADH ratios) converge on PGC1a suggesting that it is a master regulator 
of mitochondrial biogenesis and function (Ryan & Hoogenraad 2007). However, Pgc1a 
knockout mice are viable and only show a mild effect suggesting that other factors, including 
PGC1b, can compensate for its absence (Kauppila et al. 2017). This finding questions the role 
of PGC1a as a universal master regulator of mitochondrial biogenesis in vivo and suggests 
that other factors are equally or more important under physiological conditions.  
 
Several of the aforementioned transcription factors have been reported to regulate 
genes required to express mtDNA and, therefore, have the potential to coordinate the 
expression of both cellular genomes to promote mitochondrial biogenesis and function. NRF1 
has predicted binding sites in the gene coding for the mitochondrial transcription factor A 
(Tfam) and several genes coding for mitochondrial ribosomal (mitoribosomal) proteins. 
Knockdown of NRF1 in human cells has been shown to decrease transcript levels of TFAM 
(Cam et al. 2004) and the embryonic lethality in a Nrf1 knockout mouse correlates with a 
depletion of mtDNA (Huo & Scarpulla 2001). GABPA was reported to bind the upstream 
sequences of the genes encoding POLRMT, the mitochondrial transcription termination factor 
1 (MTERF1), and several factors involved in mtDNA replication (Bruni et al. 2010). TFAM and 
POLRMT have also been reported to be target genes of MYC and knockdown of MYC in 
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human cancer results in decreased protein levels of both factors (Oran et al. 2016). However, 
recent studies suggest that coordination of the expression of the two cellular genomes does 
not have to occur at the transcription level. In baker’s yeast, it was shown that transcription of 
nDNA and mtDNA are not coordinated, whereas translation of the OXPHOS subunits encoded 
in both genomes is synchronized (Couvillion et al. 2016). This synchronization was shown to 
be regulated unidirectionally from the cytosolic ribosomal translation which is consistent with 
the existence of translational activators for most mitochondrial messenger RNAs (mt-mRNAs). 
In mammals such a mechanism seems less likely as mammalian mt-mRNAs have only very 
short 5’ UTRs and to date only one translational activator for mt-Co1 called TACO1 has been 
identified (Richman et al. 2016; Weraarpachai et al. 2009). A recent study on human cells 
reported that mitochondrial ribosomes (mitoribosomes) translating mt-Co1 interact with 
OXPHOS complex assembly factors which can stall mitochondrial translation when the nDNA-
encoded subunits are absent (Richter-Dennerlein et al. 2016). 
 
1.4.2. Mitochondrial stress responses 
 
Nuclear genetic programs are activated in response to mitochondrial stress. Impaired 
coordination of nuclear and mitochondrial gene expression result in the increase of 
mitochondrial proteases and chaperones. Martinus and collaborators proposed that the 
accumulation of unfolded proteins in mammalian mitochondria cause activation of a 
mitochondrial specific stress signalling pathway called the mitochondrial unfolded protein 
response (mtUPR) (Martinus et al. 1996). This signalling pathway has been extensively studied 
in Caenorhabditis elegans where the current model is that mitochondrial dysfunction reduces 
import efficiency inhibiting the normal localization of the stress activated transcription factor 
ATFS-1 to mitochondria. Instead, ATFS-1 translocates to the nucleus where it activates 
transcription of mitochondrial stress response genes (Nargund et al. 2015). The cleavage of 
unfolded proteins in mitochondria by the mitochondrial matrix protease ClpP and subsequent 
release of the resulting peptides has been suggested to be required for the activation of this 
signalling pathway (Haynes et al. 2007). In mammals, however, there is no consensus with 
regard to the importance of this stress response pathway. It has been proposed that genes 
upregulated by mtUPR in mammals contain a binding element for the DNA damage-inducible 
transcript 3 (DDIT3/CHOP) and CCAT/enhancer-binding protein b (C/EBPb) flanked by two 
conserved elements called Mitochondrial Unfolded Protein Response Elements (MURE) 1 and 
2 (Aldridge et al. 2007; Martinus et al. 1996; Zhao 2002). However, the proposed CHOP-MURE 
1/2 elements are found in several non-mitochondrial genes (Aldridge et al. 2007) arguing 
against a mitochondrial-specific response mediated only by these regulatory elements. 
Furthermore, several mouse models deficient in mtDNA gene expression show an increase in 
mitochondrial proteases and chaperones that do not contain the CHOP-MURE 1/2 elements, 
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including the AAA+ LON P protease (LONP1), AFG3-like protein 2 (AFG3L2), and the 
mitochondrial 75 kDa heat shock protein (TRAP1) (Dogan et al. 2014; Perks et al. 2018). ATF5 
was proposed to be the closest homolog of ATFS-1 and to mediate mtUPR via a similar 
differential translocation mechanism as in C. elegans (Fiorese et al. 2016). However, the 
mitochondrial localization of ATF5 in mammalian mitochondria lacks biochemical support and 
the proposed translocation to the nucleus upon mitochondrial stress has not been shown. 
Finally, the requirement of CLPP in mammals has been refuted as a double knockout mouse 
model deficient in CLPP and the mitochondrial aminoacyl-tRNA synthetase (DARS2) activates 
mtUPR responsive genes despite the absence of CLPP (Seiferling et al. 2016). 
 
In mammals, mitochondrial dysfunction results in several changes in cellular 
metabolism regulated at the transcription level. In heart of mice deficient in mtDNA gene 
expression, a switch in metabolism from FAO to glycolysis mediated by PPARa precedes the 
increase in mitochondrial biogenesis (Hansson et al. 2004). Several studies in cell culture and 
mouse have found a strong upregulation of genes that carry a conserved amino acid response 
element (AARE) in their upstream regulatory region in response to different mitochondrial 
stresses including impaired mtDNA gene expression as well as loss of membrane potential 
and OXPHOS function (Bao et al. 2016; Quirós et al. 2017; Tyynismaa et al. 2010). This AARE 
is recognized by the ATF family of transcription factors, mainly ATF4, and upregulates genes 
encoding proteins involved in the regulation of lipid and glucose metabolism, anabolic amino 
acid synthesis, and the 1C pathway (Suomalainen & Battersby 2018). The 1C pathway obtains 
the 1C units from glycine, sarcosine, and serine and transfers them through different 
tetrahydrofolate (THF) intermediates to supply 1C units for cellular processes such as 
methylation, de novo purine synthesis, and nicotinamide adenine dinucleotide phosphate 
(NADPH) synthesis (Ducker & Rabinowitz 2017). Activation of ATF4 correlates with the 
phosphorylation of the eukaryotic translation initiation factor 2a (eIF2a) in mitochondrial 
dysfunction (Khan et al. 2017; Quirós et al. 2017), suggesting that the responses to 
mitochondrial stress converge with the cellular integrated stress response (ISR). However, the 
kinase phosphorylating eIF2a in response to mitochondrial dysfunction has not been identified 
(Quirós et al. 2017). A recent study proposed that mTOR complex 1 (mTORC1) upregulates 
the 1C pathway and purine metabolism independently of eIF2a phosphorylation (Ben-Sahra 
et al. 2016) and activation of mTORC1 signalling was found in mouse models with 
mitochondrial dysfunction (Khan et al. 2017; Perks et al. 2018). Furthermore, rapamycin 
treatment in mice with mitochondrial myopathy reversed the effect of ATF4 indicating that 
mTORC1 acts upstream of ATF4 in mitochondrial dysfunction (Khan et al. 2017). Finally, one 
of the target genes of ATF4 is the fibroblast growth factor 21 (Fgf21), whose gene product is 
released into the blood stream and can activate paracrine and endocrine effects resulting in 
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metabolic remodelling in different tissues (Fisher & Maratos-Flier 2016). FGF21 has been 
shown to be released by the skeletal muscle and heart in mitochondrial dysfunction mouse 
models (Dogan et al. 2014; Tyynismaa et al. 2010) and has been proposed as a biomarker of 
mitochondrial dysfunction in human patients (Lehtonen et al. 2016). Interestingly, 
mitochondrial stress in cell culture causes a general decrease of mitoribosomal proteins 
suggesting that mitochondrial gene expression programs respond to mitochondrial stress 
(Quirós et al. 2017). However, the mechanism leading to this downregulation has not been 
studied yet.  
 
1.4.3. A nuclear isoform of POLRMT 
 
The Polrmt gene has been reported to code for two RNA polymerases acting in the mammalian 
cells, POLRMT and the fourth nuclear RNA polymerase (spRNAP-IV) (Kravchenko et al. 2005; 
Kravchenko & Chumakov 2005). In mice and humans, the Polrmt gene contains 21 exons. 
POLRMT is the product of the predominant splice variant and is a ~140 kDa protein that 
contains an N-terminal mitochondrial targeting sequence (MTS). SpRNAP-IV is an alternative 
splicing isoform that contains a longer exon 1 producing a premature stop codon. Therefore, 
translation of spRNAP-IV would initiate from another open reading frame starting at exon 3. 
Compared to POLRMT, spRNAP-IV lacks the first 262 amino acids resulting in a ~110 kDa 
protein that does not contain an MTS (Kravchenko et al. 2005; Kravchenko & Chumakov 
2005). In the nucleus, spRNAP-IV was reported to transcribe a specific subset of nuclear 
genes including several muscle actin genes (ACTC1, ACTA1, ACTG1), the zinc-finger BTB 
domain-containing protein 1 gene (ZBTB1), the prenylcysteine oxidase gene (PCYOX1) and 
the POLRMT gene itself (Kravchenko et al. 2005; Lee et al. 2011). This observation suggests 
that transcription of mitochondrial and a subset of nuclear genes could be coupled. However, 
there are no studies of the mechanism of transcription of spRNAP-IV in the nucleus.  
 
1.5. Mammalian mitochondrial DNA gene expression 
 
1.5.1. The mammalian mitochondrial genome  
 
Mitochondrial DNA is exclusively maternally inherited and the number of copies of mtDNA per 
cell varies by several orders of magnitude between different tissues (Hällberg & Larsson 2014). 
Mammalian mtDNA is a double-stranded circular molecule of ~16.5 kb that encodes 37 genes 
(Figure 1.3A) (Anderson et al. 1981). The two strands of mtDNA have different sedimentation 
coefficients in alkaline caesium chloride gradients because of differences in guanine content. 
Consistent with these differences, the two mtDNA strands are designated the heavy (H) and 
the light (L) strand. The H strand encodes 10 mt-mRNAs, 2 ribosomal RNAs (mt-rRNAs), and 
14 transfer RNAs (mt-tRNAs). The L strand encodes one mt-mRNA and 8 mt-tRNAs (Clayton 
1991). The 11 mt-mRNAs encoded in the mitochondrial genome are translated into 13 proteins 
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as two mt-mRNAs, mt-Atp8/Atp6 and mt-Nd4l/Nd4, are bicistronic transcripts (Hällberg & 
Larsson 2014). Mitochondria use a non-universal codon code that is decoded by the mt-tRNAs 
(Larsson 2010). 
 
Figure 1.3 | Organisation of the 
mammalian mitochondrial genome  
(A) Mitochondrial genome illustrating 
both strands. (B) Schematic 
representation of the NCR with its 
regulatory elements. Abbreviations in 
alphabetic order: CI - CV, OXPHOS 
complex I-V; CSB, conserved 
sequence blocks; D-loop, 
displacement loop; H strand, heavy 
strand; HSP heavy-strand promoter; L 
strand, light strand; LSP, light-strand 
promoter; NCR, non-coding control 
region; TAS, termination associate 
sequence. Modified from Larsson 2010 
and Gustafsson et al. 2016.  
 
 
 
 
 
 
 
 
 
 
  
 
The densely packed mammalian mtDNA only contains two non-coding regions. The 
longer non-coding region (NCR), referred as the control region, is ~1.1 kb and spans from mt-
Tf to mt-Tp (Figure 1.3B). The NCR contains the promoters of transcription for each strand, 
that is the H-strand promoter (HSP) and the L-strand promoter (LSP), as well as the origin of 
replication for the H strand (OH) region. The OH region comprises the DNA sequence spanning 
from LSP until the mapped OH start site. Between LSP and OH, there are three conserved 
sequence blocks (CSB1-3) that are important regulatory sequences (Gustafsson et al. 2016). 
Abortive replication starting at OH results in a triple-stranded DNA structure as the newly 
replicated H strand remains bound to mtDNA displacing the non-template H strand. This region 
is called the displacement loop (D-loop) (Bogenhagen & Clayton 1978). The abortive mtDNA 
replication product of ~650 nucleotides is called 7S DNA and it ends in the termination-
associated sequence (TAS) that contains conserved palindromic motifs in vertebrates (Jemt 
et al. 2015). Most of the mammalian mtDNA replication events starting from OH result in 7S 
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DNA strands that are rapidly turned over (Figure 1.3) (Bogenhagen & Clayton 1978). The 
precise function and mechanisms regulating the D-loop remain elusive but it has been 
proposed to be important for the regulation of mtDNA replication and maintenance of mtDNA 
topology among others (Nicholls & Minczuk 2014).  
 
Mammalian mtDNA is tightly packed in nucleoprotein complexes of ~100 nm called the 
mitochondrial nucleoids. The main protein component of the mammalian nucleoid is TFAM 
that binds mtDNA via its two high-mobility group domains resulting in bending and compaction 
of the mtDNA molecule (Kaufman et al. 2007; Kukat et al. 2011; Kukat et al. 2015). Thus, 
TFAM is a highly abundant protein and it is estimated that there are ~1000 TFAM molecules 
per mtDNA. In addition to TFAM, several proteins required for mtDNA replication and 
transcription transiently interact with the mitochondrial nucleoid (Bonekamp & Larsson 2018; 
Bogenhagen 2012).  
 
1.5.2. Mitochondrial DNA replication and maintenance 
 
Mitochondrial DNA replication is performed by the phage-derived DNA polymerase g (POLg) 
that is composed of one catalytic subunit (POLgA) and two accessory subunits (POLgB). 
However, POLg is unable to use dsDNA as a template on its own and requires the DNA 
replicative helicase TWINKLE (gene name TWNK) that forms a hexameric ring and unwinds 
mtDNA at the replication fork (Korhonen et al. 2004). Although there are different proposed 
models for mammalian mtDNA replication, the strand-displacement model has the most robust 
experimental support (Gustafsson et al. 2016). According to this model, mtDNA replication 
starts at OH and DNA synthesis proceeds in one direction generating a new H strand. During 
the synthesis of the new H strand, the parental H strand is covered by the mitochondrial single-
stranded binding proteins (SSBP1). The single-stranded L-strand origin of replication (OL) 
forms a stable stem-loop structure that is used as template to generate the primer for L-strand 
replication. The OL is activated when the H strand replication has proceeded past this region 
and thereafter DNA synthesis from both strands proceeds continuously in opposite directions 
(Clayton 1991). Ligation of the newly replicated mtDNA molecule is performed by DNA ligase 
III (LIG3) (Lakshmipathy & Campbell 1999) and decatenation is performed by the DNA 
topoisomerase 3a (Nicholls et al. 2018).  
 
Several transgenic mouse strains have been generated to study mtDNA maintenance 
and replication in vivo. Disruption of Tfam, Twnk, PolgA, or Lig3 in mouse is embryonic lethal 
and leads to mtDNA depletion (Hance et al. 2005; Larsson et al. 1998; Milenkovic et al. 2013; 
Puebla-Osorio et al. 2006). The levels of TFAM and mtDNA correlate very well in different 
mouse models and cells, and it has been suggested that they stabilize each other (Ekstrand 
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et al. 2004; Jiang et al. 2017; Kukat et al. 2015; Larsson et al. 1994). A mechanism proposed 
to explain the concordance of TFAM and mtDNA levels is that LONP1 degrades TFAM when 
it is not bound to mtDNA (Lu et al. 2013). Interestingly, Twnk overexpression increases mtDNA 
copy number and a conditional Tfam knockout hearts have increased levels of TWINKLE, thus 
suggesting that TWINKLE is a limiting factor for mtDNA replication (Milenkovic et al. 2013). 
Super-resolution microscopy of mouse embryonic fibroblasts (MEFs) show a broad distribution 
of nucleoid sizes, indicating that different levels of compaction are present in mammalian 
mitochondrial nucleoids (Kukat et al. 2015). Increasing TFAM levels in vitro increase the 
compaction of the mtDNA template, which, in turn, inhibits mtDNA replication and transcription 
(Farge et al. 2014). Thus, TFAM modulation of nucleoid compaction could be an important 
mechanism for control of mtDNA replication and transcription in vivo.  
 
POLg requires an RNA primer to initiate replication at OH and OL but the mechanism of 
replication primer formation is still not completely understood. Mapping of RNA and DNA 
species in the human and mouse D-loop regions has identified RNA species whose 3’ ends 
corresponded to the 5’ ends of DNA molecules at OH. The 5’ end of this RNA coincides 
perfectly with LSP indicating that, in mammals, mtDNA replication uses an RNA primer and 
that primers are formed by mtDNA transcription (Figure 1.4) (Chang & Clayton 1985; Chang 
et al. 1985). In support of this hypothesis, in vitro studies have shown that transcription from 
LSP using recombinant human POLRMT results in a stable triple-stranded DNA-RNA hybrid 
(R-loop) that depends on the G-rich sequence of CSB2 (Lee & Clayton 1996; Xu & Clayton 
1996). Furthermore, a reconstituted human mitochondrial transcription system has shown that 
transcription prematurely terminates at CSB2 because of the formation of a G-quadruplex 
between CSB2 RNA and the corresponding non-template DNA strand. Since CSB2 is also the 
major site of RNA-DNA transitions in the complementary D-loop strand, it has been proposed 
that premature transcription termination at this position generates the RNA primer for H-strand 
replication (Pham et al. 2006; Wanrooij et al. 2012). However, such an RNA primer cannot 
support transcription in reconstituted in vitro systems suggesting that additional regulatory 
elements are required (Wanrooij et al. 2012). The 5’ ends of non-ligated mtDNA mainly map 
to OH, which is located ~100 bp downstream CSB2 (Attardi et al. 1979), suggesting that the 
nascent H strand is considerably processed at the 5’ end to remove the RNA primer and a 
fragment of DNA (Gustafsson et al. 2016). The ribonuclease H1 (RNASEH1) is thought to 
degrade the RNA primers on both strands and the mitochondrial genome maintenance 
exonuclease - 1 (MGME1) is thought to degrade the DNA upstream of OH (Matic et al. 2018; 
Uhler & Falkenberg 2015). An additional confounding point is that transcription from LSP also 
generates a short non-coding RNA transcript of unknown function called the 7S RNA.  This 
transcript extends from LSP to CSB1 (Jemt et al. 2015) and it has been proposed to function 
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as a primer at OH. However, 7S RNA is poly-adenylated and does not remain bound to mtDNA 
(Ojala & Attardi 1974), thus it is not likely the replication RNA primer (Gustafsson et al. 2016).  
 
 
Figure 1.4 | Regulation of transcription in the NCR 
Transcription from LSP generates three transcripts: i) the RNA primer that ends at CSB2, ii) 7S RNA that ends at 
CSB1, and iii) the full-length polycistronic mt-RNA encompassing all of the genes encoded in the L strand. The 7S 
DNA 5’ end maps to OH. The HSP polycistronic mt-RNA stops at the termination associated sequence (TAS). 
Abbreviations in alphabetic order: CSB, conserved sequence blocks; H strand, heavy strand; HSP, heavy-strand 
promoter; L strand, light strand; LSP, light-strand promoter; D loop, displacement loop, OH, heavy-strand origin of 
replication; Poly(A), poly-adenine tail; TAS, termination-associated sequence. Modified from Gustafsson et al. 2016 
 
The importance of POLRMT in replication primer formation is debated. In the nucleus 
primers are generated by specific DNA-dependent RNA polymerases, called DNA primases, 
distinct from the classical RNA polymerases (Guilliam et al. 2015). Furthermore, early studies 
identified a mitochondrial primase activity that was thought to generate the primers at the poly-
dT stretch in the stem-loop structure of OL (Ledwith et al. 1986). Phylogenetic analysis 
suggested that TWINKLE has a primase activity in most eukaryotes but this function is lost in 
metazoans (Shutt & Gray 2006). The DNA-directed primase/polymerase protein (PRIMPOL) 
was reported to localize in the nucleus and mitochondria and present primase activity (García-
Gómez et al. 2013). However, Primpol knockout mice are viable suggesting that it does not 
have an essential role in mtDNA replication. POLRMT can generate the OL primer for mtDNA 
replication in vitro (Wanrooij et al. 2008; Fusté et al. 2010) suggesting that POLRMT may be 
the primase for mtDNA replication at both OH and OL, but substantial in vivo data are missing 
to date. 
 
1.5.3. Mitochondrial DNA transcription 
 
POLRMT transcribes mtDNA starting from LSP and HSP and generates two near-genome 
length polycistronic transcripts encompassing all genes on each strand. Transcription from 
HSP is terminated in the TAS region of the NCR and transcription from LSP is terminated at 
mt-Tl1 (Figure 1.5) (Gustafsson et al. 2016; Jemt et al. 2015). 
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Figure 1.5 | Mammalian 
mtDNA transcription units  
mtDNA is transcribed from 
the two promoters to 
generate near-genome 
length polycistronic 
transcripts. Transcription 
from LSP is terminated at the 
mt-Tl1 where MTERF1 binds. 
Transcription from LSP is 
terminated at the TAS region 
before entering the D-loop in 
the NCR. Same conventions 
as Figure 1.3. Modified from 
Gustafsson et al. 2016 
 
 
 
 
 
 
POLRMT requires additional factors for promoter recognition, transcription initiation, 
transition to elongation, and transcription termination (Morozov et al. 2014; Ringel et al. 2011; 
Schwinghammer et al. 2013; Shi et al. 2012; Sologub et al. 2009). These factors include TFAM, 
the mitochondrial transcription factor B2 (TFB2M), the mitochondrial transcription elongation 
factor (TEFM), and MTERF1. TFAM and TFB2M are required for transcription initiation, TEFM 
for elongation, and MTERF1 for termination from LSP (Gustafsson et al. 2016). The 
mechanism of transcription termination from the H strand in the TAS region of the NCR (Jemt 
et al. 2015) has not been elucidated yet. 
 
 Based on biochemical and structural studies of these transcription factors and 
POLRMT in in vitro systems, a sequential model of mitochondrial transcription initiation has 
been proposed (Agaronyan et al. 2015; Hillen, et al. 2017a; Morozov et al. 2015; Posse et al. 
2014; Posse et al. 2015). According to this model, TFAM binds to specific sequences in 
upstream regions of HSP and LSP inducing conformational changes in the promoter region. 
These conformational changes allow the binding of POLRMT to TFAM and the promoter DNA 
forming the pre-initiation complex (pre-IC). Then, TFB2M is required to melt the promoter 
completing the initiation complex (IC). After transcription initiation, TFAM and TFB2M 
disengage from the complex and TEFM aids in the processivity of POLRMT to generate the 
long polycistronic transcripts (Figure 1.6).  
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Figure 1.6 | Model of mitochondrial transcription 
The initiation complex formed by POLRMT, TFAM and TFB2M assembles in the promoter region. Then, TFAM and 
TFB2M disengage from the complex and TEFM binds POLRMT forming the elongation complex. Transcription from 
LSP is terminated by MTERF1 in mt-Tl1. Transcription from HSP is terminated in the TAS region (Figure 1.5) but 
the mechanism is still unknown. Abbreviations in alphabetic order: mtDNA, mitochondrial DNA; MTERF1, 
mitochondrial transcription termination factor 1; POLRMT, mitochondrial RNA polymerase; TEFM, mitochondrial 
transcription termination factor 1; TFAM, mitochondrial transcription factor A; TFB2M, mitochondrial transcription 
factor B2; mt-RNA, mitochondrial RNA.  
 
1.5.3.1. Mitochondrial RNA polymerase 
 
POLRMT is homologous to the T7-phage RNA polymerase (T7-RNAP) (Ringel et al. 2011). It 
consists of three domains; the C-terminal domain (CTD), the N-terminal domain (NTD), and 
the N-terminal extension (NTE) that contains the MTS. The CTD is a T7-like catalytic domain 
that has a conserved mechanism of nucleic acid polymerization dependent on magnesium 
ions. The structure of the NTD also resembles T7-RNAP and it contains important elements 
for promoter recognition and melting. The NTE is a unique feature of POLRMT as it is not 
present in T7-RNAP and contains pentatricopeptide repeat (PPR) motifs (Ringel et al. 2011) 
that are degenerate 35-amino acid tandem sequence motifs found in proteins involved in RNA 
metabolism (Lightowlers & Chrzanowska-Lightowlers 2013). During transcription elongation, 
the nascent transcript emerges towards the PPR motifs of POLRMT (Schwinghammer et al. 
2013). Furthermore, a mutant POLRMT enzyme devoid of most of the NTE (D320 amino acids) 
has higher  in vitro transcription activity than the wild-type polymerase (Posse et al. 2014) 
indicating that the NTE might have an important regulatory role in POLRMT but the precise 
function is still unknown. 
 
1.5.3.2. Mitochondrial transcription factor A 
 
In addition to the previously mentioned function of TFAM in mtDNA maintenance, TFAM binds 
with high affinity to specific regions upstream of HSP and LSP inducing a 180° bend in the 
promoter (Morozov et al. 2014; Morozov & Temiakov 2016; Ngo et al. 2014; Posse et al. 2014). 
The specific binding of TFAM to the promoter region is required for mitochondrial transcription 
initiation (Dairaghi, Shadel & Clayton 1995a; Gaspari et al. 2004; Shi et al. 2012). In this 
 16 
process, the C-terminal tail of TFAM interacts with the NTE of POLRMT (Hillen et al. 2017a; 
Morozov et al. 2014; Posse et al. 2014). In agreement with the structural and biochemical data, 
the transcription factor activity of TFAM is severely impaired in absence of its C-terminal tail 
(Dairaghi, Shadel & Clayton 1995b). The interaction of TFAM, POLRMT, and promoter DNA 
is species-specific as human TFAM is a poor activator of mitochondrial transcription in mouse 
in in vivo and in vitro systems (Ekstrand et al. 2004; Gaspari et al. 2004). Importantly, the 
mtDNA maintenance function of TFAM can be dissociated from its function as a transcription 
factor because expression of human TFAM in a mouse Tfam knockout background rescues 
mtDNA copy number, but not mitochondrial transcription (Ekstrand et al. 2004; Freyer et al. 
2010). In addition to promoter specificity, TFAM is also required but not sufficient for promoter 
melting (Posse & Gustafsson 2017; Ramachandran et al. 2017).  
 
1.5.3.3. Mitochondrial transcription factor B2 
 
TFB2M has structural homology to bacterial rRNA methyltransferases but in mammalian 
mitochondria it is a bona fine transcription initiation factor (Litonin et al. 2010). Consistently, 
knockout of Tfb2m in mouse pancreatic b-cells leads to loss of mt-RNAs (Nicholas et al. 2017). 
TFB2M interacts with the NTD and CTD of POLRMT as well as with the promoter DNA and 
priming nucleotide (Morozov et al. 2015). TFB2M induces conformational changes in POLRMT 
which enables promoter opening and the correct localization of the non-template strand (Hillen 
et al. 2017a). The sequential model for transcription initiation was founded on crosslinking and 
footprinting analyses that showed that POLRMT can be recruited to the promoter without the 
requirement of TFB2M and form a stable pre-IC (Posse et al. 2014; Morozov et al. 2014). 
However, a recent study has proposed an alternative model where POLRMT and TFB2M can 
form a complex independently of promoter binding. This model is supported by equilibrium 
binding analyses that show that POLRMT and TFB2M have a similar dissociation constant as 
TFAM and LSP (Ramachandran et al. 2017).  
 
1.5.3.4. Mitochondrial transcription elongation factor 
 
TEFM is the most recently described mitochondrial transcription factor. It was identified by 
homology analyses as a putative human mitochondrial Holliday Junction resolvase. Although 
this specific activity was not found in recombinant TEFM, silencing of TEFM in human cells 
showed a specific pattern of mt-mRNA abundance whereby promoter-proximal transcripts 
were increased and promoter-distal transcripts were decreased suggesting a role in 
transcription elongation (Minczuk et al. 2011). Biochemical characterization of TEFM activity 
in in vitro transcription systems showed that TEFM increases the processivity of POLRMT in 
longer transcripts by enhancing the affinity of POLRMT to an elongating template and 
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facilitating the passage over structured or modified DNA sequences like G-quadruplexes or 8-
oxo-dG lesions (Agaronyan et al. 2015; Posse et al. 2015; Sultana et al. 2017). The crystal 
structures of TEFM and POLRMT with TEFM in an elongating complex provided important 
mechanistic insights that could explain how TEFM promotes transcription elongation (Hillen et 
al. 2017b). First, TEFM has two domains, an NTD, that contains two globular hairpin-helix-
harpin (HhH) domains of unknown function, and a C-terminal dimerization domain that forms 
the catalytic core. TEFM dimer interacts with POLRMT and the nucleic acids in the 
transcription bubble. These interactions contribute to the formation of a ‘sliding clamp’ with the 
downstream DNA that enhances the processivity of the transcription elongation complex. 
Second, TEFM binds the single-stranded non-template DNA preventing the collapse of the 
transcription bubble. Third, TEFM induces conformational changes in POLRMT that contribute 
to the formation of the RNA channel and prevent the formation of RNA G-quadruplexes during 
transcription elongation. Since TEFM prevents transcription termination at CSB2, it has been 
proposed that it is a switch between mtDNA replication and transcription (Agaronyan et al. 
2015). However, this function is debated (Posse et al. 2015) as it assumes that the primer for 
mtDNA replication at OH would be formed by premature transcription termination at CSB2 and, 
until now, this prematurely terminated transcript has not been shown to support mtDNA 
replication in vitro suggesting that additional processing is required. 
 
1.5.3.5. Mitochondrial transcription termination factor 1 
 
MTERF1 is the only known factor to date involved in transcription termination. It binds mtDNA 
in mt-Tl1 that is located downstream of mt-rRNAs in the H strand (Figure 1.5) (Shang & Clayton 
1994; Terzioglu et al. 2013) and was proposed to act as a road block for transcription of LSP 
and HSP. Termination of HSP-initiated transcription mediated by MTERF1 was suggested to 
promote the generation of a shorter polycistronic transcript encompassing the mt-rRNAs 
(Martin et al. 2005). However, in vitro and in vivo studies demonstrated that MTERF1 mainly 
terminates the transcription initiated at the LSP preventing the formation of antisense mt-
rRNAs and has no effect on the abundance of the H-strand encoded mt-rRNAs (Figure 1.5) 
(Asin-Cayuela et al. 2005; Terzioglu et al. 2013). 
 
Furthermore, it was recently shown that MTERF1 not only blocks transcription of 
antisense mt-rRNAs but also directs polar replication fork pausing. This means that MTERF1 
acts as a roadblock for the replication machinery in the H strand preventing collisions with the 
transcription machinery transcribing the mt-rRNAs (Shi et al. 2016). Collisions of replication 
and transcription machineries can result in replication stalling and genome instability (Merrikh 
et al. 2012). These collisions can cause either co-directional or heads-on replication-
transcription conflicts and different mechanisms to resolve or prevent these conflicts exist in 
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the nuclear chromosomes and in bacteria with circular genomes (García-Muse & Aguilera 
2016; Merrikh et al. 2012). The two different origins of replication are coupled so that initiation 
at OH, which depends on LSP transcription, must occur before OL can be activated. This 
arrangement may contribute to reduce the possibility of collisions between the replication and 
transcription machineries in mammalian mitochondria.  
 
Three additional members of the MTERF family of proteins have been found in 
mammalian mitochondria (MTERF2-MTERF4). MTERF3 was originally reported to be a 
negative regulator of mitochondrial transcription, but the exact binding site of MTERF3 to 
mtDNA has not been identified (Park et al. 2007). Then, MTERF3 was shown to bind mt-16S 
rRNA and facilitate assembly of the mitochondrial ribosome but the precise function is still 
unknown (Wredenberg et al. 2013).  
 
1.5.3.6. Other factors regulating mitochondrial transcription 
 
In addition, several proteins have been described to regulate mitochondrial transcription, 
including the mitochondrial ribosomal protein L12 (MRPL12) and the mitochondrial DNA 
topoisomerase 1 (TOP1MT). The role of MRPL12 in regulating mitochondrial transcription is 
debated. POLRMT was reported to bind a free pool of MRPL12, which was found to stimulate 
transcription. Here, MRPL12 may act as an allosteric activator of transcription helping in the 
transition from initiation to elongation (Nouws et al. 2016; Surovtseva et al. 2011; Wang et al. 
2007). However, MRPL12 did not stimulate mitochondrial transcription in a reconstituted in 
vitro system (Litonin et al. 2010). TOP1MT was identified as an exclusive mitochondrial protein 
acting as a negative regulator of transcription through interaction with POLRMT; however, the 
underlying mechanism is not understood (Sobek et al. 2013).  
 
1.5.4. Mitochondrial RNA processing  
  
Pioneering studies from the Attardi laboratory observed that, in mammals, most mt-mRNAs 
and mt-rRNAs are flanked by mt-tRNAs (Ojala et al. 1981). They postulated that the 
polycistronic mitochondrial transcripts were processed into the individual mt-RNAs by precise 
endonucleolytic cleavage that occurred, in most cases, in the mt-tRNAs. This model is known 
as the “tRNA punctuation model”. The cleavage of the polycistronic mitochondrial transcripts 
is performed by the mitochondrial RNase P and the mitochondrial tRNAse Z (Rackham et al. 
2012). This endonucleolytic process occurs in a hierarchical manner, that is, the 5’ ends of the 
mt-tRNAs are cleaved first followed by the 3’ ends (Brzezniak et al. 2011; Rackham et al. 
2016). RNase P is formed by three mitochondrial RNAse P proteins (MRPP1, MRPP2, and 
MRPP3) and processes the 5’ ends of the mt-tRNAs. Furthermore, RNase P also processes 
the 5’ end of mt-Co1 that does not contain a delimiting mt-tRNA but the upstream non-coding 
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sequence forms a tRNA-like structure (Sanchez et al. 2011). Zinc phosphodiesterase ELAC 
protein 2 (ELAC2) was recently identified as the enzyme processing the 3’ends of mt-tRNAs 
(Brzezniak et al. 2011).  
 
 All mitochondrial transcripts are post-transcriptionally modified to generate the mature, 
functional transcripts. The proper folding of mt-tRNAs, base pairing, and interaction with the 
aminoacyl-tRNA synthetases depend on a CCA addition to the 3’ end and the modification of 
specific bases. These modifications include methylations, formylations, and 
pseudouridylations, among others (Suzuki et al. 2011). Mt-tRNAs are amino-acylated by an 
almost exclusive set of mitochondrial tRNA synthetases that differs from the cytosolic enzymes 
(Diodato et al. 2014).  
 
Mammalian mt-mRNAs do not have introns, Shine Dalgarno sequences, conventional 
5’ and 3’ UTRs, 5’ 7- methylguanosine caps or base modifications. With the exception of mt-
Nd6, all mt-mRNAs are polyadenylated in their 3’ end and, for several of the transcripts, this 
process is essential as it completes the termination codon (Rackham et al. 2012). Contrary to 
the nucleus where polyadenylation promotes RNA degradation, in mitochondria the role of this 
process remains elusive as loss of the poly(A) tail in mt-mRNAs results in different effects on 
the abundance of mitochondrial transcripts (Bratic et al. 2016; Rorbach et al. 2011; Wilson et 
al. 2014). An important factor coordinating mt-mRNA stability and polyadenylation is the 
leucine-rich PPR motif containing protein (LRPPRC) (Ruzzenente et al. 2012). LRPPRC forms 
a complex with the mitochondrial SRA stem-loop-interacting RNA-binding protein (SLIRP) 
(Sasarman et al. 2010). This complex binds throughout the mitochondrial transcriptome and 
acts as a global RNA chaperone coordinating mt-RNA stability, polyadenylation, and 
translation (Siira et al. 2017).  In line with this, loss of LRPPRC in mouse causes a global 
decrease of all mt-mRNAs except mt-Nd6 whereas mt-tRNAs are mostly unchanged and mt-
rRNAs are increased in abundance (Ruzzenente et al. 2012). LRPPRC was previously 
reported to also stimulate mitochondrial transcription by direct interaction with POLRMT (Liu 
et al. 2011), but de novo transcription is not affected by knockout or overexpression of Lrpprc 
(Harmel et al. 2013; Ruzzenente et al. 2011).  
 
In addition to LRPPRC, the Fas-activated serine/threonine kinase (FASTK) family of 
proteins have recently emerged as key post-transcriptional regulators of mtDNA gene 
expression. It contains six members, FASTK and the FASTK-domain containing proteins 1 to 
5 (FASTKD1 to FASTKD5), all of which localize to mitochondria and interact with specific 
mitochondrial transcripts. They have been reported to coordinate several processes including 
mt-RNA processing of mt-Nd6, stability of several mt-mRNAs and mt-rRNAs, and translation 
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of mt-Co1 (Jourdain et al. 2017). The G-rich sequence factor 1 (GRSF1) was reported to 
mediate stability of several mt-RNAs and interact with RNase P in the mitochondrial matrix. 
Importantly, GRSF1 strongly binds to the mt-Nd6 and silencing of GRSF1 in human cells leads 
to the accumulation of pre-processed transcripts containing mt-Nd6 suggesting an important 
role for this protein in the processing of this transcript (Antonicka et al. 2013; Jourdain et al. 
2013). Importantly, mt-Nd6 does not contain an mt-tRNA in the junction with the non-coding 
complementary mt-Nd5. A recent study suggested that GRSF1 binds G-rich non-coding RNAs 
resulting from LSP-initiated transcription promoting their degradation (Pietras et al. 2018). 
Microscopy analyses of GRSF1 showed that it forms a distinct punctate pattern in the 
mitochondrial matrix that co-localizes with mt-RNAs and processing enzymes which lead to 
the proposal that mt-RNA processing occurs in RNA granules (Antonicka et al. 2013; Jourdain 
et al. 2013). Subsequent co-immunoprecipitation and co-localization studies have identified 
several additional proteins involved in mt-RNA metabolism to be present in the mitochondrial 
RNA granules (Antonicka & Shoubridge 2015) including the mitochondrial polyribonucleotide 
nucleotidyltransferase 1 (PNPT1; PNPase) and the mitochondrial ATP-dependent RNA 
helicase (SUPV3L1) (Borowski et al. 2013). PNPT1 and SUPV3L1 form a complex that 
degrades mitochondrial transcripts (Borowski et al. 2013; Chujo et al. 2012; Khidr et al. 2008). 
The LRPPRC/SLIRP complex has been proposed to prevent the degradation of coding 
transcripts by maintaining the RNA unfolded (Chujo et al. 2012; Siira et al. 2017). Recently, 
the b-lactamase metalloprotein LACTB2 was shown to mediate the degradation of 
mitochondrial transcripts as well (Levy et al. 2016) and the oligoribonuclease REXO2 has been 
proposed to degrade small RNA oligomers resulting from PNPT1 degradation of mt-RNAs 
(Bruni et al. 2013; Bruni et al. 2017).  
 
1.5.5. The mammalian mitochondrial ribosome 
 
The mitoribosome contains more than 80 proteins and has a high protein to RNA ratio in 
comparison to the bacterial ribosomes (Sharma et al. 2003). Mitoribosomes are anchored to 
the IMM (Liu & Spremulli 2000) and it has been suggested that mtDNA-encoded proteins are 
inserted co-translationally in the IMM to assemble in the OXPHOS complexes (Gruschke & Ott 
2010). The complete mitoribosome (monosome) is formed by two subunits: the small 
mitoribosomal subunit (28S) containing mt-12S rRNA and the large mitoribosomal subunit 
(39S) containing mt-16S rRNA. In addition, cryo-electron microscopy studies of the large 
ribosomal subunit revealed the presence of an mt-tRNA in the structure which turned out to be 
either mt-Tv or mt-Tf in all the mammalian species studied to date (Greber et al. 2014a; Greber 
et al. 2014b; Rorbach et al. 2016). Assembly of the mitoribosome initiates close to the 
mitochondrial nucleoids as mt-rRNAs are formed by transcription (Bogenhagen 2014; 
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Rackham et al. 2016) and it has been suggested that RNA granules are important centres for 
mt-rRNA post-transcriptional modification (Antonicka & Shoubridge 2015).  
 
The mt-rRNAs are the most abundant mitochondrial transcripts (Mercer et al. 2011) 
and, to date, ten post-transcriptional modifications have been identified (Pearce et al. 2017). 
mt-12S rRNA has been shown to be methylated by the mitochondrial transcription factor B1 
(TFB1M) and the 5-methylcytosine rRNA methyl transferase NSUN4. TFB1M is homologous 
to TFB2M and it was originally proposed to also act as a transcription factor (Falkenberg et al. 
2002). However, knockout of Tfb1m in mouse does no repress mitochondrial transcription but 
results in loss of mt-12S rRNA methylation and severely impaired mitochondrial translation 
(Metodiev et al. 2009). NSUN4 forms a complex with MTERF4 that coordinates the assembly 
of the monosome (Cámara et al. 2011; Metodiev et al. 2014). Mt-16S rRNA is methylated by 
a group of closely related methyl-transferases that include the mitochondrial rRNA methyl 
transferases 1 to 3 (MRM1 to 3) (Pearce et al. 2017). Additionally, it has recently been shown 
that mt-16S rRNA is regulated by a protein complex containing a set of RNA binding proteins 
that include Neugrin (NGRN), RCC1-like G exchanging factor-like protein 
(RCC1L/WBSCR16), the putative mitochondrial mRNA pseudouridine synthases RPUSD3, 
RPUSD4 and TRUB2, and FASTKD2 (Arroyo et al. 2016). RPUSD4 was recently shown to 
pseudourydilate mt-16S rRNA (Antonicka et al. 2017; Zaganelli et al. 2017) and the PPR-motif 
containing protein 2 (PTCD2) was reported to be required for this modification to occur and to 
interact with FASTKD2 and RPUSD4 (Perks et al. 2018).   
 
1.6. Mitochondrial dysfunction in human health 
 
1.6.1. Mitochondrial genetic diseases  
 
Mitochondrial diseases are one of the most common types of inherited metabolic disorders. 
They can be caused by mutations in mtDNA or in nuclear genes encoding mitochondrial 
proteins leading to different patterns of inheritance (Gorman et al. 2016). Since mtDNA is 
present in multiple copies within each cell, mutations in mtDNA can be present in all the 
molecules (homoplasmy) or in a fraction of the molecules (heteroplasmy). The levels of 
heteroplasmic mutations can vary between cells in the same organ or tissue, between organs 
within the same person, and between individuals in the same family. Moreover, the expression 
and severity of mitochondrial disease depends on whether mutated mtDNA passes a certain 
threshold (Stewart & Chinnery 2015). Mitochondrial diseases are clinically heterogenous which 
means that they can manifest at any time and with a wide variety of clinical symptoms. The 
severity of mitochondrial diseases can range from asymptomatic or oligosymptomatic carriers 
to life-threatening multisystemic disorders (Liang et al. 2014). Furthermore, they can manifest 
in a tissue-specific manner where the same genetic defect can result in different clinical 
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phenotypes (Nunnari & Suomalainen 2012). In addition to the genetic component, 
environmental factors can influence the course of mitochondrial diseases (Vafai & Mootha 
2012).  
 
Hundreds of different point mutations and re-arrangements in mtDNA have been shown 
to cause mitochondrial diseases and pathogenic mutations have been reported in in all mt-
mRNAs, mt-tRNAs, and mt-rRNAs (Lott et al. 2013). Furthermore, several mutations in nuclear 
genes required for mtDNA gene expression have also been identified including mutations in 
POLg, TWNK, MGME1, ELAC2, LRPPRC, MTPAP, several mitochondrial aminoacyl-tRNA 
synthetases and mitoribosomal proteins (Viscomi & Zeviani 2017). Mutations that affect 
mitochondrial transcription seem to be rarer. To date, only one pathogenic mutation has been 
identified in the NCR, specifically in the HSP, causing tubulointerstitial kidney disease (Connor 
et al. 2017). From the basic transcription machinery, a missense mutation in one of the high-
mobility group boxes of TFAM was recently found in two siblings born of consanguineous 
parents of Colombian-Basque descent. This mutation caused neonatal liver failure and the 
patients died before 4 months of age (Stiles et al. 2016). The multiple genetic causes, different 
patterns of inheritance, heteroplasmy in the case of mtDNA pathogenic mutations, and 
heterogeneity of clinical symptoms make the diagnosis of mitochondrial diseases a complex 
process (Gorman et al. 2016). Furthermore, even when the genetic defect causing 
mitochondrial disease is identified, the chain of events that lead to the end pathology and the 
reasons behind the clinical heterogeneity and tissue-specificity of mitochondrial diseases are 
largely unknown.  
 
Unfortunately, there is still no cure for mitochondrial diseases and, in most cases, 
clinical management remains largely supportive (Pfeffer et al. 2013). Multiple types of 
therapies targeting different aspects of mitochondrial dysfunction have been developed. These 
include therapies aimed at increasing respiratory chain substrate availability, enhancing 
electron transport transfer within the respiratory chain, bypassing respiratory chain 
components, increasing antioxidant capacity, improving energy buffering, and inducing 
adaptations to cope with OXPHOS dysfunction (Pfeffer et al. 2013). Many of these therapies 
are implemented as dietary supplements that are increasingly used due to their potential 
benefits and low-risk of developing secondary effects (Camp et al. 2016). An example of a 
commonly used supplement in patients with mitochondrial disorders is Q10 supplementation as 
it enhances electron transfer in the respiratory chain and is a potent antioxidant. Q10 
supplementation is an efficient treatment for patients with primary Q deficiency (Emmanuele 
et al. 2012). However, its efficacy to treat other mitochondrial disorders has been questioned 
as clinical trials have shown mixed outcomes that can be explained by the experimental design 
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of the trials, the poor bioavailability of supplemented Q10, and the lack of experimental support 
to define in which specific mitochondrial diseases would benefit from Q supplementation 
(Gorman et al. 2016; Pfeffer et al. 2013; Spindler et al. 2009). New treatments are currently 
being developed that include enhancers of mitochondrial proliferation, rapamycin treatment, 
hypoxia, and gene therapy approaches to reduce pathogenic heteroplasmic mtDNA mutations 
and target mutations in nuclear genes (Gorman et al. 2016; Nightingale et al. 2016).  
 
1.6.2. Ageing and age-related diseases 
 
Human ageing strongly correlates with the accumulation of mutated mtDNA molecules in 
somatic tissues leading to respiratory chain deficiency (Larsson 2010). Although it is not clear 
whether these mutations drive the ageing process or only correlate with it, there are strong 
indications that mtDNA mutations can contribute to ageing phenotypes (Kauppila et al. 2017). 
For a long time, the source of these mutations has been thought to be oxidative damage 
caused by reactive oxygen species (ROS) that leak from OXPHOS which, in turn, result in a 
vicious cycle as mutated mtDNA would generate more dysfunctional OXPHOS complexes and 
ROS (Bandy & Davison 1990). However, this hypothesis has now been extensively challenged 
as mouse models with increased mtDNA mutations do not have increased ROS (Trifunovic et 
al. 2005) and as removing ROS scavenging enzymes and mtDNA repair mechanisms does 
not induce mtDNA mutations (Kauppila et al. 2018). It has therefore been proposed that 
accumulation of mutations in specific cell types during ageing is driven by shifts in 
heteroplasmy during cell division, relaxed mtDNA replication, and replication errors (Kauppila 
et al. 2017; Stewart & Chinnery 2015). 
 
 Mitochondrial dysfunction is also found in several age-related diseases including 
cardiovascular diseases (Brown et al. 2017), neurodegenerative diseases (Golpich et al. 
2017), metabolic syndrome (Lowell & Shulman 2005), and cancer (Zong et al. 2016). Hence, 
targeting mitochondrial dysfunction has developed as a leading therapeutic strategy for many 
of these common human pathologies. However, similar to the ageing process, distinguishing 
whether mitochondrial dysfunction causes or correlates with these diseases is an important 
and challenging endeavour that will greatly improve our understanding of the pathophysiology 
of these diseases and help to develop targeted therapeutic approaches. In this regard, 
understanding the fundamental processes that regulate mitochondrial biogenesis, function, 
homeostasis and how these processes affect cellular metabolism is of great importance from 
a biological and clinical perspective.  
 24 
  
 25 
 
2. RESEARCH AIMS 
 
Elucidating the in vivo function of POLRMT and its nuclear isoform spRNAP-IV in mammals 
 
Mammalian mtDNA replication and transcription are intimately related processes as the 
priming site for H-strand replication coincides with initiation of transcription at LSP (Chang & 
Clayton 1985; Gillum & Clayton 1979). The primase function of POLRMT continued to be 
debated as an additional primase activity distinct from POLRMT was identified in mammalian 
mitochondria (Ledwith et al. 1986), DNA replication in the nucleus relies on specific primases 
that differ from the RNA polymerases needed for gene transcription (Guilliam et al. 2015), and 
the process of primer generation and processing is still largely unknown. In addition, the 
alternative isoform of the POLRMT gene, spRNAP-IV, was reported as the fourth eukaryotic 
nuclear RNA polymerase transcribing a specific set of genes in the nucleus (Kravchenko et al. 
2005; Kravchenko & Chumakov 2005; Lee et al. 2011). The relevance of spRNAP-IV for 
mitochondrial function is unknown, but it was suggested to be involved in the coordination of 
nuclear and mtDNA gene expression. Thus, the in vivo mechanisms coordinating mtDNA 
replication and transcription and the concerted expression of the two cellular genomes remain 
significant gaps in our current knowledge of mitochondrial function. Therefore, the first aim of 
this thesis is to elucidate the in vivo function of POLRMT and its nuclear isoform in mammals 
using the mouse as a model organism.  
 
Identifying the cellular consequences of progressive OXPHOS deficiency caused by loss of 
mtDNA gene expression  
 
Expression of the mtDNA is essential for the biogenesis of the OXPHOS system. Since 
metabolism is highly interconnected, OXPHOS dysfunction can result in devastating 
consequences for the whole cell, organ, or organism. Mitochondrial diseases are the clear 
example of this, as mutations in mtDNA or nuclear genes encoding mitochondrial proteins can 
result in a broad spectrum of clinical phenotypes that cannot be explained uniquely by the 
primary OXPHOS defect (Nunnari & Suomalainen 2012). The pathogenesis of mitochondrial 
diseases is still far from being understood as distinguishing the direct consequences of 
OXPHOS dysfunction from the secondary cellular responses is challenging. Therefore, the 
second aim of this thesis is to systematically study the molecular consequences of progressive 
OXPHOS deficiency caused by disrupted mtDNA gene expression for protein complexes of 
dual genetic origin as well as the secondary cellular responses caused by the primary 
OXPHOS defect at the mitoproteome and cellular transcriptome level.  
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3. RESULTS  
 
3.1. Elucidating the in vivo function of POLRMT and spRNAP-IV in mammals 
 
3.1.1. Mouse strains to study the in vivo function of POLRMT and spRNAP-IV 
 
To study the in vivo function of POLRMT and spRNAP-IV we generated several transgenic 
mouse strains with different gene dosage of Polrmt. A conditional knockout allele of Polrmt 
was generated by targeting exon 3 which disrupts the expression of the mitochondrial and 
nuclear splice variants (Figure 3.1A and B). Heart and skeletal muscle specific knockout 
(PolrmtloxP/loxP; Ckmm-cre; L/L, cre) and germline heterozygous mice (Polrmt+/-; +/-) were 
obtained by breeding mice with a heterozygously floxed Polrmt allele (+/PolrmtloxP) to mice 
expressing the cre recombinase under the control of the creatinine kinase promoter (Ckmm-
cre) or the ubiquitously expressed b-actin promoter (b-actin-cre), respectively. Analysis of 
complementary DNA (cDNA) by reverse transcription polymerase chain reaction (RT-PCR) 
verified that sequences corresponding to exon 3 of the Polrmt mRNA were lacking in the heart 
of the conditional Polrmt knockout mice (Figure 3.1C). Moreover, western blot analyses 
showed a drastic reduction of POLRMT in mitochondrial extracts from heart of the conditional 
Polrmt knockout mice (Figure 3.1D) and a 50% decrease in POLRMT levels in heart, skeletal 
muscle, and liver of Polrmt+/- mice (Figure 3.1E). 
 
 
Figure 3.1 | Generation of conditional Polrmt knockout mice 
(A) Schematic depiction of the Polrmt gene, Polrmt cDNA, and the two alternative splice variants cDNA reported in 
mouse coding for spRNAP-IV (Kravchenko & Chumakov 2005). (B) Targeting strategy for the conditional disruption 
of Polrmt. (C) RT-PCR analysis of targeted Polrmt transcripts from control (L/L) and tissue-specific knockout mice 
(L/L, cre). Different primer sets were used as indicated; exon 3: 551 bp. (D) Western blot analysis of steady-state 
POLRMT levels on isolated mitochondria from heart of L/L and L/L, cre mice at different ages. (E) Western blot 
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analysis of steady-state POLRMT levels on heart, skeletal muscle and liver of wild-type (+/+) and heterozygous 
Polrmt knockout (+/-) mice at 26 weeks of age. Loading: VDAC; Skm, skeletal muscle. From Kühl et al. 2014; 2016. 
 
Mice ubiquitously overexpressing Polrmt (Polrmt+/T; +/T) were generated using a 
bacterial artificial chromosome (BAC) transgenic strategy (Park et al. 2007). This allowed a 
moderate overexpression of Polrmt under the control of its endogenous promoter and 
surrounding regulatory sequences mimicking physiological expression of endogenous Polrmt. 
A BAC clone containing a fragment of chromosome 10 containing the Polrmt gene was 
modified by introducing a silent point mutation (c420G>T) generating a HindIII site in exon 3 
of Polrmt (Figure 3.2A and B). The restriction site was used to differentiate the transgene from 
the endogenous Polrmt alleles in the mouse. Germline transmission and expression of the 
transgene was verified by PCR and subsequent HindIII restriction digest (Figure 3.2C). 
Quantification of the transgenic allele by pyrosequencing showed that a single copy of the 
transgene was integrated into the mouse genome (Figure 3.2D), which was consistent with a 
~50% increase in Polrmt transcript levels (Figure 3.2E) in heart and increased POLRMT 
protein levels in different mouse tissues (Figure 3.2F). 
 
 
Figure 3.2 | Generation of endogenous Polrmt overexpressing mice 
(A) Scheme of BAC modification strategy. Chr, chromosome; E, exons; asterisk point mutation. The targeted exon 
is depicted in purple and the modified exon in orange. Sequencing chromatogram is shown. (B) Southern blot of 
BAC construct after HindIII restriction digest. Scheme (left) illustrates location where the probe hybridizes and the 
size of the fragments. Orange triangle, introduced HindIII site; black triangles, HindIII sites in flanking sequences of 
Polrmt gene. (C) PCR and restriction digest analysis of the Polrmt BAC transgenic allele in genomic (gDNA) and 
reverse transcribed DNA (cDNA) from wild-type (+/+) and BAC transgenic Polrmt overexpressor (+/T) mice. (D) 
Pyrosequencing analysis of the ratio of wild-type (G) and transgenic (T) alleles in DNA isolated from tail biopsies in 
+/+ and +/T mice; n: 9 per genotype. (E) qRT-PCR analysis of steady-state Polrmt transcript levels in +/+ and +/T 
mouse hearts at different ages. Normalization: tata-binding protein (Tbp); ***p<0.001; ANOVA; n: 5 per genotype 
and age. (F) Western blot of POLRMT levels in +/+ and +/T in mitochondrial extracts from different tissues in 52-
week old mice. Loading: VDAC; Skm, skeletal muscle; BAT, brown adipose tissue. Percentage (%) is calculated 
relative to +/+ levels. Error bars ± sem.  
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3.1.2. Polrmt only encodes a mitochondrial protein in mammals 
 
We evaluated the expression of the alternative transcripts of Polrmt containing intron 1 or intron 
2 sequences reported to encode spRNAP-IV (Kravchenko & Chumakov 2005; Kravchenko et 
al. 2005) in wild-type mice. We performed RT-PCR on cDNA prepared from different mouse 
tissues but, surprisingly, we did not detect the previously described alternatively spliced Polrmt 
transcripts (Figure 3.1A, 3.3A and B). Next, we performed western blot analyses using an 
antibody directed against mouse POLRMT. Although we detected a ~140 kDa protein which 
corresponds to the molecular weight of POLRMT, we did not find a ~110 kDa protein 
corresponding to the spRNAP-IV in heart, skeletal muscle, kidney, spleen, liver or brain (Figure 
3.3C). To further verify that the ~140 kDa protein corresponded to the mitochondrial isoform, 
we performed subcellular fractionation in wild-type mouse heart and found this protein enriched 
in the mitochondrial fraction (Figure 3.3D). Finally, we evaluated the steady-state transcript 
levels of the genes proposed to be transcribed by spRNAP-IV in mouse heart and skeletal 
muscle of the conditional Polrmt knockout. The expression of the sarcoplasmic/endoplasmic 
reticulum calcium ATPase2 (Serca2) was reduced in heart (Figure 3.3E) which is a common 
finding associated to cardiomyopathy (Arai, Matsui & Periasami 1994). Furthermore, the levels 
of mt-16S rRNA were strongly reduced in skeletal muscle consistent with the loss of mtDNA 
transcription (Figure 3.3F). However, none of the other nuclear genes reported to be 
transcribed by spRNAP-IV were reduced in expression.  
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Figure 3.3 | Polrmt does not encode a nuclear isoform in mouse  
(A-B) RT-PCR analysis of Polrmt RNA (cDNA) and genomic DNA (gDNA) from control (L/L) mice in heart (A) and 
additional mouse tissues (B). Different primer sets were used as indicated. (C) Western blot analysis of steady-
state POLRMT levels on total protein extracts from different tissues of L/L mice. Loading: VDAC, Tubulin, and 
Coomassie blue. (D) Western blot analysis of subcellular fractions from 4-week old L/L mouse hearts. Loading and 
purity of fractions: histone H3 and VDAC; arrow indicates ~110 kDa.  (E-F) qRT-PCR analysis of steady-state 
transcript levels of nuclear genes in L/L and conditional Polrmt knockout (L/L, cre) mouse heart (E) and skeletal 
muscle (F). Normalized to beta 2 microglobulin (B2m); n: 6 per genotype; *p<0.05, **p<0.01, ***p<0.001; two-tailed 
Student t test. From Kühl et al. 2014. 
 
 Since we did not detect spRNAP-IV in the mouse, we proceeded to evaluate whether 
POLRMT codes for spRNAP-IV in human cell lines. First, we verified that the antibody against 
human POLRMT was specific and recognised both isoforms by silencing POLRMT and 
transiently overexpressing human POLRMT-EGFP and spRNAP-IV-Flag in human cervix 
adenocarcinoma HeLa cells followed by western blot analysis (Figure 3.4A and B).  
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Figure 3.4 | Human POLRMT antibody detects POLRMT and spRNAP-IV in human cells 
(A) Western blot analysis of total protein extracts isolated from HeLa cells after one (TF1) or two (TF2) transfections 
with small interfering RNA (siRNA) against human POLRMT. The cells were also transfected with a plasmid 
encoding a POLRMT-EGFP fusion protein. Control, siRNA against GFP. (B) Western blot analysis of HeLa cells 
transfected with a plasmid encoding spRNAP-IV with a Flag tag. Membranes were incubated with antibodies against 
human POLRMT, GFP, or Flag M2. Loading: tubulin. From Kühl et al. 2014 
 
Next, we performed subcellular fractionation in HeLa cells followed by western blot 
analysis and only detected a ~140 kDa protein enriched in the mitochondrial fraction consistent 
with our mouse data (Figure 3.4A). To verify that it was not a cell line specific effect or that the 
function of POLRMT in mtDNA gene expression masked the expression of spRNAP-IV, we 
performed the subcellular fractionation in human osteosarcoma 143B cells and 143B cells 
without mtDNA (143r0) and detected exclusively the ~140 kDa mitochondrial protein (Figure 
3.4B). To further corroborate the exclusive mitochondrial localization of the ~140 kDa protein, 
we performed confocal microscopy using the endogenous POLRMT antibody (Figure 3.4C) 
and did not find the nuclear spRNAP-IV. As a control, we expressed spRNAP-IV fused to GFP 
and this construct strongly showed an extra-nuclear localization (Figure 3.4D). Finally, we 
performed RT-PCR experiments on genomic DNA (gDNA) and cDNA from different human 
cell lines to identify the alternative spliced POLRMT transcript, containing intron 1 sequences 
using the same primers as the original publication (Kravchenko & Chumakov 2005), but could 
not verify the existence of the alternative POLRMT transcript (Figure 4.3E). Collectively, our 
data in different human cell lines and mouse tissues conclusively show that Polrmt only 
encodes POLRMT which is exclusively a mitochondrial protein. 
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Figure 3.5 | Polrmt does not encode a nuclear isoform in human cells 
(A-B) Western blot analysis of subcellular fractions from HeLa (A), 143B and 143Br0 (B). Loading and purity of 
fractions: histone H3 and VDAC; arrow indicates ~110 kDa. (C) Immunostaining of endogenous POLRMT in HeLa 
cells. Scale bar: 25 mm. (D) Live-cell imaging of HeLa cells expressing spRNAP-IV fused to EGFP. Scale bar: 10 
µm. (E) RT-PCR analysis of Polrmt RNA (cDNA) and genomic DNA (gDNA) from different human cell lines. Primers 
are identical to those previously used by (Kravchenko & Chumakov 2005). From Kühl et al. 2014. 
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3.1.3. Loss of POLRMT in heart causes dilated cardiomyopathy due to severe OXPHOS 
dysfunction 
 
We proceeded to study the function of POLRMT in mammalian mitochondria. Subsequent 
intercrosses of Polrmt+/− mice did not produce any viable homozygous Polrmt knockout mice 
(Polrmt-/-) (genotyped offspring, n: 56; Polrmt+/−: 66%, Polrmt+/+: 34%, Polrmt−/−: 0%). We 
therefore analysed staged embryos at embryonic day (E) 8.5 (n: 47) and found that 23% of the 
embryos had a mutant appearance and all had the genotype Polrmt−/−, whereas the normally 
appearing embryos were either Polrmt+/+ (28%) or Polrmt+/− (49%) (Figure 3.6). Thus, loss of 
POLRMT leads to embryonic lethality at E8.5.  
 
 
Figure 3.6 | Loss of POLRMT is embryonic lethal  
Morphology of +/+ and homozygous Polrmt knockout (-/-) embryos at E8.5. Scale bar: 0.5 mm.  
 
The heart and skeletal muscle conditional knockout mice died before 6 weeks of age 
(Figure 3.7A) and showed a progressive enlargement of the heart with dilation of the left 
ventricular chamber and no apparent increase in the left ventricular wall thickness (Figure 
3.7B). The development of dilated cardiomyopathy was further confirmed by a progressive 
increase in the heart to body weight ratio during the first weeks of postnatal life (Figure 3.7C).  
 
 
Figure 3.7 | Loss of POLRMT in the heart causes dilated cardiomyopathy 
(A) Survival curve of control (L/L; n: 60) and tissue-specific knockout (L/L, cre; n: 37) mice. (B) Histological analysis 
of cardiac phenotype: vertical (upper panels) and transverse (lower panels) sections through the midportion of 
hearts of L/L and L/L, cre mouse hearts at 4 weeks of age. Scale bars: 2 mm. (C) Heart to body weight ratio of L/L 
(n: 62) and L/L, cre (n: 57) at different time points. Error bars ± sem; ***p<0.001; two-tailed Student’s t-test. From 
Kühl et al. 2016. 
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Transmission electron microscopy of terminal-stage heart tissue revealed a profound 
disruption in the cardiac tissue ultrastructure where mitochondria had an abnormal appearance 
with disorganized cristae (Figure 3.8A) suggesting a severe mitochondrial defect. Analysis of 
OXPHOS capacity in Polrmt knockout hearts confirmed that the enzyme activities of 
complexes I, IV and V were decreased, whereas the activity of the exclusively nucleus-
encoded complex II was normal (Figure 3.8B). Moreover, blue native polyacrylamide gel 
electrophoresis analysis (BN-PAGE) showed reduced levels assembled complexes I, IV, and 
V (Figure 3.8C). The observed pattern of deficient OXPHOS sparing complex II is typically 
caused by impaired mtDNA gene expression (Cámara et al. 2011; Milenkovic et al. 2013; 
Ruzzenente et al. 2012). 
 
 
Figure 3.8 | Reduced OXPHOS capacity in Polrmt knockout mouse heart  
(A) Transmission electron micrographs of myocardium of 5-week old control (L/L) and tissue-specific knockout mice 
(L/L, cre). Scale bar upper panel: 2 µm, lower panel: 0.5 µm; n: 2 per genotype. (B) Relative enzyme activities of 
respiratory chain enzymes measured in heart mitochondrial extracts from L/L and L/L, cre mice at different ages. 
Citrate synthase was used as an internal control for normalization of the samples. The enzymes measured are: CS, 
citrate synthase; Complex II (CII), succinate dehydrogenase; Complex I (CI), NADH ubiquinone oxidoreductase; 
Complex IV (CIV), Cytochrome c oxidase; Complex V (CV), ATPase oligomycin sensitive. **p <0.01, ***p <0.001; 
two-tailed Student’s t-test; n: 4 per genotype; error bars ± sem; (C) BN-PAGE analyses of isolated mitochondria 
from 5-week old L/L and L/L, cre hearts. OXPHOS complexes were detected with subunit-specific antibodies or 
Coomassie Brilliant Blue staining. NDUFA9, CI; SDHA, CII, mt-CO2, CIV, ATP5A, CV. From Kühl et al. 2016. 
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3.1.4. Moderate alterations in POLRMT do not affect OXPHOS capacity 
 
Contrary to the complete loss of POLRMT, moderate changes on POLRMT levels did not 
cause any apparent phenotype. Heterozygous Polrmt knockout and Polrmt overexpressor 
mice were viable, fertile, and healthy after 1 year of age. Polrmt overexpressors had normal 
body weight until 20 weeks of age, and normal heart to body weight ratios at 13, 26, and 52 
weeks (Figure 3.9A-C). We next proceeded to evaluate whether moderately increased levels 
of POLRMT had an effect OXPHOS capacity. Western blot analyses of respiratory chain 
subunits showed normal levels of NDUFB8 (complex I), SDHB (complex II), UQCRC2 
(complex III), mt-CO1 (Complex IV) and ATP5A1 (complex V) in the Polrmt overexpressor 
mice (Figure 3.9D). Furthermore, there were no differences in the activity of the respiratory 
chain complexes (Figure 3.9E) and respiration capacity in heart (Figure 3.9F) or liver (data not 
shown). Taken together, our data show that moderate alterations in POLRMT levels do not 
affect mitochondrial OXPHOS capacity. 
 
 
Figure 3.9 | Polrmt overexpressor mice does not have any detectable effect on OXPHOS capacity 
(A) Histogram of genotype distribution of the wild-type (+/+) and Polrmt overexpressor (+/T) offspring; n.s: p>0.05; 
chi-square test. (B) Body weight curve of male (left) and female mice (right); n: 8-16 per sex and genotype (C) Heart 
to body weight ratio at different ages; n: 3-5 per age and genotype (D) Western blot of OXPHOS subunits levels in 
isolated mitochondria from heart at different ages; loading: SDHB (complex II; CII) and VDAC. (E) Relative enzyme 
activities of respiratory chain enzymes measured in mitochondria isolated from heart at 13 weeks of age. The 
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enzymes measured are: citrate synthase (CS); Complex I (CI): NADH ubiquinone oxidoreductase, Complex II (CII): 
succinate dehydrogenase, Complex II-III: Succinate dehydrogenase - cytochrome c reductase, Complex IV (CIV): 
Cytochrome c oxidase. CS was used as an internal control for normalization of the samples; n: 3 per genotype. (F) 
Oxygen consumption analysis on isolated mitochondria. Mitochondria were incubated with pyruvate, glutamate, 
and malate to deliver electrons to CI or with succinate and rotenone to deliver electrons to CII. Permeabilized cell 
respiration was analyzed in the phosphorylating (state3), non-phosphorylating (state4), and uncoupled states. n: 3 
per genotype. Error bars ± sem. 
 
3.1.5. LSP-initiated transcription is favoured at low POLRMT levels 
 
Consistent with the function of POLRMT as the mitochondrial RNA polymerase, loss of 
POLRMT lead to a profound decrease in de novo transcription of mtDNA in the conditional 
Polrmt knockout heart (Figure 3.10A). Furthermore, northern blot and RNA sequencing 
analyses (RNA-Seq) showed a general reduction in the steady-state levels of all mt-mRNAs, 
mt-rRNAs and mt-tRNAs (Figure 3.10B-D). Thus, no other protein can compensate for the loss 
of POLRMT in mammalian mitochondria. Notably, we observed that the steady-state levels of 
most of the mitochondrial transcripts encoded on the L strand, i.e. mt-Nd6, mt-Tp, mt-Te, mt-
Ts2, mt-Tc, mt-Tn, and mt-Tq, were less reduced than transcripts encoded on the H strand, 
i.e. mt-12S rRNA, mt-16S rRNA, mt-Nd1, mt-Co1, mt-Co2, mt-Co3, mt-Nd5, mt-Cytb, mt-Tf, 
mt-Tl1, mt-Tm, mt-Tk, mt-Tl2 and mt-Tt (Figure 3.10B-D). To determine whether the difference 
in mitochondrial steady-state transcript levels was due to promoter-specific transcription 
initiation effects due to low POLRMT levels, we performed in vitro transcription assays (Figure 
3.10E and F). We detected a strong reduction of the transcription initiation from an HSP 
containing construct in comparison to the LSP at POLRMT concentrations below 32 nM (Figure 
3.10E and F), indicating that transcription initiation at the LSP is stronger at low POLRMT 
levels. 
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Figure 3.10 | LSP and HSP show different sensitivities at low POLRMT concentrations  
(A) De novo synthesized mitochondrial transcripts from hearts of 4-week old control (L/L) and conditional knockout 
(L/L, cre) mice. Steady-state levels of individual mitochondrial transcripts were verified with a radiolabelled probe 
(mt-Co1); input: western blot analysis of VDAC on radiolabelled mitochondria. (B-C) Northern blot analyses of mt-
mRNAs, mt-rRNAs and mt-tRNAs from hearts of 4-week old L/L and L/L, cre mice; loading: 18S rRNA. (D) RNA-
Seq of mt-mRNA and mt-rRNA levels in hearts of 4-week old L/L, cre and L/L mice normalized to the upper quartile 
of the gene count distribution. All mt-RNAs have p≤ 0.0001; n: 3 mice per genotype; error bars: ± sem. (E) In vitro 
transcription assay at different POLRMT levels. All reactions contained a cut plasmid template containing the human 
LSP and HSP promoters giving a run-off product of 101 nt and 180 nt, respectively. POLRMT was added at 128, 
32, 8, 2, 0.5 nM in lanes 1-5 respectively; lane 6: control without POLRMT; lane 7: molecular weight marker (New 
England Biolabs). (F) Quantification of the results from D. HSP transcription levels were normalized to LSP for each 
POLRMT concentration; n: 3 independent experiments; error bars: ± sd; from Kühl et al. 2014, 2016. 
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3.1.6. POLRMT is essential for mammalian mtDNA replication  
 
Since in vitro studies have suggested that transcription initiation from the LSP also forms the 
primers required to initiate mtDNA replication (Gillum & Clayton 1979), we evaluated the effect 
of loss of POLRMT in mtDNA replication. 7S RNA is the most promoter-proximal transcript 
formed by transcription initiation at the LSP of mtDNA (Gillum & Clayton 1979) and we found 
this transcript strongly reduced in Polrmt knockout hearts (Figure 3.11A). To further investigate 
this in vivo, we evaluated the steady-state levels of 7S DNA and found them also severely 
reduced pointing to a defect in mtDNA replication (Figure 3.11B). In line with this, there was a 
strong depletion of mtDNA in the Polrmt knockout hearts (Figure 3.11C and D). Next, we 
performed in organello mtDNA replication experiments to determine whether the reduced 
levels of 7S DNA and mtDNA molecules were due to decreased formation or increased 
degradation. We found 7S DNA and mtDNA de novo synthesis severely reduced (Figure 
3.11E) suggesting a defect in initiation of mtDNA replication. Collectively, our data demonstrate 
that POLRMT is required for mtDNA replication in vivo.  
 
 
Figure 3.11: Decreased mtDNA replication in Polrmt knockout mice 
(A) Northern blot of 7S RNA levels of total RNA from control (L/L) and tissue-specific knockout (L/L, cre) hearts at 
different ages; loading: 18S rRNA. RNA from hearts of Mterf4 conditional knockout mice (Cámara et al. 2011) with 
increased 7S RNA levels were loaded as controls. (B) Southern blot analysis on mtDNA to assess 7S DNA levels 
of 4-week old L/L and L/L, cre mice. To allow relative comparison, the loaded amount of mtDNA from knockouts 
was higher than the amount loaded from control samples. (C) Southern blot analyses on total DNA to assess mtDNA 
levels of L/L and L/L, cre mice at different ages; loading: 18S rDNA. (D) Quantification of Southern blots. mtDNA 
levels were normalized to 18S rDNA and presented as the percentage of L/L. Error bars: ± sem; **p <0.01; two-
tailed Student’s t-test. (E) De novo synthesized mtDNA of isolated heart mitochondria of 4-week old L/L and L/L, 
cre mice; input: western blot analysis of VDAC after labelling. From Kühl et al. 2016. 
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3.1.7. Heterozygous Polrmt knockout mice show increased TEFM levels and maintain 
mitochondrial transcription  
 
To assess the effect of moderate reduction of POLRMT in mtDNA replication and transcription 
we characterized the heterozygous Polrmt knockout mice. There was no significant effect on 
the steady-state levels of mt-mRNAs, mt-rRNAs and mt-tRNAs in the heterozygous Polrmt 
knockout mice (Figure 3.12A). Consistent with the normal mt-mRNA levels, the steady-state 
levels of LRPPRC, known to bind and stabilize mt-mRNAs (Ruzzenente et al. 2012), were not 
changed (Figure 3.12B). RNA-Seq analysis showed that the mt-Nd6 transcript encoded on the 
L strand was slightly reduced, whereas all other mt-rRNAs and mt-mRNAs encoded on the H 
strand showed a tendency to be increased in heterozygous Polrmt knockout hearts at 26 
weeks of age, however not significant (Figure 3.12C). Interestingly, we observed a strong 
increase in TEFM protein levels (Figure 3.12B), which may provide a compensatory response 
to the decreased levels of POLRMT by promoting productive full-length transcription 
heterozygous Polrmt knockout mice. This hypothesis was supported by the slight increase in 
de novo transcription in heart mitochondria (Figure 3.12D). The other components of the basal 
transcription machinery, TFAM and TFB2M, remained unchanged (Figure 3.12B). 
Furthermore, the levels of 7S RNA and mtDNA were normal (Figure 3.12E and F), thus 
showing that promoter proximal transcription at LSP is sufficient to maintain mtDNA replication 
and gene expression. Finally, de novo formation of 7S DNA was not decreased when POLRMT 
was reduced (Figure 3.12G). Consistent with normal mtDNA levels and replication, TFAM, 
TWINKLE, POLgA, and SSBP1 protein levels remained unchanged. Thus, a moderate 
reduction of POLRMT expression does not affect overall mtDNA replication or transcription. 
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Figure 3.12 | Characterization of heterozygous Polrmt knockout mice  
(A) Northern blot of analysis of mt-mRNAs, mt-rRNAs and mt-tRNAs in wild-type (+/+) and heterozygous knockout 
(+/-) mice; loading control: 18S rRNA. (B) RNA-Seq on mitochondrial mt-mRNAs and mt-rRNA in heart of 26-week 
old +/+ and +/- mice; normalized to upper quartile of the gene count distribution; n: 3 per genotype. (C) Western 
blot of levels of nDNA factors of mtDNA gene expression analysed on heart mitochondrial extracts of +/+ and +/- 
mice; loading: VDAC; asterisk: cross-reacting band. (D) De novo synthesized mitochondrial transcripts from heart 
of 52-week old mice in +/+ and +/- mice. Steady-state levels of individual mitochondrial transcripts were verified 
with a radiolabelled probe (mt-Co1); input: western blot analysis of POLRMT and VDAC after labelling. (D) Northern 
blot of 7S RNA levels in mouse hearts of +/+ and +/- mice; loading: 18S rRNA. (E) qPCR determination of mtDNA 
levels in +/+ /- mice with mt-Co1, mt-Nd1 and mt-Nd5 probes on mouse heart. Normalization: 18S rDNA; n: 3 per 
genotype. (F) De novo synthesized mtDNA of isolated mitochondria from hearts of 12-week old +/+ and +/- mice. 
Radioactively labelled mtDNA was boiled to release newly synthesized 7S DNA prior Southern blotting; input: 
western blotting of POLRMT and VDAC after labelling. Error bars ± sem. From Kühl et al. 2016.  
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3.1.8. POLRMT is a limiting factor for transcription initiation in vivo 
 
We then studied the effect of Polrmt overexpression on mtDNA replication and transcription in 
mouse heart. 7S RNA levels were significantly increased in different tissues of the Polrmt 
overexpressor mice (Figure 3.13A) and the levels were maintained at different ages (Figure 
3.13B and C). To evaluate whether this increased transcription initiation from LSP affected 
mtDNA replication, we performed Southern blot analysis and found a mild but significant 
increase in mtDNA levels (~17%) in Polrmt overexpressor mouse hearts (Figure 3.13D and 
E). In line with this, de novo mtDNA synthesis had the tendency to be increased (Figure 3.13F 
and G), suggesting that increased POLRMT levels might have a minor effect on mtDNA 
replication.  
 
 
Figure 3.13 | Increased 7S RNA levels in Polrmt overexpressor mice 
(A) Northern blot analysis of 7S RNA levels in different tissues of a wild-type (+/+) and overexpressor (+/T) 52-week 
old mice. (B) Northern blot analyses of 7S RNA levels in heart and at different ages. (C) Quantification of 7S RNA 
levels at different ages. Normalization 18S rRNA. ***p<0.001; ANOVA; n: 3-6 per age and genotype. (D-E) Southern 
blot analysis and quantification of mtDNA levels in heart of 14-week old mice. Normalization 18S rDNA. *p<0.05; 
two-tailed Student’s t-test; n: 4 per genotype. (F-G) In organello replication on isolated mitochondria from heart at 
different ages (F) and quantification (G). Input: Western blot of VDAC and steady-state mtDNA levels. 
Normalization: steady-state mtDNA levels; n: 5 per genotype. Error bars ± sem. 
 
Consistent with the increased 7S RNA steady-state levels, we found a strong increase 
in de novo transcript synthesis in isolated mitochondria from heart of Polrmt overexpressor 
mice (Figure 3.14A and B). There was no accumulation of specific transcription products 
indicating that the increase in de novo transcription is homogeneous and that there is normal 
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processing of the polycistronic mt-RNAs. Despite the strong increase in de novo transcript 
synthesis, steady-state levels of mt-RNAs were not changed except for the precursor mt-
Nd5/mt-Cytb, mt-Cytb, and mt-Tf that were mildly increased (Figure 3.24C-E). 
 
 
Figure 3.14 | Increased de novo transcription in Polrmt overexpressor mice 
(A) De novo synthesized mitochondrial transcripts from hearts of 14-week old wild-type (+/+) and overexpressor 
(+/T) mice. Steady-state levels of individual mitochondrial transcripts were verified with a radiolabelled probe (mt-
Nd6); input: western blot analysis VDAC on radiolabeled mitochondrial extracts. (B) Quantification of de novo 
synthesized mitochondrial transcripts of mice at different ages (14 and 26 weeks of age) normalized to VDAC and 
+/+. *p<0.05; one-sample Student’s t-test; µ: 100; n: 10 per genotype. (C) RNA-Seq of mt-rRNAs and mt-mRNAs 
on total RNA from heart of 14-week old mice. n: 3 per genotype (D) Northern blot analyses of mt-RNA levels in 
heart of 14-week old mice. (E) Quantification of mt-RNA levels; normalization 18S rRNA; *p<0.05; two-sample 
Student t-test; n: 6 per age and genotype. Error bars ± sem.  
 
Next, we evaluated the protein levels of factors required for mtDNA maintenance 
(TFAM), replication (TWINKLE, SSBP1, POLRMT), transcription (POLRMT, TFAM, TEFM, 
TFB2M), RNA processing and stability (GRSF1, ELAC2, LRPPRC, and SLIRP), and 
translation (MRPL12, MRPL37, and MRPS35) (Figure 3.15A) and found no differences except 
for POLRMT. To identify if other factors involved in mitochondrial RNA metabolism vary in the 
Polrmt overexpressor mice, we performed a label-free proteomic analysis on purified 
mitochondria isolated from heart, skeletal muscle, and liver. We did not detect any 
mitochondrial protein involved in mt-RNA metabolism to be upregulated in any of the tissues; 
in fact, the majority of significantly changed proteins were downregulated (Figure 3.15B). We 
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did not identify common proteins with differences in expression in the three tissues except for 
an isoform of glutaminase (GLS) that was downregulated in heart and liver. In heart, the ATP-
dependent RNA helicase SUPV3L1 and TFB1M were ~20 and ~50% decreased, respectively 
(Figure 3.29B). Interestingly, in the skeletal muscle, the 12S rRNA chaperone Era G-protein 
like 1 (ERAL1) was also 50% decreased in the Polrmt overexpressor mice (Figure 3.28B). 
Other proteins involved in mtDNA gene expression such as MRPL22, MRPL57, MRPL12, were 
changed in heart, and FASTKD2 in skeletal muscle, and MRPS12 in liver. These potential 
changes still have to be validated by western blot. Since additional factors required for 
mitochondrial transcription, i.e. TFAM, TEFM, and TFB2M, were not changed in Polrmt 
overexpressor mice (Figure 3.15A), our data argues that POLRMT is limiting mitochondrial 
transcription and, potentially, mtDNA replication. However, the system is very robust and 
maintains steady-state transcripts at wild-type levels. 
 
 
Figure 3.15 | Mitoproteome of Polrmt overexpressor mice in different tissues 
(A) Western blot of factors required for mtDNA gene expression in control (+/+) and Polrmt overexpressor (+/T) 
mice. Loading: VDAC. (B) Volcano plots of mitoproteomic analyses of heart, skeletal muscle, and liver in 52-week 
old mice; adj. p value: Benjamini-Hochberg adjusted p value; n: 5 per genotype; grey dots: p>0.05; black dots: 
p<0.05; dotted line, p=0.05. 
 
3.1.9. Polrmt overexpression increases transcription capacity 
 
We hypothesized that discrepancy between de novo transcription and steady-state transcript 
levels in the Polrmt overexpressor mice was explained by lack of stability due to limiting RNA 
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binding proteins stabilizing the newly synthesized transcripts. To test this hypothesis, we 
performed pulse-chase in organello transcription labelling experiments but did not find 
differences in RNA stability between wild-type and Polrmt overexpressor mice after 2 h chase 
(Figure 3.16A and B). Furthermore, we crossed the Polrmt overexpressor mice to mice 
overexpressing Lrpprc (Figure 3.16C) (Ruzzenente et al. 2012) to increase the stability of de 
novo synthesized transcripts in vivo. Importantly, overexpression of Lrpprc alone does not 
affect de novo transcript synthesis or mature steady-state mt-RNAs (Harmel et al. 2013). 
However, the steady-state transcript levels remained at wild-type levels even when POLRMT 
and LRPPRC are moderately increased (Figure 3.16D).  
 
 
Figure 3.16 | Stability of mt-RNAs is not affected in Polrmt overexpressor mice  
(A) De novo synthesized mitochondrial transcripts from hearts of 26-week old wild-type (+/+) and overexpressor 
(+/T) mice (pulse). The mRNA decay of de novo synthesized transcripts was followed after 2h (chase). Input: 
western blot analysis VDAC on radiolabelled mitochondrial extracts. (B) Quantification of de novo synthesized 
mitochondrial transcripts normalized to VDAC and pulse signal; n: 4 per genotype. (C) Western blot of steady-state 
POLRMT and LRPPRC level in mitochondrial extracts from heart. Loading: VDAC. (D) RNA-Seq of mt-rRNAs and 
mt-mRNAs on total RNA from heart of 14-week old Polrmt overexpressor or Polrmt and Lrpprc overexpressor mice. 
n: 3 per genotype (D) Northern blot analyses of mt-RNA levels in heart of 14-week old mice. (E) Quantification of 
mt-RNA levels; normalization 18S rRNA; n: 6 per age and genotype. *p<0.05; two-sample Student t-test; Error bars 
± sem.  
 
Interestingly, increased POLRMT levels have been reported as a compensatory 
response to loss of mtDNA replication in the heart  of Twinkle conditional knockout mice 
(Milenkovic et al. 2013). We verified the protein levels of POLRMT in different knockout mouse 
strains with impaired mtDNA gene expression and found it increased in all the models (Figure 
3.17A). However, Polrmt transcript levels were slightly decreased or not significantly changed 
(Figure 3.17B). These data indicate that the increase in POLRMT is not a compensatory 
response mediated at the transcriptional level and rather suggest that POLRMT is either more 
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translated or stabilized post-transcriptionally in mtDNA gene expression deficient mice. Thus, 
our data suggest that increasing POLRMT increases the transcription capacity but under 
normal physiological conditions this increase is not used further and results in the accumulation 
of prematurely terminated transcription products. However, under pathological conditions it 
might be a mechanism to rapidly increase mtDNA gene expression as a compensatory 
response.  
 
 
Figure 3.17 | POLRMT is increased in mouse models deficient in mtDNA gene expression 
(A) Western blot of POLRMT levels in mitochondrial extracts from heart from control (L/L) and knockout (L/L, cre) 
mice. Loading: VDAC. (B) RNA-Seq transcript levels of Polrmt from L/L, cre compared to L/L mice. *p<0.05, 
***p<0.001. Modified from Kühl, Miranda et al. 2017 
 
3.1.10.  Secondary changes in levels of proteins involved in mtDNA gene expression upon loss 
of POLRMT 
 
To study additional molecular changes associated with loss of mtDNA replication and 
transcription in the Polrmt knockout mouse, we assessed the expression of known nuclear-
encoded mitochondrial proteins involved in mtDNA gene expression. Despite the strong 
reduction in mtDNA replication, the protein levels of TFAM, SSBP1 and POLgA remained 
unchanged whereas the TWINKLE helicase was strongly upregulated (Figure 3.18A). 
Transcript levels of Tfam were increased by ~50% in Polrmt knockout mice suggesting an 
increase in TFAM synthesis (Figure 3.18B). To determine whether TFAM was stabilized by 
binding to the remaining mtDNA in the nucleoid, we performed linear density glycerol 
gradients. Nucleoid-containing fractions were determined by the presence of mtDNA, which 
was verified by Southern blot and the presence of mtDNA replication factors like TWINKLE 
and POLgA (Figure 3.18C). Surprisingly, in mitochondria isolated from Polrmt knockout hearts 
there was a clear increase of TFAM in the mtDNA-free fractions (Figure 3.18D and E) that is 
thus not degraded by LONP1 despite the increased steady-state levels of LONP1 (Figure 
3.18A). The other two transcription factors in mitochondria, TFB2M and TEFM, show opposite 
patters. Steady-state protein levels of TFB2M are drastically reduced the absence of POLRMT 
suggesting that POLRMT is required for its stability, whereas TEFM is stable or slightly 
increased in Polrmt knockout hearts.  
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Figure 3.18 | mtDNA-free pool of TFAM increases in Polrmt knockout hearts 
(A) Western blot analysis of steady-state protein levels of nDNA factors required for mtDNA gene expression on 
mitochondrial extracts from hearts of control (L/L) and tissue-specific knockout (L/L, cre) mice at different ages; 
loading: VDAC; asterisk: cross-reacting band. (B) qRT-PCR of transcript levels of nDNA mitochondrial proteins in 
L/L and L/L, cre mouse hearts. Normalization: beta 2 microglobulin (B2m). *p<0.05, **p<0.005, ***p<0.001; 
Student’s t-test; n: 5-21 per genotype; error bars: ± sem. (C-D) Linear glycerol density gradient fractionations of 
mitochondrial lysates from L/L and L/L, cre followed by western blot analysis and Southern blot. Gel numbers (1 to 
16) correspond to fractions with increasing density as indicated in the scheme in the left. mtDNA-containing fractions 
was determined by Southern blotting. (E) Relative TFAM and POLRMT protein distribution across the gradient from 
L/L and L/L, cre mice. From Kühl et al. 2016. 
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At the RNA processing level, both ELAC2 and GRSF1 were strongly increased in Polrmt 
knockout hearts (Figure 3.18A). On the contrary, LRPPRC is strongly decreased in line with 
the decreased mt-mRNA levels (Figure 3.18A) (Ruzzenente et al. 2012; Sasarman et al. 2010). 
Loss of POLRMT also lead to a decrease in proteins of small and large mitoribosomal subunits 
(MRPS35 and MRPL37), but not of MRPL12 that is suggested to have an additional role in 
mtDNA transcription (Surovtseva et al. 2011). In agreement with the loss of mtDNA gene 
expression and OXPHOS capacity (Figure 3.14), levels of mtDNA-encoded cytochrome c 
oxidase subunits 1 and 2 (mt-CO1 and mt-CO2) are decreased upon loss of POLRMT (Figure 
3.18A). Thus, loss of POLRMT affects protein levels of factors in several steps of mtDNA gene 
expression probably because they depend on the presence of POLRMT, mtDNA, or mt-RNAs 
for their stability or to compensate for the loss of these essential functions.
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3.2. The cellular transcriptome and mitochondrial proteome of OXPHOS deficient 
mouse heart 
 
3.2.1. An integrated omics approach to study loss of mtDNA gene expression and progressive 
OXPHOS deficiency  
 
To obtain a comprehensive view of the cellular processes affected by OXPHOS dysfunction, 
we determined the cellular transcriptome and mitochondrial proteome (mitoproteome) from 
heart of five conditional knockout mouse strains deficient on genes essential for mtDNA gene 
expression that had been previously characterized in the laboratory. Mitochondrial DNA gene 
expression was disrupted at the level of replication (Twnk; Milenkovic et al. 2013), 
maintenance (Tfam; Larsson et al. 1998), transcription (Polrmt; section 3.1 of this thesis; Kühl 
et al. 2014; Kühl et al. 2016), RNA processing and stability (Lrpprc; Ruzzenente et al. 2012), 
and translation (Mterf4; Cámara et al. 2011). All of these knockouts have a drastically reduced 
lifespan ranging from <6 – 21 weeks of age due to severe cardiomyopathy caused by 
progressive OXPHOS dysfunction (Figure 3.19A; Table 3.1).  
 
Table 3.1: Summary of the main characteristics of the tissue-specific mouse strains 
Mouse strain Twnk Tfam Polrmt Lrpprc Mterf4 
Gene product Mitochondrial 
DNA replicative 
helicase 
TWINKLE 
Mitochondrial 
transcription 
factor A 
Mitochondrial 
RNA 
polymerase 
Leucine-rich 
pentatrico-
peptide repeat 
containing 
protein 
Mitochondrial 
transcription 
termination 
factor 4 
Lifespan 
(weeks) 
<19 <10 <6 <16 <21 
mtDNA levels ¯ ¯ ¯ ~ ­ 
mt-RNA levels ¯ ¯ ¯ ¯* ­ 
OXPHOS ¯ ¯ ¯ ¯ ¯ 
Reference Milenkovic et al. 
2013 
Larsson et al. 
1988 
This thesis; 
Kühl et al. 
2014; 2016 
Ruzzenente et 
al. 2011 
Cámara et al. 
2011 
* except mt-12S rRNA, mt-16S rRNA, mt-Nd6, and most mt-tRNAs. 
Arrows: increase or decrease; ~ not changed. 
From Kühl, Miranda et al. 2017 
 
The cellular transcriptome was determined using RNA-Seq on total RNA isolated from 
heart of all the knockouts at their end-stage and corresponding age-matched controls. In 
parallel, we determined the mitoproteome of all the knockout strains using label-free mass 
spectrometry quantification (LFQ) on percoll-purified mitochondria from heart (Figure 3.19B). 
The transcriptomic and mitoproteomic data was used to generate three datasets. First, we 
characterized the changes in mitochondrial biogenesis and gene expression in a time-course 
analysis of wild-type or control mice from infancy (3 weeks) until adulthood (26 weeks). 
Second, we performed differential expression analysis of each knockout compared to its age-
matched control which resulted in a catalogue of expression profiles of genes encoding 
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mitochondrial proteins affected by loss of mtDNA gene expression at different stages and 
severe OXPHOS deficiency. Third, we complemented our knockout comparison with a 
temporal mitoproteomic analysis of heart of Lrpprc conditional knockouts and age-matched 
controls at 2, 3, 5, 7 and 10 weeks of age to study the progression of OXPHOS deficiency 
(Figure 3.19B and C).  
 
 
Figure 3.19 | Omics approach to study progressive OXPHOS dysfunction  
(A) Schematic representation of the tissue-specific knockout (L/L, cre) mouse strains with disrupted mtDNA gene 
expression and corresponding controls (L/L). mtDNA-encoded proteins are depicted in blue and nDNA 
mitochondrial proteins in yellow. (B) Experimental workflow of data acquisition and analysis of the transcriptome 
and mitoproteomes from mouse heart generating three datasets (1-3). (C) Western blot (left) and LFQ quantification 
(right) of LRPPRC steady-state levels in time-course analysis of Lrpprc knockout strain. Loading: VDAC. From Kühl, 
Miranda et al. 2017. 
 
Filtering for mitochondrial proteins in all datasets was performed based on MitoCarta 
2.0 (Calvo, Clauser & Mootha 2016) and all differentially regulated mitochondrial transcripts or 
genes were manually classified into 18 functional categories based on annotated functions in 
Uniprot database (The UniProt Consortium 2017) and literature search (Table 3.2; Figure 
3.19B).  
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Table 3.2: List of manually classified functional categories 
Functional category 
 
Apoptosis 
Degradation and stress response 
Iron sulphur cluster and heme biogenesis 
Lipid and acetyl CoA metabolism 
Mitochondrial transcription and mt-RNA metabolism 
Mitochondrial 1C pathway 
Mitochondrial carriers or transport 
Mitochondrial import and chaperones 
Mitochondrial morphology 
Mitochondrial ribosome 
mtDNA maintenance and replication 
Nucleotide synthesis 
Other mitochondrial protein synthesis factors 
OXPHOS 
OXPHOS assembly and biogenesis 
Pyruvate and amino acid metabolism 
Ubiquinone biosynthesis 
Other 
 
 
The resulting databases from this study were published as a resource and are available 
to the scientific community (Kühl et al. 2017). 
  
3.2.2. Technical considerations of transcriptomic and mitoproteomic data acquisition and 
analysis 
 
The heart is a complex tissue with a high dynamic range in terms of RNA and protein 
abundance. RNA-Seq techniques have a broad dynamic range which allows the accurate 
quantification of lowly and highly abundant transcripts simultaneously. This was reflected in 
the >27000 quantified transcripts in the different knockout strains, from which ~1118 encode 
mitochondrial proteins. In proteomics, however, the dynamic range is still problematic as highly 
abundant proteins limit the detection of lowly abundant ones. It was recently shown that 
mitochondrial contribution to the total heart protein mass in humans ranges from 2 to 21% 
depending on the heart region (Doll et al. 2017). Therefore, we analysed isolated heart 
mitochondria that had been purified on percoll gradients to reduce the complexity of the 
samples and gain more depth in our mitoproteome mass spectrometry analyses. We had a 
very high enrichment of mitochondrial proteins which accounted for ~99% of the total protein 
mass quantified. In total, we identified ~1000 proteins in the different knockout strains from 
which ~750 were quantified and ~650 were mitochondrial (Figure 3.20A). We did not find any 
significant bias in the detection of proteins based on their charge or hydrophobicity as 
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evidenced by cumulative distribution plots of the quantified and non-quantified proteins versus 
isoelectric point or GRAVY score, respectively (Figure 3.20B and C). However, we still had a 
significant bias against the detection of lowly abundant proteins (Figure 3.20D).  
 
 
Figure 3.20 | Enrichment of mitochondrial proteins and systematic bias in mitoproteome data acquisition. 
(A) Number of identified, quantified, and mitochondrial proteins in each knockout mouse strain. Error bars: ± sem. 
(B-D) Cumulative distribution of quantified mitochondrial proteins based on isoelectric point as a measure of charge 
(B), GRAVY score as a measure of hydrophobicity (C), and mean RNA count of control (L/L) samples across all 
mouse strains as a measure of protein abundance (D). Isoelectric point and GRAVY scores were calculated using 
the amino-acid sequence of each protein without the first methionine and predicted N-terminus mitochondrial 
targeting sequence. Black, quantified in at least one knockout strain; red, not quantified. From Kühl, Miranda et al. 
2017. 
 
To evaluate the reproducibility in the data acquisition we calculated the Pearson 
correlation of the normalized counts for transcriptomics and LFQ intensity for proteomics. We 
had a very high reproducibility with Pearson correlation coefficient > 85% across all samples 
and > 95% between biological replicates for both, transcriptomics and proteomics (Figure 
3.21). The high reproducibility and good number of biological replicates for a mouse omics 
study (n > 3 for all the analyses) allowed us to have good statistical robustness for subsequent 
analyses.  
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Figure 3.21 | High reproducibility of transcriptomic and mitoproteomic data 
(A-B) Heatmaps showing the Pearson correlation coefficient (r) for RNA-Seq normalized counts (A) and LFQ 
intensity (B) of all the controls (L/L) and knockouts (L/L, cre). As an example, a scatter plot for the LFQ intensity 
values and r for two Polrmt L/L, cre samples is shown. Each square represents the comparison of two biological 
samples. Heatmaps were generated using the same scale. From Kühl, Miranda et al. 2017. 
 
 Standard inclusion criteria for proteomic data analysis filters for proteins that are 
quantified in at least half of the samples analysed. However, we included all the proteins that 
were quantified in at least half of the samples of a single genotype in the comparison of the 
knockouts to identify proteins that are lowly abundant in one genotype (i.e. controls or 
knockouts) but are present at detectable levels in the other genotype. The missing values were 
imputed following standard procedures which assume that missing values are normally absent 
because they correspond to lowly abundant proteins and thus imputed values normally fall in 
the lower quantification range. To assess the effect of the filtering criteria and data imputation 
we plotted the average LFQ intensity versus the fold-change (knockouts / controls) and found 
that lowly abundant proteins in controls tend to have high fold-change values whereas lowly 
abundant proteins in the knockouts tend to have low fold-change values (Figure 3.22). The 
proteins that presented this pattern have several imputed values indicating that quantification 
of proteins that are present in one genotype but not the other is largely influenced by imputed 
values and, therefore, the fold-change estimations are not accurate. Despite this bias in the 
fold-change estimations of lowly abundant proteins, the filtering criteria used allowed us to gain 
valuable biologically relevant information such as the previously described loss of SLIRP when 
LRPPRC is absent (Ruzzenente et al. 2012) or the increase in proteins of the 1C or proline 
synthesis pathways (discussed in section 3.2.8). 
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Figure 3.22 | Lowly abundant proteins have broader fold-change distribution 
MA plots showing the fold-change distribution in the mitoproteome mice compared to the average LFQ intensity of 
control (L/L) (top) and knockout (L/L, cre) (bottom) mice per knockout mouse strain. Black, p < 0.05, grey, p > 0.05 
in differential expression analyses of L/L, cre versus L/L. From Kühl, Miranda et al. 2017. 
 
3.2.3. Mitochondrial remodelling during normal post-natal development of mouse heart is 
mainly regulated at the post-transcriptional level  
 
To get a better understating of the normal post-natal development of mitochondria in mouse 
heart during the time encompassing the lifespan of the knockout strains used in this study, we 
compared the mtDNA levels, mitoproteome, and total cellular transcriptome of wild-type or 
control mice from infancy (2-3 weeks) until adulthood (26 weeks) (Figure 3.19B). Mitochondrial 
DNA content increases steadily in mouse heart until 6 weeks of age (Figure 3.23A) and protein 
levels of traditional markers of mitochondrial biogenesis such as TFAM and the voltage 
dependent anion channel 1 (VDAC) follow this trend (Figure 3.23B). We therefore evaluated 
the transcript levels of factors regulating mitochondrial biogenesis in heart and did not find 
differences in gene expression between the different time-points analysed (Figure 3.23C). 
Furthermore, only 14% of the transcripts of genes encoding mitochondrial proteins were 
differentially regulated (Figure 3.23D) suggesting that there is not a major shift in the 
transcriptional regulation of mitochondrial biogenesis after 3 weeks of age in mouse heart. In 
contrast, differential expression analyses of the mitoproteome showed that 391 out of the 756 
mitochondrial proteins quantified in control mice changed during post-natal development 
(Figure 3.23E). 
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Figure 3.23 | Rapid post-natal increase of mtDNA levels and factors required to express mtDNA in wild-type 
mouse heart 
(A) mtDNA levels determined by qPCR on total cellular DNA isolated from heart of wild-type (+/+) mice at different 
ages. Normalization: 18S rDNA. Error bars ± sem of technical replicates. (B) Western blot quantification of nDNA 
mitochondrial proteins on heart protein extracts of wild-type mice. Normalization: a-tubulin. Percentage (%) was 
calculated relative to the average normalized value of all the time-points. (C) Expression level of genes encoding 
transcription factors involved in mitochondrial biogenesis in heart of control (L/L) mice at different ages measured 
by RNA-Seq. (D-E) Venn diagrams illustrating the number genes encoding mitochondrial that are differentially 
expressed during post-natal development of L/L mouse heart at the transcript (D) and protein (E) level. m.a. = 
mature adulthood. Modified from Kühl, Miranda et al. 2017. 
 
 To evaluate the changes in protein levels through time we performed hierarchical 
clustering analysis on the differentially expressed proteins. 91.3% of the proteins were 
distributed in four main clusters with distinct patterns of protein abundance (Figure 3.24A and 
B). Clusters 1 and 4 contained most mitochondrial proteins and had opposite patterns of 
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protein expression; while proteins from cluster 1 increase in abundance until 8 weeks of age, 
proteins from cluster 4 decrease. Clusters 2 and 3 also showed opposite patterns where 
proteins from cluster 2 decrease between 4 to 8 weeks and then increase to the original level 
between 9 and 12 weeks and proteins from cluster 3 increase until 8 weeks of age and then 
decrease between 9 and 12 weeks (Figure 3.24B). Next, we performed category enrichment 
analyses on each of the clusters using our manual functional category annotations (Table 3.2).  
Cluster 1 had an enrichment of proteins involved in pyruvate, amino acid and lipid metabolism 
(Figure 3.24B). Noteworthy, several proteins required for branched-chain amino acid 
metabolism and b-oxidation of fatty acids are in this cluster. Cluster 2 contained 50% of the 
significantly changed OXPHOS proteins and cluster 3 contained proteins involved in 
mitochondrial transcription, RNA metabolism and protein synthesis. Interestingly, cluster 4 had 
an enrichment of mitoribosomal proteins containing 93% of the proteins in this category (Figure 
3.24B).  
 
 
Figure 3.24 | Mitoproteome changes during post-natal development of mouse heart 
(A) Dendrogram of hierarchical clustering analysis heatmap of mitoproteomes of control (L/L) mice. Fold-changes 
relative to 3-week-old mice were Z-scored normalized. Proteins in grey (rest) were not classified in the main clusters. 
(B) Cluster analysis. From left to right: pie chart illustrating the distribution in percentage of differentially expressed 
mitochondrial proteins in each cluster (1-4), in white: not classified; protein distribution patterns through time on 
each cluster; category enrichment analysis of proteins on each cluster. Top three categories are presented. Dotted 
line: Benjamini-Hochberg adjusted p < 0.05. Parenthesis indicate the number of significantly changed proteins in 
that category / total number of proteins in that category. m.a = mature adulthood. From Kühl, Miranda et al. 2017. 
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2D annotation enrichment analysis (Cox & Mann 2012) of the mitochondrial transcripts 
and proteins at the different time-points showed that the global decrease on the mitoribosomal 
proteins is most-likely explained by decreased protein stability as the transcript level of most 
of these proteins is not changed (Figure 3.25A and B). Taken together, the post-natal shift in 
metabolism seems to extend up to 8 weeks of age where the increased levels of key 
mitochondrial metabolism proteins and mtDNA levels stabilize but proteins involved in mtDNA 
expression and maintenance drop.  
 
 
Figure 3.25 | Decrease of mitoribosomal subunits in caused by decreased protein stability 
(A) Mitochondrial transcriptomic and proteomic 2D-enrichment analysis of functional categories in control (L/L) mice 
at different ages. Enrichment scores were calculated on the fold-change relative to 3-4-week old mice. (B) 
Scatterplots of fold-changes relative to 3-4-week old mice of mitoribosomal transcript and proteins in L/L mice at 
different ages. Black line indicates the trend. From Kühl, Miranda et al. 2017. 
 
3.2.4. Loss of mtDNA gene expression profoundly alters the transcript and protein levels of 
nuclear genes encoding mitochondrial proteins  
 
We compared the transcriptomes and mitoproteomes of the five knockout mouse strains to 
identify common hallmarks of mitochondrial dysfunction in mouse heart. We found extensive 
changes in the transcript and protein levels of genes encoding mitochondrial proteins (Figure 
3.26A and B). At the transcript level, 38% of the quantified mitochondrial genes were 
differentially expressed in all knockouts, and most of these transcripts were decreased (Figure 
3.26C). At the protein level, ~65% of the quantified proteins were significantly changed and 
most of these were increased (Figure 3.26D). Furthermore, not only were there many changes 
in gene expression, but also the range of fold-changes was very high (log2 fold-change 
between -9 to 9) in both the transcriptomes and mitoproteomes (Figure 3.26A and B). Unless 
indicated otherwise, further downstream analyses were performed including all the genes that 
changed significantly in at least one knockout strain. In total, we found 310 genes whose 
expression changed only at the transcript level, 186 genes at the protein level, and 470 genes 
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at both, transcript and protein levels (Figure 3.26E). Therefore, severe mitochondrial 
dysfunction results in a massive remodelling of the expression of genes encoding 
mitochondrial proteins.    
 
 
Figure 3.26 | Extensive remodelling of the mitochondrial transcriptome and proteome 
(A-B) Volcano plots of genes encoding mitochondrial proteins (A) and mitoproteomes (B) for each knockout strain; 
black: p<0.05, grey: p>0.05. p values were adjusted using the Benjamini-Hochberg method. (C-D) Number of 
significantly changed mitochondrial transcripts (C) and proteins (D) from knockouts (L/L, cre) compared to controls 
(L/L); red: increased, blue: decreased. (E) Venn diagram of number of mitochondrial transcripts and proteins 
quantified and significant in ³1 knockout strain. Modified from Kühl, Miranda et al. 2017. 
  
To assess to what extent the variation in transcript levels result in corresponding protein 
abundance changes in the OXPHOS deficient hearts, we determined the Pearson correlation 
using all the genes for which we had quantification at the transcript and protein level. There 
was a significant correlation in all knockout strains with adjusted p values below 1.631 x 10-18 
and correlation values between 32 – 56% (Figure 3.27A). From all the knockouts, Polrmt had 
the lowest correlation value which could be explained by the early age at which they die (Table 
3.1). These data suggest that the composition of the mitoproteome is strongly influenced by 
post-transcriptional processes. Therefore, we performed 2D annotation enrichment analysis to 
identify categories of proteins that were regulated at a transcriptional or post-transcriptional 
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level (Figure 3.27B). There were very few categories of proteins that presented an anti-
correlative behaviour such as other mitochondrial protein synthesis factors and lipid and acetyl 
CoA metabolism. On the contrary the majority of the categories showed a concordant 
upregulation of transcript and protein levels including apoptosis, degradation and stress 
response, mitochondrial import and chaperones, and the mitochondrial 1C pathway. 
Interestingly, the categories of OXPHOS, the mitochondrial ribosome, and ubiquinone (Q) 
biosynthesis showed a high absolute enrichment scores at the protein level but not at the 
transcript level suggesting that the protein abundance is mostly defined by post-transcriptional 
processes. Heatmaps for the individual genes on each category are presented in 
supplementary material (section 8.1.1). 
 
 
Figure 3.27 | Correlation between the transcriptome and mitoproteome 
(A) Heatmap showing the Pearson correlation (r) of the changes in transcript and protein level in knockouts (L/L, 
cre) compared to controls (L/L); as an example, a scatter plot of the transcriptome and proteome fold-changes in 
the Mterf4 knockout is shown. adj. p: Benjamini-Hochberg adjusted p value. (B) 2D enrichment analysis of the 
mitochondrial transcriptome and proteome in all knockouts showing the trend and degree of regulation of 15 
functional categories that had p<0.05. Modified from Kühl, Miranda et al. 2017. 
 
3.2.5. mtDNA gene expression is required to stabilize the OXPHOS complexes and the 
mitoribosome 
 
Reduced mtDNA gene expression results in loss of OXPHOS subunits in the five knockout 
mouse strains (Cámara et al. 2011; Kühl et al. 2016; Milenkovic et al. 2013; Ruzzenente et al. 
2012; Wang et al. 1999). To validate our omic approach, we compared the transcript and 
protein levels of genes encoding OXPHOS subunits in the different knockouts. Transcript 
levels of mtDNA-encoded subunits were decreased in Twnk, Tfam Polrmt, and Lrpprc 
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knockouts whereas in Mterf4 knockout they were increased accurately reflecting the stage at 
which mtDNA gene expression is disrupted (Figure 3.19A, 3.28A, and Table 3.1). The 
transcript levels of nuclear genes encoding subunits of complexes I to V were, in general, 
slightly decreased and did not show a specific pattern of expression in the different knockouts 
(Figure 3.28A).  
  
Consistent with our analysis of systematic bias (Figure 3.20), we quantified in all the 
knockout strains the protein levels of 84 out of 95 OXPHOS subunits which, despite being 
highly hydrophobic, are very abundant. There was a severe decrease in the protein levels of 
complexes I, III, IV, and V encoded by both, mtDNA and nDNA (Figure 3.28A and B). The 
exclusively nucleus-encoded complex II and the nucleus-encoded subunits of complex V that 
can form stable sub-assembled F1 complex in OXPHOS deficient mitochondria (i.e. ATP 
synthase subunits alpha (ATP5A1), beta (ATP5B), gamma (ATP5C1), delta (ATP5D), and 
epsilon (ATP5E)) (Mourier et al. 2014), were slightly increased or unaffected in all knockouts. 
The stronger downregulation of subunits of complex I and IV is consistent with the degree of 
reduction on the enzyme activity of these complexes in the different knockouts (Cámara et al. 
2011; Kühl et al. 2016; Ruzzenente et al. 2012; Wang et al. 1999). Furthermore, we verified 
the protein levels of some OXPHOS subunits via western blot and obtained consistent results 
with our mitoproteomic data (Figure 3.28C). Interestingly, the protein levels of the nDNA 
subunits were homogeneous within each complex, indicating that the stability of the individual 
subunits depend on the stability of the assembled or sub-assembled complexes. Furthermore, 
in the case of complexes I, III, IV, and F0-subunit of complex V, the stability of the complexes 
depends on the presence of the mtDNA-encoded subunits. Finally, we evaluated the levels of 
the OXPHOS complexes at different ages in heart of the Lrpprc knockout (Figure 3.19B, C and 
Figure 3.28D) and detected a progressive decline of the different complexes validating our 
temporal mitoproteomic approach to study the progression of OXPHOS deficiency.  
 
Protein levels of OXPHOS assembly and biogenesis factors were in general increased 
in the different knockouts, with complex IV assembly factors COX15, COX19 and SCO2 
showing the particularly high levels (Figure 3.28E). However, the transcript level of OXPHOS 
assembly and biogenesis factors were either not changed or slightly decreased suggesting 
that the increase in proteins is likely a compensatory response to the loss of OXPHOS subunits 
that occurs at the post-transcriptional level.  
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Figure 3.28 | Stability of OXPHOS complexes depend on the presence of the mtDNA-encoded subunits 
(A) Heatmaps illustrating the fold-change in transcript (left) and protein (right) levels of OXPHOS subunits in heart 
of knockouts (L/L, cre) compared to controls (L/L). mtDNA-encoded subunits are presented first followed by the 
nDNA subunits in alphabetic order. (B) Scatterplot of fold-changes in transcript and protein levels of OXPHOS 
subunits; black line indicates the trend; blue: mtDNA-encoded subunits, yellow: nDNA subunits. (C) Western blot 
of OXPHOS subunits on isolated mitochondrial extracts from L/L and L/L, cre mouse hearts; Loading: SDHA. (D) 
Protein levels of OXPHOS complexes at different time points in Lrpprc knockout mouse hearts. The graph shows 
the average fold-change for all the proteins in each complex. *p<0.05, **p<0.01, ***p<0.001; error bars: ± sem. (E) 
Heatmap of OXPHOS assembly and biogenesis factors. Blank boxes: not detected or quantified. Modified from 
Kühl, Miranda et al. 2017. 
 
Since mtDNA also codes for the two mt-rRNAs, we evaluated the expression of the 
mitoribosomal protein complexes. The abundance of mitoribosomal proteins clearly depended 
on the level at which mtDNA gene expression was disrupted. Knockouts with reduced steady-
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state levels of mt-rRNAs, such as Twnk, Tfam and Polrmt, showed massively reduced levels 
of mitoribosomal proteins, whereas knockouts with increased mt-rRNA levels, such as Lrpprc 
and Mterf4, had increased levels of mitoribosomal proteins (Figure 3.29). In contrast, transcript 
levels of genes encoding mitoribosomal proteins were mildly affected. Our data thus show that 
the stability of individual mitoribosomal proteins depend on the assembly of the mitoribosomal 
subunits and strongly support the model that mt-rRNAs stabilize the nucleus-encoded 
mitoribosomal subunits which are produced and imported into mitochondria in excess.  
 
  
Figure 3.29 | Stability of mitoribosomal protein complexes depend on the abundance of mt-rRNAs 
Heatmaps illustrating the fold-change in transcript (left) and protein (right) levels of the small (left) and large (right) 
mitoribosomal subunits in heart of knockouts (L/L, cre) compared to controls (L/L). Blank boxes: not detected or 
quantified. From Kühl, Miranda et al. 2017. 
 
In conclusion, our comprehensive transcriptomic and mitoproteomic data not only 
reproduces the previous molecular characterization of the knockout mouse strains with severe 
OXPHOS deficiency but also argue that intra-mitochondrial protein level regulation has a 
predominant role in the biogenesis of the OXPHOS system and the mitoribosome. 
Furthermore, our findings show that expression of mtDNA-encoded genes determines the 
abundance of a large proportion of the mitoproteome.  
 
3.2.6. Loss of mtDNA gene expression causes secondary coenzyme Q deficiency  
 
Our 2D annotation enrichment analyses showed that the Q biosynthesis category in Lrpprc 
knockout clustered very closely with the OXPHOS category (Figure 3.28B). We evaluated the 
expression profiles of the enzymes required for intra-mitochondrial Q biosynthesis in all the 
knockouts and found them severely reduced at the protein level with the exception of COQ4, 
COQ8B and PDSS2 (Figure 3.30A and B). PDSS1 and COQ2 were not quantified. The levels 
of mevalonate pathway enzymes such as HMG-CoA synthase (HMGCS1) and farnesyl 
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pyrophosphate synthase (FDPS) were normal or slightly increased in all the knockouts (Figure 
3.30C). Moreover, the transcript levels of genes encoding cytoplasmic HMGCS1, 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR) and FDPS were either unaffected or increased 
(Figure 3.30D). Together with the increased levels of PDSS1 which catalyse the polymerization 
of the isoprenoid chain, our data suggests that there is no impairment in the mevalonate 
pathway when mtDNA gene expression is disrupted.  
 
 The decrease in the protein levels of COQ3, COQ5, COQ6, COQ8A, COQ9, and 
COQ10A was apparent at an early stage in the Lrpprc knockout strain and decreased further 
with the progression of OXPHOS deficiency (Figure 3.30E). Although the transcripts encoding 
Q biosynthesis enzymes were slightly decreased or unchanged, the atypical kinases Coq8a 
and Coq8b showed a consistent regulation at the transcriptional level with opposite patterns 
in all the knockouts. Coq8a was downregulated whereas Coq8b was upregulated at both the 
transcript and protein level (Figure 3.30B and D). In this regard, it is worth to note that COQ8B 
protein levels increased sharply after 5 weeks of age in the Lrpprc knockout hearts whereas 
the other enzymes progressively declined (Figure 3.30E), suggesting that it could be a 
compensatory mechanism. Interestingly, COQ8A and COQ8B have been recently suggested 
to interact differentially with the Q biosynthesis complex in mammalian cell lines depending on 
whether metabolism is adapting to glycolytic or respiratory conditions (Floyd et al. 2016). 
Finally, we evaluated whether the decreased levels of the intra-mitochondrial Q biosynthesis 
enzymes affected the cellular steady-state levels of Q. Mice have two forms of Q, Q9 and Q10, 
from which Q9 is the most abundant (Tang et al. 2004). We therefore measured the levels of 
both compounds in mouse heart tissue extracts using targeted mass spectrometry and found 
that, in control mice, Q9 was around tenfold more abundant than Q10 (Figure 3.30F), 
consistent with previous reports (Tang et al. 2004). In the knockout mice, Q9 was profoundly 
decreased, consistent with the downregulation of the intra-mitochondrial Q biosynthesis 
pathway. Taken together, our data show that loss of mtDNA gene expression causes 
secondary Q deficiency by a progressive loss of intra-mitochondrial Q biosynthesis enzymes. 
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Figure 3.30 | OXPHOS dysfunction leads to secondary Q deficiency caused by a defect in intra-
mitochondrial Q biosynthesis 
(A) Scheme of the mevalonate pathway, intra-mitochondrial Q biosynthesis, and OXPHOS complexes. Coloured 
boxes: protein levels; red: increased, blue: decreased, grey: not quantified. (B) Heatmaps illustrating the fold-
change in transcript (left) and protein (right) levels of Q biosynthesis enzymes in heart of knockouts (L/L, cre) 
compared to controls (L/L). Blank boxes: not quantified. (C) Western blot of enzymes of the mevalonate pathway 
on total protein extracts from L/L and L/L, cre mouse hearts; Loading: tubulin. (D) Transcript levels of genes 
encoding enzymes of the mevalonate and Q biosynthesis pathway in L/L and L/L, cre hearts. Normalization: beta-
2-microglobulin (B2m). (E) Time-course analysis of protein levels of all enzymes of Q biosynthesis quantified in 
Lrpprc L/L, cre compared to L/L. Adjusted p across time <0.05. Yellow line: average value of OXPHOS complex IV 
(CIV) subunits. (F) Quinone quantification (Q9 and Q10) in L/L, cre and L/L mouse hearts. *p<0.05, **p<0.005, 
***p<0.001; error bars: ± sem. From Kühl, Miranda et al. 2017. 
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3.2.7. Transcriptome-wide analyses indicate that ATF4 and MYC mediate cellular stress 
responses to loss of OXPHOS function  
 
We found a general increase in the transcript and protein levels of several genes in the 
categories of apoptosis, degradation and stress response, and mitochondrial import and 
chaperones (Figure 3.27B and Figure 3.31) indicating the activation of nuclear stress 
responses. We found an increase the transcript and protein levels of some reported mtUPR 
chaperones such as HSPD1, HSPE1, and HSPA9 in all the knockouts (Figure 3.31B and C). 
However, despite the severe OXPHOS deficiency, several of the reported mammalian mtUPR-
regulated factors were not changed such as Clpp, mitochondrial DnaJ homolog subfamily A 
member 3 (Dnaja3), endonuclease G (Endog), and the ATP-dependent zinc metalloprotease 
(Yme1l1). In agreement with Seiferling and colleagues that report that CLPP is dispensable 
for the induction of mtUPR in mammals (Seiferling et al. 2016), we did not detect differences 
in the protein levels of this mammalian matrix protease. Thus, our results indicate that there is 
a nuclear transcriptional response to mitochondrial stress that differ from the proposed mtUPR 
mechanism in worms.  
 
 
Figure 3.31 | Apoptosis, degradation and stress response, and mitochondrial import and chaperones are 
upregulated in OXPHOS dysfunction 
Heatmaps illustrating the fold-change in transcript (left) and protein (right) levels of apoptosis (A), degradation and 
stress response (B), and mitochondrial import and chaperones (C) in heart of knockouts (L/L, cre) compared to 
controls (L/L). Blank boxes: not quantified. From Kühl, Miranda et al. 2017. 
 
To identify factors mediating the nuclear responses to OXPHOS deficiency caused by 
mtDNA gene expression in mouse heart, we performed transcription factor enrichment 
analyses using as input the differentially expressed genes in all five knockouts. We identified 
several transcription factors predicted as the top regulators of the differentially expressed 
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genes including the nuclear factor NFE2, ATF-4, and MYC (Table 3.3). From the top scored 
transcription factors, only Atf4 and Myc were upregulated in our transcriptomic data.  
 
Table 3.3: Transcription factor enrichment analysis 
Motif or track id AUC NES Transcription factors 
 
swissregulon-NFE2.p2 
 
0.0352041 
 
5.01091 
 
NFE2, NFE2L2, BACH1, MAFK, NFE2L1, 
MAFG, JUND, JUNB, FOSB, FOSL1, FOS, 
JUN, FOSL2, BATF, SPI1, BACH2, MAFF, 
MAFA, MAF, MAFB, NFE2L3 
homer-M00001 0.0351042 4.97971 
 
taipale-NNATGAYGCAATN-ATF4-
DBD 
0.0346771 4.84631 ATF4, ATF3, CEBPB 
wgEncodeSydhTfbsK562CmycStdPk.
narrowPeak.gz 
0.0431751 4.73114 MYC 
taipale-NGGATGATGCAATM-Atf4-
DBD 
0.0340163 4.6399 ATF4, CEBPB 
lcbTfbs_mcf7_p53 0.0426344 4.61952 TP53 
yetfasco-966 0.033346 4.43051 JUNB, JUND, JUN, FOSL1, FOS, BATF, 
FOSL2, BACH2, SPI1, BACH1, FOSB, 
NFE2, ARNT, TGIF2LY, TGIF2, TGIF2LX, 
TGIF1, SRF 
wgEncodeSydhTfbsK562CmycIfng6h
StdPk.narrowPeak.gz 
0.040073 4.0908 MYC 
wgEncodeSydhTfbsK562CmycIfna30
StdPk.narrowPeak.gz 
0.0394589 3.96404 MYC 
GSM1208654_batch1_chrom1_LoVo
_MYC_PassedQC_peaks_hg19  
0.0394281 3.95768 MYC 
AUC: Area under the cumulative recovery curve; NES: normalized enrichment score 
 
MYC and ATF4 have been implicated in mitochondrial biogenesis and endoplasmic 
reticulum-stress responses, respectively (Morrish & Hockenbery 2014; Pakos-Zebrucka et al. 
2016), and we verified their expression levels via quantitative real time PCR (qRT-PCR). The 
transcript levels of Atf4 and Myc were strongly induced in all the knockouts in contrast to other 
transcription factors regulating mitochondrial biogenesis such as Nrf1, peroxisome proliferator- 
Pgc1a, and Gabpa (Figure 3.32A). Furthermore, canonical pathway enrichment analyses 
identified several signalling pathways that were enriched from which ATF4 and MYC are 
important transcription factors including eIF2, calcium, and the mTOR signalling (Figure 
3.32B). From the non-mitochondrial transcripts, it is worth to mention that several cytosolic 
ribosomal proteins, translation initiation factors, and tRNA synthetases were upregulated.  
 
We next evaluated the mitochondrial target genes of MYC and ATF4 that changed at 
the transcript levels in all the knockouts and found a general increase in ATF4 target genes 
and differences in gene expression in several MYC target genes (Figure 3.32C and D; 
supplementary material section 8.1.2). Several chaperones and proteases associated with 
mitochondrial stress and apoptosis that are target genes of these transcription factors are 
upregulated such as LONP1, HSPE1, the apoptosis regulator BAX, and the BH3-interacting 
domain death agonist (BID). Interestingly, genes that presented the strongest upregulation in 
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transcript and protein levels (e.g. mitochondrial bi-functional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase (Mthfd2), mitochondrial pyrroline-5-carboxylate reductase 1 
(Pycr1), and delta-pyrroline-5-carboxylate synthase (Aldh18a1)), are also target genes of 
these transcription factors.  
 
 
Figure 3.32 | Enrichment of signalling and metabolic pathways in mouse heart with severe OXPHOS 
dysfunction 
(A) Transcript levels of genes encoding transcription factors involved in mitochondrial biogenesis in control (L/L) 
and knockout (L/L, cre) mouse hearts. Normalization: beta-2-microglobulin (B2m). *p<0.05, **p<0.005, ***p<0.001; 
two-tailed Student’s t-test; error bars: ± sem. (B) Canonical pathway enrichment analysis of significantly changed 
genes in all knockouts. Top 12 categories are shown organized by p value. Fisher’s exact test; rectangles in 
horizontal heatmaps: average expression level in the five knockouts of each gene detected per pathway; 
parenthesis: fractions of genes detected per pathway. (C-D) Average transcript expression levels of target genes 
of ATF4 (C) and MYC (D) encoding mitochondrial proteins. p < 0.05 for all genes; error bars ± sd. From Kühl, 
Miranda et al. 2017. 
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3.2.8. Identification of early markers of OXPHOS dysfunction in mouse heart 
 
To identify markers of mitochondrial dysfunction, we focused on proteins that were strongly 
upregulated in all the knockout mouse strains. We found a strong increase on the transcript 
and protein levels of the enzymes of the mitochondrial 1C cycle (Figure 3.33A and B). In 
contrast, the cytosolic C-1 tetrahydrofolate synthase (MTHFD1) enzyme was unaltered at the 
protein level (3.33C). To evaluate the levels of the 1C donors, we performed targeted mass 
spectrometry metabolomic analysis and found increased levels of glycine, sarcosine, and 
serine (Figure 3.33D). Consistent with previous studies (Bao et al. 2016), the transcript levels 
of enzymes required for de novo serine synthesis in the cytosol were strongly upregulated in 
all the knockouts (data not shown). Temporal mitoproteomic analysis of the mitochondrial 1C 
cycle enzymes in the Lrpprc knockout showed that all the central enzymes are increased 
before there is a decrease in proteins from OXPHOS complex IV (Figure 3.33E), which is the 
most downregulated complex in Lrpprc knockout (Figure 3.28A). Our results support a link 
between mitochondrial dysfunction and the mitochondrial 1C pathway (Bao et al. 2016; 
Nikkanen et al. 2016) and show that it is an early event in the progression of OXPHOS 
dysfunction. 
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Figure 3.33 | Mitochondrial 1C pathway enzymes are upregulated early in the progression of OXPHOS 
dysfunction 
(A) Scheme of 1C pathway. Coloured boxes represent protein levels; red: increased, grey: not quantified. (B) 
Heatmaps illustrating the fold-change in transcript (left) and protein (right) levels of knockouts (L/L, cre) and control 
(L/L) mouse hearts. (C) Western blot of enzymes of the 1C pathway on total protein extracts from L/L and L/L cre 
hearts. Loading: tubulin. (D) Quantification of 1C donor metabolite levels in L/L, cre and L/L. *p < 0.05, **p < 0.01, 
***p < 0.001; two-tailed Student’s t-test; error bars ± sem. (E) Time-course analysis of protein levels of enzymes of 
the 1C pathway quantified in Lrpprc L/L, cre compared to L/L. Adjusted p across time <0.05. Yellow line: average 
value of OXPHOS complex IV subunits. From Kühl, Miranda et al. 2017. 
 
ALDH18A1 was among the most upregulated proteins in most knockout mouse strains 
(Figure 3.34A and B). Since ALDH18A1 is the first enzyme in the synthesis of proline from 
glutamate in mitochondria (Pérez-Arellano et al. 2010), we investigated the other enzymes in 
this pathway. There was a strong increase in the protein levels of PYCR1 and PYCR2, whereas 
the levels of the delta-1-pyrroline-5-carboxylate dehydrogenase (ALDH4A1) and proline 
dehydrogenase 1 (PRODH), which catalyse the reverse reaction from proline to glutamate 
(Pérez-Arellano et al. 2010), were normal (Figure 3.34B). Transcript levels of the genes in this 
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pathway showed a similar direction as the protein levels with increased levels of Aldh18a1 and 
Pycr1, and decreased levels of Aldh4a1. To assess the effect of this protein imbalance in the 
metabolic flux, we determined the levels of glutamate and proline by targeted metabolomics 
and found a drastic increase in the proline to glutamate ratio in the knockout mouse hearts 
(Figure 3.34C). Similar to the 1C pathway, temporal proteomic analysis in the Lrpprc knockout 
showed a steep increase of ALDH18A1 levels early in the progression of OXPHOS dysfunction 
(Figure 3.34D)  
 
 
Figure 3.34 | Increased proline synthesis from glutamate upon OXPHOS dysfunction 
(A) Scheme of glutamate to proline conversion pathway. Coloured boxes represent protein levels; red: increased, 
blue: decreased. (B) Heatmaps illustrating the fold-change in transcript (left) and protein (right) levels of knockouts 
(L/L, cre) and control (L/L) mouse hearts. (C) Time-course analysis of protein levels of enzymes of the glutamate 
to proline conversion pathway quantified in Lrpprc L/L, cre compared to L/L. Adjusted p across time <0.05. Yellow 
line: average value of OXPHOS complex IV (CIV) subunits. (D) Quantification of proline to glutamate ratio in L/L, 
cre and L/L hearts. **p<0.01; error bars ± sem. From Kühl, Miranda et al. 2017. 
 
To identify additional early markers of OXPHOS deficiency, we performed clustering 
analysis with the significantly changed proteins in the Lrpprc time-course mitoproteome (Figure 
3.19B). Two clusters presenting opposite patterns showed marked changes in protein levels 
at 3 weeks of age (Figure 3.35). The first cluster contained LRPPRC and its interacting partner 
SLIRP that rapidly decline after birth due to knockout of Lrpprc in the heart (Figure 3.19C). The 
second cluster contained proteins that were strongly upregulated and includes MTHFD2, 
ALDH18A1, amine oxidase [flavin-containing] A (MAOA), phosho-enol pyruvate carboxykinase 
(PCK2), MTHFD1L, and PYCR1. The identification of 1C pathway and proline biosynthesis 
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enzymes in this cluster is a proof of concept that our integrated omics approach comparing 
different knockout mouse strains deficient of mtDNA gene expression combined with the time-
course analysis in the Lrpprc knockout can be used to identify early markers of the progression 
of OXPHOS deficiency.  
 
Figure 3.35 | Early markers of OXPHOS dysfunction 
Heatmaps illustrating proteins that decrease (left) and increase (right) early in time-course analysis of Lrpprc 
knockouts (L/L, cre) and controls (L/L) mouse hearts at different ages.  
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4. DISCUSSION  
 
Mammalian mtDNA codes for a handful of genes and the mitoproteome contains a few 
thousand proteins. The fact that all the components required to express mtDNA are encoded 
in the nucleus raises the question of how the two cellular genomes coordinate and regulate 
their expression to build and maintain a functional OXPHOS system. In this thesis we address 
two aspects of this fundamental question. First, we investigated the in vivo function of POLRMT 
in the regulation of mtDNA replication and transcription as well as its potential role coordinating 
nDNA and mtDNA gene expression programs via its nuclear isoform spRNAP-IV. Second, we 
studied the molecular consequences of impaired mtDNA gene expression as well as the 
secondary cellular responses, both locally at the mitoproteome level but also globally at the 
cellular gene expression level. 
 
The POLRMT gene was reported to code for two different single-subunit RNA 
polymerases, i) POLRMT that transcribes mtDNA and ii) spRNAP-IV that has been proposed 
to transcribe a specific subset of nuclear genes. The regulation of gene expression of both 
cellular genomes under the control of a single gene is an interesting possibility to coordinate 
the crosstalk between the two genetic systems. However, we did not find the mRNA of the 
reported nuclear splice variant in mouse tissues or human cell lines using RT-PCR analyses. 
Furthermore, using an antibody that recognizes both protein isoforms, we only detected a 
protein of the size of POLRMT (~140 kDa) that exclusively localizes in mitochondria. Finally, 
knocking out both putative Polrmt gene products in mouse had no effect in the transcript levels 
of the genes reported to be transcribed by spRNAP-IV. Therefore, we conclude that the 
POLRMT gene only encodes a mitochondrial protein with an exclusive function in this 
organelle in mammals.  
 
 Importantly, loss of POLRMT had a severe effect on mtDNA gene expression. 
Disruption of Polrmt in heart caused a global decrease of mt-RNAs and abolished de novo 
transcription, demonstrating that no other RNA polymerase can replace POLRMT in 
mammalian mitochondria. Although there was a strong decrease in all mt-RNAs in the Polrmt 
knockout hearts, we found that the transcripts encoded on the L strand were less reduced than 
the transcripts encoded on the H strand. Previous studies have reported the stabilization of L-
strand transcripts, in particular mt-Nd6 when silencing or knocking out the Lrpprc gene 
(Ruzzenente et al. 2012; Wolf & Mootha 2014). LRPPRC levels are strongly reduced in the 
Polrmt knockouts consistent with the previously observed correlation between LRPPRC and 
mt-mRNA levels (Lagouge et al. 2015). Since LRPPRC binds all mt-mRNAs, the reduced 
stability in the absence of Lrpprc could be explained by loss of polyadenylation which does not 
affect mt-Nd6 (Siira et al. 2017). Furthermore, Polrmt and Lrpprc knockout mice have 
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increased levels of GRSF1 which has been suggested to interact and regulate mt-Nd6 and its 
precursor strand (Antonicka et al. 2013; Jourdain et al. 2013). A compensatory stabilization of 
mature mt-mRNAs was previously reported upon knockdown of POLRMT in human cell lines 
(Wolf & Mootha 2014). However, it is unlikely that the strand-specific effect observed in the 
Polrmt knockout is explained by differences on the individual transcript stabilities because mt-
mRNAs, mt-rRNAs and mt-tRNAs are all stabilized by different mechanisms (Rorbach & 
Minczuk 2012).  
Differences in promoter strength between HSP and LSP have been reported but remain 
controversial as in vitro transcription experiments can be strongly influenced by reaction 
conditions and the promoter template used (Morozov & Temiakov 2016; Shi et al. 2012). A 
recent study showed that the pre-IC complex has a similar topology in both promoters based 
on crosslinking studies between TFAM and promoter sequences. According to this model, 
transcription machineries can assemble in both promoters and, in that way, be regulated 
simultaneously (Morozov & Temiakov 2016). On the contrary, previous studies have shown 
that LSP is a stronger promoter and its activity is strictly dependent on TFAM binding even 
under permissive conditions that allow promoter breathing like supercoiling or low salt 
concentrations (Lodeiro et al. 2010; Shi et al. 2012). This suggests that different structural 
requirements can apply to each promoter. Our in vitro transcription data using a single template 
containing both HSP and LSP show that transcription from LSP is better maintained than 
transcription from HSP when POLRMT:DNA ratios are low. Importantly, TFAM and TFB2M 
concentrations were maintained constant in this experiment. Together with the specific mt-
RNA abundance pattern, our data indicates that there is a differential regulation of the 
promoters in vivo when POLRMT levels are low.  
The defect in mtDNA replication provides conclusive evidence that transcription 
initiation from LSP forms the primer required for mtDNA replication at OH and no other primase 
can compensate for this function in the absence of POLRMT. Differential regulation of LSP 
compared to HSP could reflect a preference to use LSP-mediated transcription initiation to 
maintain mtDNA replication. Under normal conditions, most of the replication events are 
prematurely terminated generating 7S DNA (Bogenhagen & Clayton 1978). When Polrmt is 
depleted 7S DNA is not formed suggesting that most of the residual replication events continue 
to full length replication. Furthermore, there is a strong increase in the levels of TWINKLE and 
the levels of TFAM are not changed despite the strong mtDNA depletion. Overexpression of 
these two factors have been shown to increase mtDNA copy number (Ekstrand et al. 2004; 
Kukat et al. 2015; Milenkovic et al. 2013). Although the exact mechanism by which TWINKLE 
regulates mtDNA copy number is unknown, this factor can be loaded at the 3’ end of 7S DNA 
to promote full length replication (Jemt et al. 2015).   
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The interdependence of TFAM and mtDNA has been shown in different mouse models 
(Ekstrand et al. 2004; Larsson et al. 1994; Kukat et al. 2015) and it was suggested that mtDNA-
free TFAM turnover is mediated by LONP1 (Lu et al. 2013; Matsushima et al. 2010). 
Remarkably, the Polrmt knockout is the first model where TFAM levels are stable despite the 
strong mtDNA depletion and increased LONP1 levels. Importantly, Tfam transcript levels were 
upregulated suggesting a transcriptional compensatory response to maintain TFAM levels in 
mitochondria. TFAM stability in the Polrmt knockout could be explained by TFAM binding to 
other proteins or to different post-translational modifications (King et al. 2018). Comparing the 
post-translational modifications or interaction partners of TFAM in the Polrmt knockout to other 
mouse models where TFAM and mtDNA levels correlate like Twnk or Mterf4 knockouts would 
provide important insights into the regulation of TFAM and mtDNA copy number. 
Finally, we did not detect accumulation of the 7S RNA transcript in the Polrmt knockout 
further suggesting that when POLRMT levels are low, LSP-transcription initiation is dedicated 
to maintain productive mtDNA replication. Based on our in vivo findings, we propose that 
promoter-specific transcription initiation can fine-tune the balance between mtDNA replication 
and transcription and this mechanism is active when POLRMT levels are low as illustrated in 
Figure 4.1.  
 
Figure 4.1 | Model of POLRMT regulating replication 
primer formation and mtDNA gene expression  
At low POLRMT levels only LSP is active and generates 
the RNA primer for mtDNA replication. At high POLRMT 
levels, transcription initiation is activated from HSP and 
LSP resulting in mtDNA gene expression. Abbreviations 
in alphabetical order: HSP, H-strand promoter; LSP, L-
strand promoter; OH, heavy-strand origin of replication; 
POLRMT, mitochondrial RNA polymerase. Modified 
from Kühl et al. 2016. 
 
 
 
 
 
 
Our data on the heterozygous Polrmt knockout and Polrmt overexpressor mice verifies 
that mitochondrial transcription is a very robust process with multiple levels of regulation. 
Despite the decrease in POLRMT levels, the heterozygous Polrmt knockout mice maintain the 
steady-state mt-RNA levels and have no differences in mtDNA synthesis indicating that one 
copy of Polrmt is sufficient to maintain mtDNA replication and transcription. Interestingly, we 
found increased TEFM protein levels in these mice suggesting that the decreased POLRMT 
levels are compensated by promoting transcription elongation. The Polrmt overexpressor 
mouse showed increased de novo transcription proportional to the levels of POLRMT. Since 
the protein levels of the other transcription factors, TFAM, TFB2M and TEFM are not changed 
in this mouse model, the increase in de novo transcripts suggests that a 50% increase of 
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POLRMT is sufficient to upregulate mtDNA transcription; in other words, POLRMT is a limiting 
factor for transcription in mammalian mitochondria. The formation of the mitochondrial 
transcription initiation complex and the transition to elongation are rate-limiting steps in in vitro 
transcription of mtDNA (Lodeiro et al. 2010). In line with this, our in vivo findings suggest that 
engaging more mtDNA molecules in transcription by increasing POLRMT levels or promoting 
transcription elongation by increasing TEFM are potential mechanisms to regulate 
mitochondrial transcription in vivo. Furthermore, increased POLRMT levels have been found 
in different mouse models of mitochondrial dysfunction (Milenkovic et al. 2013; Perks et al. 
2018; Kauppila et al. 2018), indicating that regulating POLRMT levels is a compensatory 
mechanism operating when mtDNA gene expression in impaired in vivo.  
Contrary to the increased de novo transcription, steady-state transcript levels in the 
Polrmt overexpressor mice do not reflect a general increase in mitochondrial transcription as 
only 7S RNA, precursor mt-Nd5/mt-Cytb, and mt-Tf are mildly increased. Thus, one possibility 
is that POLRMT promotes transcription of polycistronic transcripts in vivo, but the transcripts 
are not stabilized. The observed increase in precursor transcripts would support this scenario 
but it is a very mild effect. Furthermore, we did not find differences in the steady-state transcript 
levels after parallel overexpression of the mt-mRNA stabilizing factor Lrpprc together with 
Polrmt. Although we cannot exclude that other factors in addition to LRPPRC are limiting the 
stabilization of newly synthesized transcripts in the Polrmt overexpressor mice, we did not find 
differences in the transcript stability in pulse-chase de novo transcription experiments. This 
suggests that isolated mitochondria with increased POLRMT levels in energizing buffer 
conditions results in increased transcription and normal transcript processing and stability 
without the requirement of additional factors.  
Another possibility is that the in organello transcription does not reflect the in vivo 
situation but rather the transcription capacity and that in the mouse heart the additional levels 
of POLRMT lead to increased mitochondrial transcription initiation but is not continued to 
generate full-length polycistronic transcripts. The robust accumulation of 7S RNA transcript is 
consistent with a strong increase in LSP-initiated transcription in the Polrmt overexpressor 
mice and occurs in most of the tissues evaluated and throughout different ages. Although the 
function of the 7S RNA is largely unknown, our findings support the hypothesis that 7S RNA 
is an abortive transcription product that accumulates when LSP-initiated transcription is not 
used to generate mtDNA replication primers or full-length polycistronic transcripts. In line with 
this and the model presented in Figure 4.1, the effect of Polrmt overexpression on mtDNA 
replication is minor. With the experiments performed so far, we cannot differentiate whether 
the higher levels of 7S RNA compared to the HSP-proximal transcript mt-Tf reflect differences 
in the stability of these two transcripts or increased LSP transcription initiation. Interestingly, 
silencing TEFM in human cells results in a gradual decline of the mt-RNAs proportional to the 
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distance of the promoter, but also in an accumulation of LSP-proximal mt-Tp (Minczuk et al. 
2011) supporting that POLRMT is constantly reloading at the promoters to initiate transcription. 
In agreement with our findings, Surovtseva and collaborators reported that overexpression of 
POLRMT in HeLa cells did not affect steady-state mt-mRNA levels; however, they report a 
mild decrease in respiration and in the steady-state protein levels of the mt-CO2 (Surovtseva 
& Shadel 2013), that we do not find in our mice. This discrepancy can be explained by the 
differences in the model organism and the level of overexpression of POLRMT. 
 
In the nucleus, protein-coding genes are typically present in two copies per cell and, 
therefore, activation of a large number of genes is controlled by different combinations of 
transcription factors binding to the promoter regions. In contrast to the nucleus, mtDNA is 
present in multiple copies in the cell and all the genes are controlled by only two promoters. 
This means that mtDNA transcription can be regulated by engaging more mtDNA templates in 
transcription, increasing transcription from HSP and LSP, or a combination of both. Our in vivo 
data suggests that under normal physiological conditions POLRMT is constantly initiating 
transcription at available templates but most of this transcription is abortive and results in 7S 
RNA products, similar to the 7S DNA product that is synthesized after mtDNA replication start 
(Bogenhagen & Clayton 1978). Increasing POLRMT levels either increase transcription 
initiation from each promoter and/or engage more mtDNA molecules in transcription which 
would explain the increased transcription capacity in the Polrmt overexpressor mice and the 
accumulation of promoter-proximal transcripts. An increase in TEFM observed in the 
heterozygous Polrmt knockout, would result in the stimulation of productive transcription 
elongation and evens the transcription rate despite reduced POLRMT levels. However, the 
balance between mtDNA replication and transcription is not likely mediated by template 
availability as both machineries require access to the NCR. We thus propose that differential 
promoter-specific transcription initiation via POLRMT is part of a mechanism mediating this 
balance as our data suggests that when POLRMT levels are low transcription initiation from 
LSP is favoured to maintain mtDNA replication (Figure 4.1). 
 
 Previous studies from our laboratory have shown that mt-mRNAs are in excess in 
mammalian mitochondria as mice can tolerate relatively well severe reductions in steady-state 
transcript levels (Lagouge et al. 2015). This raises the question of why it is important to regulate 
mitochondrial transcription in the mammalian system. Our multi-omic comparison of hearts 
from five different knockouts identified that the abundance of nDNA-encoded proteins of 
complexes of dual genetic origin, i.e. the OXPHOS complexes and the mitoribosome, are 
regulated at the post-transcriptional level. However, the abundance of the complex reflects the 
expression of mtDNA. On the one hand, the five knockout mouse strains have impaired mtDNA 
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gene expression and, therefore, the mtDNA-encoded proteins are strongly reduced in all the 
mouse strains. Consequently, most of the OXPHOS complexes containing mtDNA-encoded 
proteins decline. On the other hand, disrupting different steps of mtDNA gene expression 
results in differences in mt-rRNAs levels which are reflected in the abundance of the 
mitoribosomal proteins. In Escherichia coli subunits of multiprotein complexes are produced 
proportional to their required stoichiometry and synthesis is regulated at the translation level 
as they are encoded in polycistronic mRNAs (Li et al. 2014). In mammals, a small percentage 
of the proteins, mainly components of protein complexes, are degraded in a non-exponential 
manner, which means they are rapidly degraded in the first few hours after synthesis and then 
stabilized with time (McShane et al. 2016). Our data supports that the few genes encoded by 
the mtDNA are limiting factors that regulate the protein complex abundance in the complexes 
of dual genetic origin. In this way, nDNA encoded proteins are produced in excess, imported 
into mitochondria and assembled into the complexes or degraded. This model is supported by 
the fact that mtDNA-encoded proteins are required for early steps of assembly of OXPHOS 
complexes I, III, and IV (Fernandez-Vizarra & Zeviani 2018; Guerrero-Castillo et al. 2017; 
Stroud et al. 2015) and that the mitoribosome assembly initiates co-transcriptionally (Rackham 
et al. 2016). On the contrary, in complex V that can form sub-assembled complexes, the 
mtDNA-encoded subunits are part of the later assembly stages (He et al. 2018). Furthermore, 
a recent study using SILAC pulse-chase experiments showed that the mitoribosomal proteins 
are indeed produced in excess and degraded when they are not assembled (Bogenhagen et 
al. 2018). Although, we show that biogenesis of complexes of dual genetic origin does not 
result from proportional transcript synthesis in both genomes, the question remains whether 
there is a coordination at the translational level as it has been proposed in yeast and for mt-
Co2 in mammalian cells (Couvillion et al. 2016; Richter-Dennerlein et al. 2016). We propose 
that regulating the expression of mtDNA that only encodes a few genes under the control of 
two promoters is much more efficient than regulating the expression of the ~180 nDNA 
encoded genes that form the OXPHOS complexes and the mitoribosome. Thus, robust 
regulation of mtDNA is required to rapidly respond to changes in the cellular energetic 
demands. 
 
 The multi-omics systematic study presented in this thesis revealed a wholesome 
remodelling of the cellular transcriptome and mitochondrial proteome as a consequence of 
loss of mtDNA gene expression. This reflects the extent of the secondary cellular responses 
evoked by the primary OXPHOS defect. Although, some of these secondary responses can 
be adaptive to maintain mitochondrial function over certain physiological ranges, in a 
pathogenic situation they are not sufficient to compensate for the primary defect and can 
further contribute to the disease progression. The latter is supported by the recent successful 
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reports where the phenotype of mitochondrial disease mouse models is improved after 
treatment with rapamycin (Felici et al. 2017; Johnson et al. 2013; Khan et al. 2017; Siegmund 
et al. 2017) or hypoxia (Ferrari et al. 2017; Jain et al. 2016) without fixing the primary defect. 
However, the mechanisms by which mTORC1 inhibition or activation of hypoxia responses 
reduce the progression of mitochondrial disease are still unknown and can be explained by 
the contribution of secondary responses to the pathogenic process, a different modulation of 
cellular metabolism that partially bypasses the mitochondrial defect, or probably a combination 
of both. Nevertheless, ascertaining which are the secondary responses, how they contribute 
to disease progression, and in which settings are they triggered is an important endeavour to 
understand mitochondrial diseases and develop effective diagnostic and treatment strategies. 
 
  We found that impaired mtDNA gene expression in mouse heart results in secondary 
Q deficiency caused by defective intra-mitochondrial Q biosynthesis that correlates with the 
progressive OXPHOS deficiency. Q deficiency caused by downregulation of the cytosolic 
mevalonate pathway was shown to drive respiratory defect in a mitofusin 2 (Mfn2) knockout 
mouse (Mourier et al. 2015). This indicates that the defect of the intra-mitochondrial Q 
biosynthesis that we report here is specific to loss of mtDNA gene expression and not a 
common secondary consequence of mitochondrial dysfunction. Although the function of 
several of the Q biosynthesis enzymes is not known, it has been shown that they form a 
complex in the inner mitochondrial membrane (Stefely & Pagliarini 2017). Since the abundance 
of the OXPHOS complexes is not affected in the Mfn2 knockout and the decline in Q 
biosynthesis enzymes is not regulated at the transcriptional level, it is possible that the loss of 
membrane integrity caused by the decreased OXPHOS complexes leads to the instability of 
the Q biosynthesis complex. As it occurs in the Mfn2 knockout and in patients with autosomal 
recessive mutations in genes of the Q biosynthesis pathway (Garrido-Maraver et al. 2014; 
Wang & Hekimi 2016), Q deficiency can further aggravate the OXPHOS deficiency in these 
mouse models. Q supplementation is a common treatment for mitochondrial diseases but its 
efficacy has been questioned due to contradicting clinical trial results (Pfeffer et al. 2013). Our 
study provides experimental evidence to support that impaired mtDNA gene expression, which 
is found in a large number of mitochondrial patients, can develop secondary Q deficiency and 
would benefit from Q supplementation. Patients with inherited autosomal recessive forms of Q 
deficiency respond well to oral Q supplementation. Therefore, we propose that Q 
measurements should be performed in all patients with mitochondrial disease and clinical trials 
of Q supplementation focused in patients with impaired mtDNA gene expression should be 
performed. 
The integration of transcriptomic and proteomic data also allows the identification of 
mitochondrial processes affected by OXPHOS deficiency that are regulated at the 
 78 
transcriptional level and, therefore are controlled by nDNA transcription programs. Enrichment 
analyses combining canonical pathways and transcription factors including the differentially 
expressed genes in all the knockouts predicted that the ATF family of transcription factors and 
MYC were enriched in our datasets as well as genes involved in cellular signalling pathways 
including eIF2, eIF4, calcium and mTOR. We evaluated the expression levels of the target 
genes of ATF4 and MYC using published chromatin immunoprecipitation sequencing (ChIP-
Seq) data sets (Han et al. 2013; Seitz et al. 2011) and found several of them to be mostly 
upregulated, in particular the ATF4 targets. During the course of this thesis several reports 
linking mitochondrial dysfunction to the activation of ATF4 transcriptional program via eIF2a 
and/or mTORC1 were published (Bao et al. 2016; Dogan et al. 2014; Khan et al. 2017; Quirós 
et al. 2017). Within the ATF4 targets there are several enzymes involved in the mitochondrial 
1C pathway and synthesis of proline from glutamate. These pathways included some of the 
most upregulated genes in transcript and protein levels in the five different knockouts and its 
miss-regulation shifted the abundances of metabolites involved. Remodelling of the serine 
synthesis and 1C pathway was also identified in cell lines expressing a dominant negative form 
of POLG (Bao et al. 2016), cell lines treated with different mitochondrial poisons (Quirós et al. 
2017), flies expressing Pink1 mutations leading to mitochondrial dysfunction (Tufi et al. 2014), 
and a mouse model with mtDNA deletions that results in mitochondrial myopathy (Tyynismaa 
et al. 2010; Nikkanen et al. 2016), indicating that it is a common effect that occurs in 
mitochondrial dysfunction.  
Today, most of the mitochondrial stress responses are attributed to the activation of 
ATF4 via the cellular ISR as eIF2a has been shown to be phosphorylated in different model 
systems of mitochondrial dysfunction (Khan et al. 2017; Quirós et al. 2017). While it remains 
to be confirmed whether Myc is upregulated in other models of mitochondrial dysfunction or 
only in mouse heart, within the MYC target genes there are several of the target genes reported 
to be activated by ATF4 and part of the proposed mitochondrial-stress activated ISR including 
Gdf15, Lonp1, Mthfd2, Phgdh and Psat1. Furthermore, in addition to Lonp1, MYC target genes 
also include the chaperones  Hspa9 (mtHSP70) and Hspe1 that are increased in different 
models of mitochondrial dysfunction and are currently used as makers of mtUPR (Khan et al. 
2017; Münch & Harper 2016; Seiferling et al. 2016). Our work underscores that the 
transcriptional programs activated upon mitochondrial dysfunction result from the synergistic 
action of different transcription factors in vivo. These transcription factors likely include different 
members of the ATF family of transcription factors, MYC, and potentially factors modulating 
mitochondrial biogenesis that might not be regulated at the transcript level and, therefore, we 
did not identify in our analyses. It is important to consider that most of the studies, including 
the one presented in this thesis, predicted the activation of ATF4 and its target genes based 
on enrichment of conserved regulatory sequences and/or ChIP-Seq data sets in the 
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differentially expressed genes. However, to our knowledge, the direct action of ATF4 has only 
been verified in a handful of genes (~10 different in total in all the studies) in the context of 
mitochondrial dysfunction (Bao et al. 2016; Quirós et al. 2017).  
 
Comparing the same tissue in five isogenic knockout mouse models with defects in 
mtDNA gene expression leading to a similar primary OXPHOS defect and housed under the 
same controlled environmental conditions, identified ~5000 differentially expressed transcripts, 
from which ~1500 are common for all the knockouts. Since our knockout models have severe 
mitochondrial dysfunction leading to dilated cardiomyopathy, the transcriptional changes 
identified in the end-stage reflect the responses to the primary OXPHOS defect, to secondary 
metabolic alterations, and to the severe cardiomyopathy. Furthermore, our temporal proteomic 
analysis in the Lrpprc knockout revealed that the increase of the 1C pathway and proline 
synthesis enzymes is detectable early in the progression of OXPHOS deficiency. This finding 
is consistent with the early expression of Atf4 and FGF21 in the heart of a Dars2 knockout 
mouse (Dogan et al. 2014) and supports that some nuclear transcriptional responses are 
triggered before measurable OXPHOS deficiency develops in mouse heart. Taking these 
findings into consideration, during the last years we have advanced substantially identifying 
miss-regulated processes in mitochondrial dysfunction and some of the upstream factors 
regulating these processes, but we still cannot differentiate proximal consequences of 
OXPHOS dysfunction from secondary ripple-effects.  
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5. CONCLUSION AND FUTURE PERSPECTIVES 
 
The comprehensive analysis presented in this thesis that includes transcriptomics, proteomics 
and metabolomics in different well-characterized mouse models with impaired mtDNA gene 
expression show the extent to which mtDNA is determinant in the biogenesis of complexes of 
dual genetic origin in comparison with nDNA. Therefore, regulation of mtDNA gene expression 
is fundamental for proper mitochondrial function and allows local and rapid adaptation to 
changes in the energetic or metabolic demands. The extensive resources generated are a 
valuable source to generate hypothesis to study unsolved fundamental mitochondrial biology 
questions, understand pathophysiology of human diseases, identify biomarkers to diagnose 
mitochondrial diseases, and provide experimental rational for patient treatment. 
 To exemplify, the specific pattern of mitoribosomal protein abundance can be used 
to identify core mitoribosomal proteins or proteins whose stability depends on the presence of 
the mitoribosome. As proof of principle, the mitochondrial 28S ribosomal protein 36 (MRPS36), 
which is still reported as a mitoribosomal subunit in the Uniprot database, did not show the 
same profile of gene expression as the other mitoribosomal subunits. MRPS36/KGD4 was 
reported to have a conserved role in the organization of mitochondrial a-ketoglutarate 
dehydrogenase complex instead of the mitoribosome in Saccharomyces cerevisiae (Heublein 
et al. 2014) and was not identified in the structure of the human mitoribosome (Amunts et al. 
2015). On the contrary, the mitochondrial ribosome associated GTPase 1 (MTG1) and the 
mitochondrial translation initiation factor 3 (MTIF3) showed the same pattern as the 
mitoribosomal proteins. Both, MTG1 and MTIF, were reported to interact with the large 
mitochondrial subunits (Kotani et al. 2013; Koc & Spremulli 2002).  
Another interesting example is the changes in the abundance of the mitoribosome in 
control mice after three weeks of age. This decrease could explain the longer lifespan of 
knockout models with impaired mitochondrial translation (Cámara et al. 2011; Metodiev et al. 
2009; Metodiev et al. 2014; Park et al. 2007). The mouse heart has been established as good 
model system for the human heart (Wessels & Sedmera 2003). Interestingly, in mitochondrial 
patients, severe defects in mtDNA translation usually manifest as fatal perinatal or early-
infantile rapidly progressive cardiomyopathies. However, the few patients that survive show a 
spontaneous stabilization of the heart condition at around 6 years of age (Gorman et al. 2016). 
It is possible that a reduced requirement of mitochondrial translation after a certain time 
threshold as we report in mice, explains the stabilization in these patients.  
The abundance of some enzymes that are strongly upregulated in affected tissues and 
the metabolic changes caused their altered steady-state levels should be evaluated as early 
biomarkers of mitochondrial dysfunction and the progression of OXPHOS deficiency. 
Furthermore, elucidating whether the secondary responses are adaptive or maladaptive can 
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result in targeted treatment strategies as suggested with the Q supplementation for patients 
with primary mtDNA gene expression defects.  
 
With regard to the regulation of mtDNA transcription by POLRMT, there are several 
questions that we are further investigating. First, we want to elucidate whether LSP activity is 
only increased when POLRMT levels are low or it is a constitutive characteristic of the 
promoters in vivo that is enhanced in the Polrmt knockout conditions. This question can be 
addressed by evaluating whether the accumulation of 7S RNA in the Polrmt overexpressor 
mice results from increased transcription initiation from LSP in comparison to HSP or increased 
transcript stability. Second, we are currently performing exercise challenges in the Polrmt 
overexpressor mice to investigate whether the increase in transcription initiation is 
advantageous when a boost in mitochondrial biogenesis and function is stimulated. Third, we 
are performing POLRMT pulldowns to identify potential interaction partners or post-
translational modifications mediating the function of this enzyme. This could provide valuable 
information on the regulation of POLRMT binding to the promoter regions, transcription, and 
the crosstalk between mtDNA replication and transcription. Finally, we are interested in 
understanding how POLRMT levels are regulated in different models of mitochondrial 
dysfunction. In the cancer field, it has been proposed that Polrmt is regulated by the MYC 
transcription factor (Oran et al. 2016). However, despite the strong increase in Myc transcript 
levels and several of its target genes, Polrmt transcripts are not increased in Tfam, Twnk, 
Lrpprc or Mterf4 knockouts suggesting that a different mechanism is mediating the increased 
POLRMT levels. 
 
To understand the pathogenesis of OXPHOS dysfunction, the differentiation of 
proximal consequences of OXPHOS dysfunction from secondary ripple-effects, is still an 
important yet challenging venture that requires multidisciplinary approaches to address. 
Obtaining a better time-resolution early in the progression of OXPHOS deficiency will be 
important to distinguish early transcriptional responses from later ones. Furthermore, 
complementation with metabolic measurements (both steady-state and changes in the fluxes) 
could help identify early changes in mitochondrial function that lead to nuclear transcriptional 
responses. As the transcription factors identified so far can have broad downstream targets, 
determining which targets they are binding to in a mitochondrial dysfunction setting would help 
to define the different transcription programs. Disrupting the activity of these factors in vivo 
would have a profound effect on many cellular aspects and their role in mitochondrial 
dysfunction would be difficult to differentiate. Therefore, identifying the genes that these 
transcription factors bind in vivo in current models of mitochondrial dysfunction using 
techniques like ChIP-Seq or DNA affinity purification sequencing (DAP-Seq) would provide 
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more conclusive experimental evidence of the transcriptional programs they regulate in this 
specific context.  
Studying the effects of each miss-regulated pathway in detail would help to understand 
the net effect of that pathway to the end pathology. For example, recent studies have knocked 
out enzymes of the mitochondrial 1C pathway and identified that it is important to maintain 
mitochondrial translation (Minton et al. 2018; Morscher et al. 2018). However, it has not been 
studied yet what happens when the enzymes are overexpressed as it occurs in mitochondrial 
dysfunction and whether the net-effects observed (increased levels of enzymes, THF-
intermediates, and decreased formate) result from the upregulation of the enzymes or changes 
in the redox balance as NAD+/NADH and NADP+/NADPH are cofactors required for these 
reactions. The definition and mechanistic study of these processes will be important to 
understand which nDNA responses contribute to compensate for a primary OXPHOS defect, 
aggravate the disease progression, or induce gene expression changes reflected in the 
transcript and protein levels that correlate with mitochondrial dysfunction but are neither 
beneficial or harmful. Furthermore, it would help explain the end pathology that results from a 
primary OXPHOS defect and provide valuable information to understand the broad clinical 
spectrum and pleiotropic tissue manifestations of these diseases.  
Finally, understanding how these processes result in mitochondrial diseases can be 
translated to understand the contribution of mitochondrial dysfunction to other common human 
pathologies with similar molecular signatures. To exemplify, the 1C pathway enzymes, Mthfd2 
and Shmt2, and the enzyme involved in proline synthesis from glutamate, Pycr1, have also 
been identified as highly upregulated in human tumors (Nilsson et al. 2014). Moreover, the 
same expression pattern that we report for the proline synthesis from glutamate was found in 
cancer cell models and suggested to be mediated by MYC (Liu et al. 2012). Importantly, the 
proteomic, transcriptomic, and metabolomic findings we report in mouse should be 
corroborated in patient samples.  
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6. MATERIALS AND METHODS 
 
6.1. Experimental models 
 
6.1.1. Mouse strains  
 
The targeting vector to disrupt Polrmt in embryonic stem cells (derived from C57Bl/6N mice) 
was generated using BAC clones from the RPC10-731 BAC library by TaconicArtemis GmbH. 
Exon 3 of Polrmt locus was flanked by loxP sites and a positive selection marker (PuroR) 
flanked by FRT sites was introduced into intron 2. The puromycin resistance cassette was 
removed by mating the Polrmt +/loxP-pur mice with transgenic mice ubiquitously expressing flp 
recombinase that recognizes the FRT sites. Next, the resulting Polrmt+/loxP mice were mated 
with transgenic mice ubiquitously expressing the cre recombinase under the control of the b-
actin promoter (b-actin cre) to generate heterozygous knockout Polrmt+/- mice. Heart- and 
skeletal muscle- specific knockouts for Twnk, Tfam, Polrmt, Lrpprc, and Mterf4 were obtained 
by mating mice containing an exon of the gene of interest flaked by loxP sites with mice 
expressing the cre recombinase from the muscle creatinine kinase promoter (Ckmm-cre). The 
targeting strategy for the generation of Twnk, Tfam, Lrpprc and Mterf4 were published 
previously (Table S1 in supplementary material section 8.2).  
 
BAC clones containing a fragment of chromosome 10, including Polrmt, were 
purchased from the C57Bl/6N BAC library of DNA Bank, RIKEN BioResource Center. The 
BAC library was generated in the pBAC3.6 vector. The BAC clone BgN01-092D16 was 
modified by Red/ET recombination using the counter-selection BAC modification kit 
(Genebridges). A silent point mutation was introduced into exon 3 leading to a unique HindIII 
restriction site. Briefly, to modify the BAC, streptomycin-resistant bacteria containing the BAC 
clone were transformed with a temperature sensitive pRed/ET plasmid that encodes the 
proteins required for homologous recombination. Then, the bacteria were transformed with a 
PCR-generated fragment containing Polrmt sequences flanking the mutated regions, the 
mutations, and a cassette that confers resistance to kanamycin and susceptibility to 
streptomycin. Finally, to replace the antibiotic resistance cassette, bacteria were transformed 
with a PCR-generated fragment containing the Polrmt sequences flanking the mutated regions 
and the mutations. Positive clones were selected for streptomycin resistance and verified by 
PCR followed by restriction digest, Sanger sequencing, and Southern blotting (section 6.3.6). 
All transformations were performed by electroporation at 1350 V and 5 msec. Modified BAC 
was purified via caesium chloride gradient (section 6.3.2) and injected into the pronucleus of 
fertilized oocytes. Transgenic BAC lines were maintained as heterozygous. List of transgenic 
lines used in this thesis is in table S1 and genotyping primers is in table S2.  
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Animals were housed in individually ventilated cages under specific-pathogen-free 
conditions with constant temperature (21°C) and humidity (50 - 60%) and a 12 h light/dark 
cycle. All mice were fed commercial rodent chow and provided with acidified water ad libitum. 
Mice were sacrificed by cervical dislocation. The health status of the animals is specific 
pathogen free according to the Federation of the European Laboratory Animal Science 
Association (FELASA) recommendations. All animal procedures were conducted in 
accordance with European, national and institutional guidelines and protocols (no.: AZ.: 84-
02.05.50.15.004 and AZ.: 84-02.04.2015.A103) were approved by the Landesamt für Natur, 
Umwelt und Verbraucherschutz, Nordrhein-Westfalen, Germany. 
 
6.1.2. Cell lines 
 
HeLa (ATTC CCL-2) and 143B (CRL8303) cells were maintained at 37°C and 5% CO2 in 
Dulbecco’s modified eagle medium with high glucose (DMEM GlutaMax, 4.5 g/L glucose, 
Gibco) and supplemented with 10% foetal bovine serum (Gibco) and 1% 
Penicillin/Streptomycin (Gibco). 143Br0 (King & Attardi 1989) cell culture media was 
supplemented with uridine (50µg/mL). All cell lines were tested to be negative for Mycoplasma.  
 
6.2. Methods in cell culture 
 
6.2.1. Cell harvesting and passaging 
 
Cells were passaged when they reached 80 - 100% confluency. To harvest the cells, the 
culture media was removed and the cells were washed with Dulbecco’s modified PBS (DPBS, 
Gibco) to remove residual traces of the culture medium. Next, 0.05% trypsin/0.02% EDTA 
(Gibco) was added to the cells followed by a 5 min incubation at 37°C under a 5% CO2 
atmosphere to detach the adherent cells from the culture flasks. The detached cells were 
resuspended and passaged to a new flask containing fresh culture media.  
 
6.2.2. Cell thawing and freezing  
 
Cells were harvested as described in section 6.2.1 and resuspended in freezing media (DMEM 
GlutaMax, 4.5 g/L glucose, supplemented with 20% FBS and 10% DMSO). Cells were 
transferred to a cryo-vial (Nalgene) and placed in a Mr. Frosty Cryo container (Nalgene) with 
isopropanol, placed at -80°C for 24 h and then transferred to a liquid nitrogen tank for long 
term storage. To thaw, cells were transferred directly from the cryo-storage liquid nitrogen tank, 
to a 37 °C water bath. After thawing, the cells were transferred on T175 culture flasks with 
standard pre-warmed cell culture medium. The medium was changed after 24 h. 
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6.2.3. Transfection of mammalian cells 
 
Transfection of cell lines to was performed by lipofection using lipofectamine 2000 or 3000 
(Invitrogen) for expression vectors and lipofectamine RNAi max (Invitrogen) for small 
interference RNA (siRNA). For mammalian expression vectors, 70 - 80% confluent cells were 
transfected according to manufacturer’s instructions for 24 - 48 h. For siRNA, 50% confluent 
cells were transfected and transfections were repeated every 24 h.  
 
6.3.  Methods in molecular biology 
 
6.3.1. DNA isolation from mouse tissues and mitochondria 
 
For genotyping and pyrosequencing, tail or ear-clip biopsies DNA was extracted using 
chloroform and ethanol precipitation. Briefly, samples were lysed overnight in 400 µL TNES 
buffer (0.5% SDS, 0.1 M NaCl, 50 mM Tris pH 8.0, 2.5 mM EDTA pH 8.0) and 8 µL proteinase 
K (10 mg/mL) at 56°C. Next, 75 µL potassium acetate was added followed by 500 µL cloroform. 
The samples were vortexed and centrifuged at maximum speed for 10 minutes. The 
supernatant was collected and DNA was precipitated with 100% ethanol at -20 or -80°C. After 
centrifugation, the DNA pellet was washed with 70% ethanol and resuspended in dH2O. For 
Southern blotting or qPCR snap frozen tissues were grinded in a cold mortar. 20 - 30 µg of 
grinded tissue or ~ 9 x 106 frozen cells were used to extract DNA using the blood and tissue 
kit or the Gentra Puregene tissue kit (Qiagen) following manufacturer’s instructions. All 
samples used for Southern blotting and qPCR were treated with RNase (Qiagen). Frozen 
crude mitochondria were used for mtDNA isolation. Briefly, mitochondria were lysed in 400 µL 
TNES buffer and 10 µL proteinase K (10 mg/mL) for 2 – 3 h at 56°C. Then, lysates were treated 
with 3 µL RNase A (4 mg/mL) (Qiagen) and incubated 5 min at room temperature. DNA was 
extracted using 1 mL Phenol:Chloroform:Isoamyl alcohol (25:24:1 v/v) (ambion), followed by 
~400 µL of chloroform. DNA was precipitated overnight with 1/10 v/v 3M NaAc (ambion) and 
100% ethanol at -20 °C, washed with 75% ethanol, and resuspended in nuclease-free water.  
 
6.3.2. BAC DNA isolation for pro-nuclear injection 
 
BAC DNA was isolated as previously described (Milenkovic et al. 2013). Bacteria containing 
the BAC were streaked in LB agar with 18 µg/µL chloramphenicol and 50 µg/µL streptomycin. 
Single colonies were selected for overnight pre-cultures in 3 mL LB with antibiotics. The 
following day, 600 µL of the preculture were used to inoculate 1 L LB agar with antibiotics and 
cultured shaking at 180 rpm overnight. Next, bacterial cultures containing the mutated BACs 
were pelleted by centrifugation 6000 rcf at room temperature. Bacterial pellets were carefully 
resuspended in 50 mL buffer P1 (Qiagen) with RNase, followed by alkaline lysis using 50 mL 
of buffers P2 and P3 (Qiagen) on ice. Lysates were cleared by two sequential centrifugations 
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at 10000 rpm at 4 °C for 20 min and filtered using a 70 µm cell strainer. DNA was precipitated 
with isopropanol and pelleted at 10000 rcf for 15 min. The DNA pellet was resuspended in 3.8 
mL of nuclease-free water under gentle rotation overnight at 4°C. Then, 3.8 g of CsCl2 were 
added to the resuspended DNA and dissolved by gentle rotation. 290 µL of ethidium bromide 
(10 mg/µL; Sigma) were added to the resuspended DNA and homogenized by gentle inversion. 
Samples were centrifuged at 3000 rcf at room temperature to remove protein precipitates and 
ultra-centrifuged in a 100Ti rotor (Beckman Coulter) at 70000 rpm for 22 h at 25°C in a 
Beckman Coulter Optima L-100 XP ultracentrifuge. Supercoiled BAC DNA was visualized 
under a UV lamp (UVP) and collected. The ethidium bromide was eliminated by organic solvent 
extraction using 1-butanol. Finally, the DNA was precipitated using ice-cold 95% ethanol, 
washed with 70% ethanol, and resuspended in embryo-toxic free water. The isolated DNA was 
quantified using a Qubit Fluorometer and microinjected into the pro-nuclei of one-cell stage 
mouse embryos.  
 
6.3.3. RNA isolation from cells, mouse tissues, and mitochondria 
 
Total RNA from mouse tissues was extracted from snap-frozen tissues using the ToTALLY 
RNATM Kit (Ambion) or miRNAeasy kit (Qiagen) following the manufacturers’ instructions. 50-
100 mg of grinded mouse tissues were homogenized using lysing matrix D (MPBio) in a fast 
prep machine with 2x 30 sec pulses at speed 6 (MPBio). The homogenization step was 
repeated after 5 min incubation at room temperature.  Cells pellets were resuspended in Qiazol 
by pipetting (Qiagen). The isolated RNA was DNase treated using by in-column digestion using 
RNase-free DNase I (Qiagen) or TURBO DNA-freeTM kit (Ambion). The RNA concentration 
was measured with a NanoDrop 2000c spectrophotometer (Peqlab). Concentration, purity, and 
integrity of RNA for RNA-Seq were confirmed using Bioanalyzer or northern blotting (section 
6.4.7). Mitochondrial pellets were either resuspended in Qiazol and extracted using the 
miRNAeasy kit (Qiagen) or in Trizol LS (Life technologies) and extracted following 
manufacturer’s instructions.  
 
6.3.4. Pyrosequencing 
 
Quantification of Polrmt c420G>T was performed on tail DNA using a PyroMark Q24 
pyrosequencer (Qiagen). Allele Quantification assay was developed using PyroMark assay 
design software v. 2.0 (Qiagen). A single PCR reaction was employed to amplify a 192 bp 
fragment spanning the c.420G>T mutation site, using a biotinylated forward primer and a non-
biotinylated reverse primer. PCR products were combined with distilled water, PyroMark 
binding buffer (Qiagen), and 1µL Streptavidin sepharose TM high performance beads (GE 
Healthcare). Next, PCR products were purified and denatured using a Pyromakr Q24 vacuum 
workstation (Qiagen). Sequencing was performed with PyroMark Gold Q24 reagents according 
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to manufacturer’s instructions using the sequencing primer. Primer sequences are listed in 
Table S2 (supplementary material section 8.2). 
 
6.3.5. RNA sequencing 
 
RNA sequencing was performed on total RNA by the Cologne Genomics Centre (Cologne, 
Germany) on the Illumina HiSeq platform, according to the Illumina Tru-Seq protocol. Random 
hexamer primers were used for cDNA library generation and cytoplasmic rRNA depletion using 
the Ribo-Zero rRNA removal kit was carried out. The alignment to the Mus musculus reference 
genome (GRCm38) was performed using HISAT2 version 2.0.4 (hisat2 -p 8 --dta) (Kim et al. 
2015). Alignment files were sorted and indexed with SAMtools version 1.3.1 (samtools sort -
@ 8; samtools index -b)(H. Li et al. 2009). The transcript abundances were estimated with 
StringTie 1.2.4 (stringtie -p 18 -e –B –G) using the Ensembl 81 annotation (Pertea et al. 2016). 
The raw reads count matrix at gene-level was extracted with prepDE.py script provided at 
http://ccb.jhu.edu/software/stringtie/dl/prepDE.py on Python version 2.7.6.  
 
Paired-end deep sequencing of the mitochondrial RNAs was performed as previously 
described (Mercer et al. 2011) on an Illumina MiSeq according to the manufacturer’s 
instructions. Sequenced reads were aligned to the mouse genome (GRCm38) with HISAT 
0.1.6 (66) (–fr –rna-strandness RF; total RNA library). Reads that aligned to mtDNA were 
extracted and subsequently realigned with spliced alignment disabled to reflect the unspliced 
nature of the mitochondrial transcriptome and prevent the introduction of spurious splice 
junctions. Gene-specific counts were summarized with featureCounts 1.3.5-p4 (67) (-p -s 2 -Q 
10; total RNA library) using the Ensembl 75 gene annotation for nuclear-encoded genes and 
a modified annotation for mitochondrial genes. The modified annotation contains merged mt-
Atp8/mt-Atp6 and mt-Nd4l/mt-Nd4 annotations to reflect their bicistronic nature. Initially, genes 
with a zero count in any sample were filtered from the count table (in addition to mt-tRNAs), 
followed by loess and upper quartile normalization for guanine/cytosine content and 
sequencing depth, performed with EDASeq 2.3.2 (68).  
 
6.3.6. Southern blotting  
 
1 - 3 µg of digested DNA were separated in 0.8% agarose gel and transferred to HybondTM-XL 
or Hybond N+ membranes (Amersham Biosciences) by capillary transfer in 20X SSC (3M NaCl, 
0.3 M sodium citrate, pH 7.0). Prior transfer, the gels were treated for 10 min with 0.2 M HCl, 
15 min in denaturation solution (1.5 M NaCl; 0.5 M NaOH) and 15 min in neutralization solution 
(1.5 M NaCl, 0.5 M Tris pH 7.4). After ultraviolet (UV) crosslinking, the membranes were 
successively hybridized with various probes at 65°C in RapidHyb buffer (Amersham) and then 
washed in 2x and 0.2x SSC/0.1% SDS before exposure. Probes used were gel-purified 
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restriction fragments labelled with [a -32P]2’-deoxycytidine-5′-triphosphate (dCTP) and the 
Prime-IT Random Primer Labeling kit random priming kit (Agilent). The Polrmt probe was 
generated by PCR amplification of Polrmt cDNA containing exon 2 to exon 4. The PCR product 
was cloned into pCRII-blunt TOPO vector (Invitrogen), excised by restriction digest using 
EcoRI, and gel-purified using Qiaquick Gel extraction kit (Qiagen). All other probes were 
previously generated previously in the laboratory (Table S3 in supplementary material section 
8.2). Radioactive signals were detected by autoradiography and the quantifications were 
performed using the programs ImageJ or MultiGauge with images generated from a 
Phosphorimager. For the D-loop Southern, samples were heated for 5 min at 95°C prior 
loading and hybridization was performed at 42 °C. BAC DNA was digested with HindIII and 
mouse DNA for mtDNA detection was digested with SacI.  
 
6.3.7. Northern blotting 
 
1-3 μg of total RNA was separated in a 1.8% formaldehyde-MOPS [3-(N-morpholino) 
propanesulfonic acid] agarose gel and transferred to HybondTM-XL or Hybond N+ membranes 
(Amersham Biosciences) by capillary transfer in 20X SSC. After UV crosslinking, the blots 
were successively hybridized with various probes at 42 or 65°C in RapidHyb buffer 
(Amersham) and then washed in 2x and 0.2x SSC/0.1% SDS before exposure. Mitochondrial 
probes used for visualization of mt-mRNA and mt-rRNA levels were gel-purified restriction 
fragments labelled with [a -32P]dCTP and the Prime-IT Random Primer Labeling kit random 
priming kit (Agilent). Mt-tRNAs and 7S RNA were detected using specific end-labelled 
oligonucleotides with 30 µCi [γ-32P]ATP and the T4 Polynucleotide kinase (New England 
Biolabs). The membranes were stripped before rehybridization. The images were obtained by 
autoradiography and the quantifications were performed using the programs ImageJ or 
MultiGauge with images generated from a Phosphorimager. The list of probes and 
oligonucleotides is in Table S4 (supplementary material section 8.2).  
 
6.3.8. RT-PCR and qRT PCR 
 
cDNA synthesis was performed on 1-2 µg of DNase treated RNA using the High Capacity 
cDNA reverse transcription kit (Applied Biosystems). qRT-PCR was performed using the 
Taqman 2x Universal PCR mastermix, No Amperase UNG (Applied Biosystems) and 
commercially available assays against mouse from Life technologies on a 7900HT or 
QuantStudio 6 RealTime PCR System (Applied Biosystems). List of oligonucleotides for RT-
PCR and Taqman assays are listed in tables S3 and S4 (supplementary material section 8.2), 
respectively. 
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6.3.9. In organello replication and transcription assays 
 
In organello replication and transcription assays were performed on mitochondria isolated from 
mouse hearts by differential centrifugation as described in section 6.4.1. 0.5-1 mg of freshly 
isolated mitochondria were resuspended in transcription labelling buffer (25 mM sucrose, 75 
mM sorbitol, 100 mM KCl, 10 mM K2HPO4, 50 μM EDTA, 5 mM MgCl2, 1 mM ADP, 10 mM 
glutamate, 2.5 mM malate, 10 mM Tris pH 7.4, 1 mg/ml of bovine serum albumin (BSA), and 
1 mM ADP) and incubated with 40 μCi of [α-32P]uridine-5’-triphoshphate (UTP) under rotation 
for 1 h at 37°C. To reduce the background signal, mitochondria were washed and resuspended 
in transcription labelling buffer containing 0.2 mM UTP and incubated at 37°C for 10 min. 
Finally, mitochondria were pelleted and resuspended in washing buffer (10% glycerol, 10 mM 
Tris-HCl pH 6.8, and 0.15 mM MgCl2). An aliquot of resuspended mitochondria was collected 
as the input and analysed by western blot (section 6.4.9). Mitochondrial RNA was isolated from 
the final pellet using the TRIzol LS reagent (Ambion) and resuspended in 10 μl of nuclease-
free water to which 10 μL of 2X RNA Sample loading buffer (Sigma) was added. Samples were 
heated for 10-15 min at 65°C, separated in 1.2% formaldehyde-MOPS horizontal agarose gels 
at 120 V for 2 h or 1.8% formaldehyde-MOPS vertical agarose gels at 80 V for 1 h and 160 V 
for 4-5 h. RNA was transferred by northern blotting (section 6.3.7). UV-crosslinked membranes 
were exposed to autoradiography or decorated with radiolabelled probes. 
 
 For in organello replication, the same procedure was performed with the following 
modifications. Labelling buffer was supplemented with 50 mM dCTP, dTTP 2′-deoxythymidine-
5′-triphosphate (dTTP), 2′-deoxyguanosine-5′-triphosphate (dGTP), and 20 µCi of [a-
32P]deoxyadenosine-5’-triphosphate (dATP) (PerkinElmer or Hartmann analytics). Incubation 
in labelling buffer was performed for 2 h. mtDNA was isolated by phenol:chloroform:isoamyl 
alcohol extraction or by Puregene Core Kit A (Qiagen) (section 6.3.1), and radiolabelled 
replicated DNA was analysed by D-loop Southern blotting and visualized by autoradiography 
(section 6.3.6). Quantifications of mtDNA and transcript levels were performed using the 
program MultiGauge with images generated from a PhosphorImager instrument.  
 
6.3.10. In vitro transcription assay 
 
Transcription reactions were performed in 25 µl total volume containing 25 mM Tris pH 8.0, 10 
mM MgCl2, 64 mM NaCl, BSA (100 mg/ml), 1 mM dithiothreitol (DTT), 400 µM ATP, 150 µM 
guanosine-5′- triphosphate (GTP), 150 µM CTP, 10 µM uridine 5′-triphosphate (UTP), 0.02 µM 
[a-32P]UTP, and 4 U RNase Inhibitor Murine (New England Biolabs). The transcription 
template was added at 4 nM and consisted of a restriction cut (HindIII/EcoRI), purified 
(QIAquick PCR Purification Kit) human LSP/HSP plasmid, where a fragment consisting of 
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positions 325 to 742 of human mtDNA was cloned between the SmaI and HindIII sites of 
pUC18  (Farge et al. 2014). For each reaction, 128 nM human TFB2M and 320 nM human 
TFAM (corresponding to 1 TFAM per 40 bp) were added. Human POLRMT was added at five 
different concentrations: 128, 32, 8, 2, and 0.5 nM. The reactions were incubated at 32°C for 
30 min and stopped by the addition of stop buffer (10 mM Tris pH 8.0, 0.2 M NaCl, 1 mM 
EDTA, and proteinase K (100 mg/ml)) followed by incubation at 42°C for 45 min. The 
transcription products were ethanol-precipitated, dissolved in 20 ml loading buffer (98% 
formamide, 10 mM EDTA, 0.025% xylene cyanol FF, and 0.025% bromophenol blue), and 
analyzed on 4% denaturing polyacrylamide gels (1× tris-borate EDTA and 7 M urea). 
Quantifications of transcript levels were performed using the program MultiGauge with images 
generated from a PhosphorImager instrument.  
 
6.3.11. Linear density glycerol gradients 
 
10 to 45% linear density glycerol gradient were modified from previous studies (Lee et al. 
2013). Crude mitochondria (1 - 3 mg) from 4 to 5 week-old mouse hearts were isolated by 
differential centrifugation as described in section 6.4.1, pelleted by centrifugation 15 min at 
9.300 rcf and 4°C, and then lysed in a glass potter on ice in lysis buffer (5% glycerol, 20 mM 
NaCl, 30 mM Hepes pH 8.0, 1 mM EDTA, 2 mM DTT, and 1.2% Triton X-100 supplemented 
with EDTA-free complete protease inhibitor cocktail and PhosSTOP Tablets (Roche)). After 10 
min of incubation, lysates were cleared by centrifugation 5 min at 800 rcf and 4°C and overlaid 
on top of a 10 to 45% linear glycerol gradient prepared in 20 mM NaCl, 25 mM Hepes pH 8.0, 
1 mM EDTA, 1 mM DTT, 0.2% Triton X-100, and EDTA-free complete protease inhibitor 
cocktail (Roche). Gradients were centrifuged in a SW41 rotor at 21000 rcf at 4°C for 3 hours 
in a Beckman Coulter Optima L-100 XP ultracentrifuge. Gradients were prepared using 
Gradient Master (Biocomp Instruments Inc) in 14 mm × 89 mm Ultra-Clear Centrifuge Tubes 
(Beckman Instruments Inc.). Fractions of 750 ml were collected from the top of the gradients, 
and 20 µl of each fraction were analysed and western blotting (section 6.4.9). For analysis of 
mtDNA sedimentation profiles, mtDNA was isolated from two-thirds of each fraction using 
phenol/chloroform extraction (section 6.3.1), digested with SacI, and subjected to Southern 
blotting (section 6.3.6).  
 
6.4. Methods in biochemistry 
 
6.4.1. Total protein isolation from mouse tissues 
 
Frozen heart tissue was pulverized with liquid nitrogen and 20-30 mg were resuspended in 
tissue lysis buffer (25 mM HEPES pH 7.5, 5 mM MgCl2, 0.5 mM EDTA, 1% NP-40, and 140 
mM NaCl) containing 1X complete protease inhibitor cocktail (Roche). The tissue homogenate 
was mixed by pipetting and then sonicated for 10 cycles (30 sec sonication and 30 sec rest). 
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Finally, the samples were centrifuged at 13000 rpm for 10 min at 4°C to remove cell debris. 
The supernatant with the total proteins was collected and kept at -20°C. Total proteins were 
quantified using the Protein DC – Lowry based assay (BioRad). 
 
6.4.2. Isolation of crude mitochondria from mouse tissues 
 
Mouse heart, kidney, liver, brown adipose tissue, and spleen were washed in ice-cold PBS, 
minced, and homogenized using a Potter S homogenizer (Sartorius) in mitochondrial isolation 
buffer (320 mM sucrose, 1 mM EDTA, and 10 mM Tris-HCl pH 7.4) containing 1X complete 
protease inhibitor cocktail (Roche). Then, the homogenized tissue was centrifuged at 1000 rcf 
for 10 min to pellet cell debris and nuclei and the supernatant was re-centrifuged at 10000 rcf 
for 15 min to pellet the mitochondria. The mitochondrial pellet was resuspended in 
mitochondrial isolation buffer and the differential centrifugation was repeated to obtain more 
pure mitochondria.  
  
Isolation of mitochondria from skeletal muscle was performed as previously described 
(Frezza et al. 2007). Briefly, skeletal muscle was collected in ice-cold DPBS with 10 mM EDTA, 
trimmed from visible fat, ligaments and connective tissue, and minced into small pieces. After 
washing three times in DPBS with 10 mM EDTA, samples were incubated with 0.05% trypsin 
in DPBS for 30 min, transferred to IBm1 buffer (67 mM sucrose, 50 mM Tris pH 7.4, 50 mM 
KCl, 10 mM EDTA, 0.2% BSA) and homogenised using a Potter S homogenizer (Sartorius). 
Tissue homogenates were centrifuged two times 10 min at 800 rcf, and the supernatant was 
centrifuged at 8000 rcf for 10 min. The mitochondrial pellet was then resuspended in IBm2 
buffer (250 mM sucrose, 3 mM EGTA/Tris pH 7.4, 10 mM Tris pH 7.4) and centrifuged at 8000 
rcf for 10 min.  
 
All the isolation steps were performed on ice and the centrifugations at 4°C. Mitochondria 
were snap-frozen in liquid nitrogen and kept at -80°C. An aliquot of the isolated mitochondria 
was quantified using the Bradford reagent. Absorbance at 595 nm was measured using a 
Tecan 2000 microplate reader. A BSA standard curve was used to determine the protein 
concentration. 
 
6.4.3. Subcellular fractionation from cells and mouse tissues 
  
Subcellular fractionation of mouse heart was performed as previously described (Cox & Emili 
2006). Hearts were minced and washed in ice cold DPBS (Gibco) to remove excess of blood. 
Then, tissues were rinsed and homogenized using a Potter S homogenizer (Sartorius) in ice 
cold 250-STMDPS buffer (250 mM sucrose, 50 mM Tris pH 7.4, 5 mM MgCl2, 1 mM DTT, 
Spermine 25 mg/mL, Sermidine 25 ml/mL) containing 1x complete protease inhibitor cocktail. 
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An aliquot was collected as the total input fraction. The tissue homogenate was centrifuged 
800 rcf for 15 min at 4°C. The supernatant was re-centrifuged and saved for mitochondrial 
isolation. The pellet from the first centrifugation round was resuspended in buffer 250-STMDPS 
and re-homogenized using a Potter S homogenizer for 1 min. The homogenized tissue was 
centrifuged at 800 rcf for 15 min at 4°C. The nuclei were resuspended in 4 volumes of buffer 
2 M STMDPS (2M sucrose, 50 mM Tris pH 7.4, 5 mM MgCl2, 1 mM DTT, Spermine 35 mg/mL, 
Spermidine 25 mg/mL) containing 1x complete protease inhibitor cocktail. The resuspended 
nuclei were added to a 14 mm × 89 mm Ultra-Clear Centrifuge Tubes (Beckman Instruments 
Inc.) containing 4 mL of buffer 2 M STMDPS and centrifuged at 80000 rcf for 35 min at 4°C in 
SW 41Ti rotor using a L-100 XP ultracentrifuge (Beckman Instruments Inc). The pellet 
containing pure nuclei was saved as the nuclear fraction. The supernatant containing the 
mitochondria were centrifuged at 6000 rcf for 15 min to pellet the mitochondria and the 
mitochondrial pellet was resuspended as the mitochondrial fraction. Equal volumes of each 
fraction were lysed using 2x LDS buffer (Invitrogen) with 50 mM DTT and analysed by western 
blotting (section 6.4.9).   
 
Subcellular fractionation of cells was performed using the cell fractionation kit (Abcam). 
70-90% confluent cells were harvested using 0.05% trypsin (Gibco), washed in cold DPBS and 
pelleted by centrifugation at 800 rcf for 5 min. 6.6 x 106 cells were resuspended in buffer A and 
an equal volume of buffer B (buffer A + 1:1000 v/v detergent I) was added. An aliquot was 
collected as the total input fraction. The cell suspension was mixed for 7 min by constant 
rotation at room temperature followed by centrifugation at 5000 rcf for 1 min at 4°C. The 
supernatant was then re-centrifuged at 10000 rcf for 1 min at 4°C and the resulting supernatant 
was collected as the cytoplasmic fraction. The pellets resulting from both centrifugation steps 
containing nuclei and mitochondria were resuspended in an equal starting volume of buffer A 
and an equal volume of buffer C (buffer A + 1:25 v/v detergent II) was added. The samples 
were mixed for 10 min by constant rotation at room temperature followed by centrifugation at 
5000 rcf for 1 min at 4°C. The supernatant was then re-centrifuged at 10000 rcf for 1 min at 
4°C and the resulting supernatant was collected as the mitochondrial fraction. The pellets 
resulting from both centrifugation steps were resuspended in two times the original volume of 
buffer A and corresponded to the nuclear fraction. Equal volumes of each fraction were lysed 
using 2x LDS buffer (Invitrogen) with 50 mM DTT and analysed by western blotting (section 
6.4.9).   
 
6.4.4. Percoll-purification of mitochondria from mouse tissues 
 
Crude mitochondria from mouse tissues were isolated as described in section 6.4.1. 
Mitochondria isolation buffer was in addition supplemented with PhosStop tablets (Roche). 
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Mitochondrial pellets were washed in 1x M buffer (220 mM mannitol, 70mM sucrose, 5mM 
HEPES pH 7.4, 1 mM EGTA pH 7.4; pH was adjusted with potassium hydroxide; supplemented 
with EDTA-free complete protease inhibitor cocktail and PhosSTOP Tablets (Roche)) and 
purified on a Percoll density gradient (12%:19%:40% prepared with 2x M buffer) via 
centrifugation in a SW41 rotor at 15.500 rpm at 4°C for 1 h in a Beckman Coulter Optima L-
100 XP ultracentrifuge using 14 mm × 89 mm Ultra-Clear Centrifuge Tubes (Beckman 
Instruments Inc.). Mitochondria were harvested at the interphase between 19% and 40%, 
washed three times with buffer 1xM. Mitochondrial pellets were snap-frozen in liquid nitrogen 
and stored at -80°C.  
 
6.4.5. Peptide digestion and stage-tip peptide clean-up for label-free mass spectrometry 
 
Percoll-purified frozen mitochondria pellets were suspended in lysis buffer (6 M guanidinium 
chloride, 10 mM Tris(2-carboxyethyl)phosphine hydrochloride, 40 mM chloroacetamide, and 
100 mM Tris-HCl) (Kulak et al. 2014). After complete lysis, samples were diluted 1:10 in 20 
mM Tris pH 8.0 and quantified a NanoDrop 2000c spectrophotometer (Peqlab).  80 μg of 
protein were mixed with 3 μg of Trypsin gold (1m/mL)(Promega) and incubated overnight at 
37°C to achieve complete digestion. Peptides were cleaned with home-made STAGEtips 
(Rappsilber et al. 2003) (Empore Octadecyl C18; 3M) and eluted in 60% acetonitrile/0.1% 
formic acid buffer. Samples were dried in a SpeedVac apparatus (Eppendorf concentrator plus 
5305) at 45°C and the peptides were suspended with 0.1% formic acid. Approximately 1.5 μg 
of peptides were analysed by LC-MS/MS.  
 
6.4.6. LC-MS/MS analysis 
 
For mass spectrometric analysis, peptides were separated on a 25 cm, 75 μm internal diameter 
PicoFrit analytical column (New Objective, Part No. PF7508250) packed with 1.9 μm ReproSil-
Pur 120 C18-AQ media (Dr. Maisch, Mat. No. r119.aq) using an EASY-nLC 1000 or EASY-
nLC 1200 (Thermo Fisher Scientific). The column was maintained at 50°C. Peptides were 
separated on a segmented gradient of buffer A (0.1% formic acid) from 2% to 5% buffer B 
(0.1% formic acid in acetonitrile) for 10 min, from 5% to 20% buffer B for 100 min, from 20% 
to 25% buffer B for 10 min, and from 25% to 45% buffer B for 10 min at 200 nl / min (EASY-
nLC 1000). Using the EASY-nLC 1200 system, peptides were separated on a segmented 
gradient of buffer A from 3% to 6% buffer B’ (80% acetonitrile, 0.1% formic acid) for 10 min, 
from 6% to 25% buffer B’ for 100 min, from 25% to 31% buffer B’ for 10 min, and from 31% to 
60% buffer B’ for 10 min, at 200 nl / min. Eluting peptides were analysed on a QExactive HF 
mass spectrometer (Thermo Fisher Scientific). Peptide precursor mass to charge ratio (m/z) 
measurements (MS1) were carried out at 60000 resolution in the 300 to 1800 m/z range. The 
top ten most intense precursors with charge state from 2 to 7 only were selected for HCD 
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fragmentation using 25% collision energy. The m/z of the peptide fragments (MS2) were 
measured at 30000 resolution using an AGC target of 2e5 and 80 ms maximum injection time. 
Upon fragmentation precursors were put on an exclusion list for 45 sec. Peptides from the five 
knockout strains were analysed in two runs and Polrmt knockout was used to control for the 
variability within runs. The time course analysis on Lrpprc knockout was performed in a single 
run. Peptides from different tissues of the Polrmt overexpressor mice were analysed in a single 
run.  
 
6.4.7. Determination of Coenzyme Q and amino acid content from mouse tissues 
 
Quinones were extracted as previously described (Mourier et al. 2015). 20 mg of pulverized 
frozen mouse hearts were resuspended in 200 µl 1 mM cupric sulfate (CuSO4) and 200 µl 
100% ethanol and then sonicated for 10 cycles (30 sec sonication and 30 sec rest; diagenode 
Bioruptor plus). Then, 400 µl of hexane were added, the samples were vortexed and sonicated. 
The upper face was collected and samples were dried in a SpeedVac apparatus (Eppendorf 
concentrator plus 5305) at 60°C for 25 min. For absolute quantification of Q9 and Q10 in 
positive ESI multiple reaction monitoring (MRM) mode, an Acquity UPLC system (Waters) was 
connected to a Xevo TQ (Waters). An Acquity UPLC (Waters). A BEH C18 1.7 μm, 2.1 × 50 
mm column was used at 40°C. Solvent A was 90% methanol + 10% propanol + 0.1% FA, and 
solvent B was 45% acetonitrile/acetone + 10% propanol + 0.1% FA. A linear gradient of solvent 
A ranging from 100% to 0% in 3.5 min at a low rate of 0.45 ml/min was used. Between 2 and 
6 μl of the samples were injected. The sample manager was set to 6°C for the standards and 
the samples were defrozen and directly injected. The source temperature was set to 150°C, 
desolvation temperature was 650°C, desolvation gas was set to 800 L/h, and cone gas was 
set to 50 liter/h. All compounds were freshly prepared daily and dissolved in ethanol/methanol 
(9:1). Quality control standards of each standard were used during sample analysis and 
showed between 0.5% and 40% deviation for Q9 and Q10. Standard curve range was 4 – 
3500 ng/mL for Q10 and 100-2800 ng/mL for Q9.  
 
Other metabolites analysed in this study were extracted from 20-30 mg grinded frozen 
mouse hearts in 1 mL sample buffer (methanol:H2O:chloroform in a 7:2:1 ratio). Samples were 
mixed, sonicated (10 cycles; 30 sec sonication and 30 sec rest; diagenode Bioruptor plus) and 
centrifuged at 15000 rcf at 4°C for 5 min. Supernatants were centrifuged through 0.25 μm 
Centrifugal filters (VWR) and re-centrifuged twice at 15000 rcf for 5 min, placed at -80°C for 2 
h and re-centrifuged. Supernatants were dried in a SpeedVac apparatus (Eppendorf 
concentrator plus 5305) at 45°C for 1h. Next, samples were suspended in 100 µl and diluted 
1/20 in 5 mM ammonium formiate + 0.15% formic acid (Sigma), mixed, sonicated for 2 min 
and filtrated through a 0.2 µm modified nylon centrifugal filter (VWR). For absolute 
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quantification in positive and negative ESI MRM (multi reaction monitoring) mode an Acquitiy 
UPLC I-Class System (Waters) was connected to a XevoTM TQ-S (Waters). A Discovery HS 
F5-3 (Supelco) 3 µm, 2.1 x 100 mm column was used at 25°C. Solvent A was 5 mM ammonium 
formiate + 0.15% formic acid and B was acetonitrile (VWR). A gradient from 100% A to 80% 
in 3 min, to 4 min isocrate, to 4,5 min 50%, to 7 min 0%, to 10 min isocrate at a flow rate of 
0.35 ml/min was used. An equilibration step of 7 min was performed after each injection. The 
dilutions were injected twice of each injection volume, 0.1 µL and 8 µL. The sample manager 
was set to 8°C and the source temperature to 150°C, desolvation temperature was 500°C and 
desolvation gas was set to 800 L/h, cone gas to 150 L/h. The following MRM transitions were 
used as quantifier for sarcosine m/z 89.84 to 44.02 cone 14 V collision 18 V, glycine m/z 75.9 
to 30.08 cone 28 V collision 6 V and in a negative mode serine m/z 105.9 to 42.09 cone 72 V 
collision 10 V. All compounds were freshly prepared and dissolved in 5 mM ammonium 
formiate + 0.15% formic acid. An external standard calibration curve was calculated using 11 
concentrations from 100 to 20000 ng/ml (all of them were prepared from stock solutions 100 
µg/ml). Correlation coefficient: r < 0.990, the peak integrations were corrected manually, if 
necessary. Quality control standards of each standard were used during sample analysis and 
showed between 0.5% and 40% deviation respectively. Blanks after the standards, quality 
control and sample batch proved to be sufficient. No carry over was detected. The MassLynx 
(Waters) software was used for data management and TargetLynx (Waters) was used for data 
evaluation and absolute quantification of all metabolite compounds. Two to three technical 
replicates were performed for each measurement. 
 
6.4.8. Mitochondrial enzyme activity and respiration measurements  
 
To measure mitochondrial respiratory chain complex activities 15 to 50 µg of mitochondria 
were diluted in phosphate buffer (KH2PO4 50 mM, pH 7.4), followed by spectrophotometric 
analysis of isolated respiratory chain complex activities at 37°C, using a HITACHI UV-3600 
spectrophotometer. To follow citrate synthase activity, increase in absorbance at 412 nm 
(E=13600M-1.cm-1) was recorded after addition of acetyl-CoA (0.1 mM), oxaloacetate (0.5 
mM) and DTNB (0.1 mM). Succinate dehydrogenase (SDH) activity was measured at 600 nm 
(E=21000M-1.cm-1) after the addition of 10 mM succinate, 35 µM dichlorphenolindophenol 
(DCPIP) and 1 mM KCN. Succinate dehydrogenase - cytochrome c reductase (II-III) activity 
was measured at 550 nm after the addition of 10 mM succinate, 0.5 mg cytochrome c, and 1 
mM KCN. NADH dehydrogenase activity was determined at 340 nm (E=6220M-1.cm-1) after 
the addition of 0.25 mM NADH, 0.25 mM duroquinone, and 25 mM Azide and controlling for 
Antimycin A sensitivity. Cytochrome c oxidase activity was measured by standard TMPD 
ascorbate/KCN sensitive assays. Each activity was normalized to mg protein using the Lowry-
based BioRad protein DC kit. All chemicals were obtained from Sigma Aldrich. 
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Mitochondrial oxygen consumption flux was measured at 37°C using 65–125 µg of 
crude mitochondria diluted in 2.1 ml of mitochondrial respiration buffer (120 mM sucrose, 50 
mM KCl, 20 mM Tris-HCl, 4 mM KH2PO4, 2 mM MgCl2, 1 mM EGTA, pH 7.2) in an Oxygraph-
2k (OROBOROS INSTRUMENTS, Innsbruck, Austria). The oxygen consumption rate was 
measured using either 10 mM pyruvate, 5 mM glutamate, and 5 mM malate or 10 mM 
succinate and 10 nM rotenone. Oxygen consumption was assessed in the phosphorylating 
state with 1 mM ADP or non-phosphorylating state by adding 2.5 µg/ml oligomycin. Respiration 
was uncoupled by successive addition of carbonyl cyanide m-chlorophenyl hydrazone (CCCP) 
up to 3 µM to reach maximal respiration. 
 
6.4.9. Western blot 
 
5-50 µg of isolated mitochondria of total protein extracts were resuspended in NuPage LDS 
sample buffer with 50 mM DTT (Invitrogen). Proteins were separated by SDS-PAGE using 
either 4-12% or 10% precast gels (Invitrogen) and then transferred onto polyvinylidene 
difluoride membranes (HybondTM-P from GE Healthcare). Immunodetection was performed 
according to standard techniques using enhanced chemiluminiscence (Immun-Star HRP 
Luminol/Enhancer from BioRad). The antibodies used are listed in table S5 
 
6.4.10. BN-PAGE and in gel enzyme activity 
 
100 mg of crude heart mitochondria were solubilized in solubilization buffer (1% (w/v) digitonin 
(Calbiochem), 20 mM Tris pH 7.4, 0.1 mM EDTA, 50 mM NaCl, 10% (v/v) glycerol) and 
incubated on ice for 15 min. Non-solubilized material was removed by centrifugation and the 
supernatant was mixed with loading die (5% (w/v) Coomasie Brilliant Blue G-250 (Serva), 100 
mM Tris pH 7.0, 500 mM 5-aminocaproic acid). Samples were resolved on a 4 – 10% (w/v) 
acrylamide gradient BN- gels (Schägger & Jagow 1991). BN gels were further subjected to 
western blot (section 6.4.9) or Coomassie Brilliant Blue R staining. The antibodies used are 
listed in Table S5 (supplementary material section 8.2) 
 
6.4.11. Immunofluorescence 
 
HeLa cells were grown at 37°C, 5% CO2 on coverslips. To detect spRNAP-IV, cells were 
transfected with a mammalian expression vector encoding spRNAP-IV fused to an EGFP tag 
using lipofectamine 2000 (Invitrogen). Cells were stained with MitoTracker red CMXRos 
(Invitrogen) and subsequently fixed with 4% paraformaldehyde. To visualize endogenous 
POLRMT, cells were incubated with antibodies against human POLRMT and visualized using 
AlexaFluor 488 goat anti-rabbit secondary antibody. After immunolabelling, samples were 
stained with 1 g/mL DAPI (AppliChem) and mounted in Prolong Gold (ThermoFisher). The 
image acquisition was performed with a Leica TCS SP8-X inverted confocal microscope (Leica 
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Microsystems) using a 100×/1.4 oil objective. The antibodies used are listed in Table S5 
(supplementary material section 8.2) 
 
6.4.12. Morphological analyses heart sections 
 
Hematoxylin and eosin stainings were performed on paraformaldehyde (PFA)–fixed 
cryosections from 4-week old mouse hearts that were immediately embedded in OCT Tissue-
Tek in cooled methyl-butan. Images of heart sections were generated by stitching of several 
images taken with the Nikon Eclipse Ci microscope. For transmission electron microscopy, 
pieces of the mouse heart apex were fixed in 2% glutaraldehyde and 2% PFA in 0.1 M sodium 
cacodylate buffer (pH 7.4). Specimens were postfixed in 1% osmium tetroxide [in 0.1 M sodium 
cacodylate buffer (pH 7.4)]. After thorough washing with water, specimens were dehydrated in 
ethanol followed by acetone and embedded in medium-grade Agar Low Viscosity Resin 
(Plano). Ultrathin sections (70 to 80 nm) were cut with a Reichert-Jung Ultracut E 
Ultramicrotome, stained with 2% uranyl acetate in 70% ethanol, followed by lead citrate, and 
examined with a Hitachi H-7650 transmission electron microscope operating at 100 kV fitted 
with a midmounted AMT XR41-M digital camera (Advanced Microscopy Techniques).  
 
6.5. Data and statistical analyses  
 
6.5.1. LC-MS/MS data analysis 
 
The raw data were analysed with MaxQuant version 1.4.1.2 (Cox and Mann, 2008) using the 
integrated Andromeda search engine (Cox et al. 2011). Peptide fragmentation spectra were 
searched against the canonical and isoform sequences of the mouse reference proteome 
(proteome ID UP000000589, August 2015 from UniProt). The database was complemented 
with 245 sequences of contaminating proteins by MaxQuant. For the analysis methionine 
oxidation and protein N-terminal acetylation were set as variable modifications. The digestion 
parameters were set to “specific” and “Trypsin/P,” allowing for cleavage after lysine and 
arginine also when followed by proline. The minimum number of peptides and razor peptides 
for protein identification was 1; the minimum number of unique peptides was 0. Protein 
identification was performed at a peptide spectrum matches and protein false discovery rate 
(FDR) of 0.01. The “second peptide” option was on to identify co-fragmented peptides. 
Successful identifications were transferred between the different raw files using the “Match 
between runs” option, using a match time window of 0.7 min. LFQ (Cox et al. 2014) was 
performed using a minimum ratio count of 2. 
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6.5.2. Protein LFQ quantification analysis 
 
Analysis of the LFQ results was done using the Perseus computation platform (Tyanova et al. 
2016), version 1.5.0.0 and R, version 3.3.0 (R Development Core Team, 2010). For the 
analysis, LFQ intensity values were loaded in Perseus and all identified proteins marked as 
“Reverse”, “Only identified by site”, and “Potential contaminant” were removed. The 
corresponding L/L and the L/L, cre genotypes were loaded separately in Perseus, the LFQ 
intensity values were log2 transformed and all proteins that contained less than two to five 
missing values in one of the groups (L/L or L/L, cre) were removed. Missing values in the 
resulting subset of proteins were imputed with a width of 0.3 and down shift of 1.8. Imputed 
LFQ intensities were loaded into R where a two-sided moderated t-test analysis was performed 
using limma, version 3.30.13 (Ritchie et al. 2015). Proteins with an adjusted p value (“BH” 
correction) of less than 0.05 were designated as differentially expressed. Our list of 
differentially expressed proteins was combined with annotations from MitoCarta2.0 (Calvo, 
Clauser & Mootha 2016). The first of the semicolon separated entries in the “Gene names” 
column was used to merge annotations through the “Symbol” or “Synonyms” columns of the 
Mouse.MitoCarta2.0.txt file. For protein entries that lacked a “Gene names” entry, gene name 
information was retrieved using UniProt.ws, version 2.14 (Carlson, 2017). Using the principles 
of the ‘Total Protein approach’ (Wiśniewski et al. 2014), the LFQ intensity values were used to 
calculate the contribution of all mitochondrial proteins, according to MitoCarta2.0, to the total 
protein mass. Log2 transformed LFQ intensity and fold changes were used to generate density 
ad MA-plots plots. The mean LFQ value of controls was used to generate MA-plots.  
 
Mouse MitoCarta2 protein sequences (Mouse.MitoCarta2.0.fasta) were downloaded 
from https://www.broadinstitute.org/scientific-community/science/programs/metabolic-
disease-program/publications/mitocarta/mitocarta-in-0. The sequences were combined with 
the Mouse Mitocarta2 protein annotations using the RefSeq ID and the protein length. In cases 
of multiple matches with identical sequences, a single sequence was randomly selected. The 
extracted sequences were analyzed using TargetP 1.1 (Emanuelsson et al. 2000). The 
analysis was performed using “Non-plant” and “no cutoffs” parameters. The “Perform cleavage 
site predictions” option (Nielsen et al. 1997) was enabled. Protein sequences predicted to 
localize to the Mitochondrion, indicated by “M” in the Loc column, with reliability class (RC) of 
one, two, or three, were N-terminally trimmed by the value of predicted mitochondrial target 
peptide (mTP) presequence length (TPlen columns). The initial methionine was removed from 
the remaining of sequences. In addition, a second set of sequences was derived by removing 
the initial methionine only. The seqinr package (Charif and Lobry, 2007) was used to calculate 
the isoelectric points (pI) and the grand average of hydropathy (GRAVY) scores of the two sets 
of sequences. The GRAVY scores were computed by calculating the sum of the Hydropathy 
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index (Kyte and Doolittle, 1982) of all amino acids in the protein sequence and dividing the 
value by the protein sequence length. The pI and GRAVY score values were combined with 
the average log2 RNA reads count per L/L, cre genotype and with the number of genotypes 
that had quantification values in the proteomic analysis. The data was divided into two disjoint 
sets, namely proteins quantified in zero genotypes and proteins quantified in at least one 
genotype. The empirical cumulative distributions of the pIs, GRAVY scores and the average 
log2 RNA counts of the two sets were visualized using the stat_ecdf function of the ggplot2 
package. 
 
Mitochondrial proteins were manually placed in functional categories based on literature and 
Uniprot (The UniProt Consortium 2017). For the L/L comparison across different time points, 
MaxQuant’s proteinGroups.txt file was combined with annotations from MitoCarta2.0 (Calvo, 
Clauser & Mootha 2016) as described above. The MitoCarta annotated data were imported 
into Perseus and filtered for at least nine valid LFQ intensity values across all samples (26 in 
total). Only proteins annotated as mitochondrial, according to the “MitoCarta2_List” column, 
were kept for analysis. Missing values were imputed as described above. Limma’s F-statistic 
was used to detect proteins with significant differences in protein expression across the time 
points. Testing was performed after the data were grouped per week (nine week-groups in 
total). The fold changes of the average LFQ intensity for all time points, relative to week three 
were calculated, scaled, and z-score normalized in R. Hierarchical clustering of the normalized 
data was performed with pheatmap, version 1.0.8 (Kolde, 2015), using Euclidean distance as 
a metric. The rows (proteins) dendrogram was cut into to ten clusters and proteins, which 
partitioned into the four main clusters. Profiles plots of the normalized fold change values were 
color-coded using the distance of each profile from the cluster center (mean value).    
 
For the Lrpprc knockout time course analysis data were imported into Perseus, filtered 
for at least 23 valid LFQ intensity values across all samples (46 in total), and missing values 
were imputed as described above. Limma’s F-statistic was used to detect proteins with 
significant differences in protein expression across the time-points for either the L/L or the L/L, 
cre genotype. In addition, the F-statistic was used to identify differentially expressed proteins 
that have a significant difference in the profile across the time-points. To compare complete 
categories of proteins, Wilcoxon signed-ranked test followed by FDR correction was 
performed.  
 
6.5.3. RNA-Seq data analysis 
  
Differential expression analyses of total RNA-Seq were performed with DESeq2 package R 
version 3.3.2 according to the standard DESeq2 tutorial that is part of the package (Love et al. 
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2014). Mt-RNAs were analysed according to the same protocol except the NUMT regions were 
masked, filtered to reads in proper pairs and analysed by DESeq2 as described above. 
Differential expression analysis of PARE sequencing was performed in R 3.2.0 with edgeR 
3.11.2 using a generalized linear model approach with tagwise dispersion estimates, and the 
offsets were generated by EDASeq (Robinson et al. 2010). 
 
 RNA-Seq data were analysed through the use of Ingenuity Pathways Analysis 
(Ingenuity® Systems, www.ingenuity.com). Log2 transformed fold changes and adjusted p 
values were uploaded to the program. Genes from the data set that met the adjusted p value 
cutoff of 0.05 in all the knockout strains of this study and were associated with a canonical 
pathway in Ingenuity’s Knowledge Base were considered for the analysis. The significance of 
the association between the data set and the canonical pathway was measured in 2 ways: 1) 
A ratio of the number of molecules from the data set that map to the pathway divided by the 
total number of molecules that map to the canonical pathway is displayed, 2) Fisher’s exact 
test was used to calculate a p value determining the probability that the association between 
the genes in the dataset and the canonical pathway is explained by chance alone. Genes from 
the RNA-Seq data sets that had a p value < 0.05 for all the knockout strains were loaded into 
Cytoscape (version 3.5.0; Shannon et al. 2003) and used as queries to the iRegulon plug-in 
(Janky et al. 2014). The putative regulatory region was selected to be 20 kb centred on the 
transcriptional start site (TSS), the normalized enrichment score (NES) threshold was set at 
3.0, and the maximum FDR on motif similarity was set at 0.001. Transcription factor enrichment 
analyses were performed based on motif or ChIP-Seq peaks enrichment using the 10K (9713 
PWMs) motif collection and the 1120 ChIP-Seq track collection, respectively. Target genes for 
MYC and ATF4 were obtained from published ChIP-Seq experiments (Han et al. 2013; Seitz 
et al. 2011).  
 
6.5.4. 2D annotation enrichment analysis 
 
2D annotation enrichment analysis of the proteomic and transcriptomic data was performed 
with Perseus (Cox & Mann 2012) using Benjamini-Hochberg FDR for truncation and a 
threshold value of 0.2. For the evaluation of the protein abundances during the post-natal 
development, identification of overrepresented functional categories in separate clusters was 
performed using Fisher exact test in Perseus. Benjamini-Hochberg FDR for truncation with a 
threshold value of 1. The top three overrepresented categories in each cluster, based on 
adjusted p value, are shown.  
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6.5.5. Statistical analyses 
 
Each mouse was considered an independent biological replicate (n) and repeated 
measurements of the same biological replicate were considered technical replicates. Unless 
indicated otherwise, ≥3 biological replicates of transgenic mouse strain and their respective 
age-matched control mice were used for all the experiments presented. Statistical analyses for 
RNA-Seq and MS protein quantification analyses were performed as described above. For 
qRT-PCR and metabolomics analyses variance was assessed using an F-test and statistical 
significance was assessed by a two-sample, two-tailed unpaired Student’s t-test in Excel. In 
organello experiments were analysed using a one-sample, two-tailed Student’s t-test with µ: 
100. Multiple comparison was corrected using Benjamini-Hochberg or Bonferroni correction as 
indicated in the figure legends. Statistical analyses were performed in Excel or R Studio version 
1.1.383. Data visualization in R was done using ggplot2 version 2.2.1 or pheatmap R packages 
version 1.08, respectively. The definition of centre and precision measures, and p values are 
provided in the figure legends. p < 0.05 was considered significant.  
 
6.6. Copyright of the main publications included in this thesis 
 
Results figures were reproduced from Kühl et al. 2014, Kühl et al. 2016, and Kühl et al. 2017 
from which I am co-author. The authors retain the rights on Kühl et al. 2014 for non-commercial 
use (https://www.nature.com/reprints/permission-requests.html). Material from Kühl et al. 2016 
is reproduced under the Creative Commons Attribution-Non Commercial 4.0 International 
licence (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/). Material from Kühl 
et al. 2017 is reproduced under a Creative Commons Attribution 4.0 International (CC BY 4.0) 
(https://creativecommons.org/licenses/by/4.0/).  
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8. SUPPLEMENTARY MATERIAL  
 
8.1. Heatmaps of gene expression profiles 
8.1.1. Transcript and protein expression profiles of genes encoding mitochondrial proteins by 
category (excluding other and unknown) 
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8.1.2. Transcript expression profiles of MYC and ATF4 target genes 
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8.2. Lists of reagents 
 
Table S1: List of transgenic strains 
 
Mouse strain Reference Genotyping primers 
LrpprcloxP/loxP, Ruzzenente et al. 2011 Lrpprc F and R 
LrpprcloxP/loxP, +/Ckmm-cre Ruzzenente et al. 2011 Ckmm cre F and R 
Lrpprc+/T Ruzzenente et al. 2011 Lrpprc +/T F and R 
Mterf4loxP/loxP, Camara et al. 2011 Mterf4 loxP F and R 
Mterf4loxP/loxP, +/Ckmm-cre Camara et al. 2011 Ckmm cre F and R 
PolrmtloxP/loxP, This thesis; Kühl et al. 2014; 2016 Polrmt loxP F and R 
PolrmtloxP/loxP, +/Ckmm-cre This thesis; Kühl et al. 2014; 2016 Ckmm cre F and R 
Polrmt+/- This thesis; Kühl et al. 2014; 2016 Polrmt loxP F and R and Polrmt KO R 
Polrmt+/T This thesis Polrmt +/T F and R 
Polrmt+/T; Lrpprc+/T This thesis  Same as single transgenic lines 
TfamloxP/loxP, Larsson et al. 1998 Tfam loxP F, R1 and R2 
TfamloxP/loxP, +/Ckmm-cre Larsson et al. 1998 Ckmm cre F and R 
TwnkloxP/loxP, Milenkovic et al. 2013 Twnk loxP F and R 
TwnkloxP/loxP, +/Ckmm-cre Milenkovic et al. 2013 Ckmm cre F and R 
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Table S2: List of oligonucleotides for genotyping, cloning, RT-PCR, and 
pyrosequencing 
 
Primer Sequence  
Genotyping Lrpprc loxP F 5’ GGAGAACAGGCCGCATCACAA 3’ 
Genotyping Lrpprc loxP R 5’ TGCCTTCCACCTCAGCTTACCACT 3’ 
Genotyping Lrpprc +/T F 5’ GCTGAAAGCTTGGGTACTCG 3’ 
Genotyping Lrpprc +/T R 5’ AAAAGGCCCAGCGACTAAAT 3’ 
Genotyping Mterf4 loxP F 5’ GGGATGTCCAGCCTTTTGATAGTA 3’  
Genotyping Polrmt loxP F 5’ CACTGGAGAGCCCCACCTCCCTTCTCCAGAAGGGT 3’ 
Genotyping Polrmt loxP R 5‘ CCACTAACCATGGCTGTCTGC 3’ 
Genotyping Polrmt KO R 5‘ GGCACATACTTGATACAGCTTGG 3‘ 
Genotyping Polrmt +/T F 5’ GAGGCTCGGGTGCGGCAGCTC 3’ 
Genotyping Polrmt +/T R 5‘ GTGCAGTGTGAGCACCTGCTGTC 3‘ 
Genotyping Tfam loxP F 5’ CTGCCTTCCTCTAGCCCGGG 3’ 
Genotyping Tfam loxP R1 5’ GTAACAGCAGACAACTTGTG 3’ 
Genotyping Tfam loxP R2 5’ CTCTGAAGCACATGGTCAAT 3’ 
Genotyping Twnk loxP F 5’ CAGGGATGGTAGTTGGTTCC 3’ 
Genotyping Twnk loxP R 5’ CTAGCTGAGACCTTGCATGG 3’ 
Genotyping Ckmm cre F 5’ CACGACCAAGTGACAGCAAT 3’ 
Genotyping Ckmm cre R 5’ AGAGACGGAAATCCATCGCT 3’ 
Figure 3.1 primer a 5′ CGGCGCTCCGGTGGACCCGAAGCG 3’ 
Figure 3.1 primer b 5’ GTGGCTTCTGCAGCTCAAGA 3’ 
Figure 3.1 primer c 5’ GCATCACGGTGTTGTACATGTGC 3’ 
Figure 3.1 primer d 5’ TCTTGAGCTGCAGAAGCCAC 3’ 
Figure 3.1 primer e 5‘ CGACGAGAAGTGACTGGACCAG 3‘ 
Figure 3.3 primer a 5’ CTTGGCCGGGTTCTGCGCTCC 3’ 
Figure 3.3 primer b 5’ TCCAGCAGTTCAGCATGGCC 3’ 
Figure 3.3 primer c 5’ GTGGCTTCTGCAGCTCAAGA 3’ 
Figure 3.3 primer d 5’ TTCACCCTCATCTCAGGTG3’ 
Figure 3.3 primer d’ 5’ CTTCACCCTCATCTCAG 3’ 
Pyrosequencing Polrmt +/T F 5’ AGAGGCGCCAAAAGGAAGTT 3’ 
Pyrosequencing Polrmt +/T R- biotin  5’ TCTTGCTTGGCTGCAGGTAG 3’ 
Pyrosequencing Polrmt +/T Seq 5’ CAAGATCTGGAACAAGAA 3’ 
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Table S3: List of probes and oligonucleotides for radioactive labelling  
 
Probe Sequence  
7S DNA AGTACATAAATTTACATAGTACAACAGTACATTTATGTATATCGTACATTAAACTATTTTCC
CCAAGCATATAAGCTAGTACATTAAATCAATGGTTCAGGTCATAAAATAATCATCAACATA
AATCAATATATATACCATGAATATTATCTTAAACACATTAAACTAATGTTATAAGGACATATC
TGTGTTATCTGACATACACCATACAGTCATAAACTCTTCTCTTCCATATGACTATCCCCTTC
CCCATTTGGTCTATTAATCTACCATCCTCCGTGAAACCAACAACCCGCCCACCAATGCCC
CTCTTCTCGCTCCGGGCCCATTAAACTTGGGGGTAGCTAAACTGAAACTTTATCAGACAT
CTGGTTCTTACTTCAGGGCCATCAAATGCGTTATCGCCCATACGTTCCCCTTAAATAAGAC
ATCTCGATGGTATCGGGTCTAATCAGCCCATGACCAACATAACTGTGGTGTCATGCATTT
GGTATCTTTTTATTTTGGCCTACTTTCATCAACATAGCCGTCAAGGCATGAAAGGACAGCA
CACAGTCTAGACGCACCTACGGTGAAGAATCATTAGTCCGCAAAACCCAATCACCTAAGG
CTAATTATTCATGCTTGTTAGACATAAATGCTACTCAATACCAAATTTTAACTCTCCAAACC
CCCCACCCCCTCCTCTTAATGCCAAACCCCAAAAACACTAAGAACTTGAAAGACATATAAT
ATTAACTATCAAACCCTATGTCCTGATCAATTCTAGTAGTTCCCAAAATATGACTTATATTT
TAGTACTTGTAAAAATTTTACAAAATCATGTTCCGTGAACCAAAACTCTAATCATACTCTAT
TACGCAATAAACATTAACAA 
 
7S RNA GACATATAATATTAACTATCAAACCCTATGTCCTGATCAATTCTA 
18S rRNA GGTCTACAAGACGCCACATCCCCTATTATAGAAGAGCTAATAAATTTCCATGATCACACAC
TAATAATTGTTTTCCTAATTAGCTCCTTAGTCCTCTATATCATCTCGCTAATATTAACAACA
AAACTAACACATACAAGCACAATAGATGCACAAGAAGTTGAAACCATTTGAACTATTCTAC
CAGCTGTAATCCTTATCATAATTGCTCTCCCCTCTCTACGCATTCTATATATAATAGACGAA
ATCAACAACCCCGTATTAACCGTTAAAACCATAGGGCACCAATGATACTGAAGCTACGAA
TATACTGACTATGAAGACCTATGCTTTGATTCATATATAATCCCAACAAACGACCTAAAAC
CTGGTGAACTACGACTGCTAGAAGTTGATAACCGAGTCGTTCTGCCAA 
 
mt-12S TACACATGCAAACCTCCATAGACCGGTGTAAAATCCCTTAAACATTTACTTAAAATTTAAG
GAGAGGGTATCAAGCACATTAAAATAGCTTAAGACACCTTGCCTAGCCACACCCCCACGG
GACTCAGCAGTGATAAATATTAAGCAATAAACGAAAGTTTGACTAAGTTATACCTCTTAGG
GTTGGTAAATTTCGTGCCAGCCACCGCGGTCATACGATTAACCCAAACTAATTATCTTCG
GCGTAAAACGTGTCAACTATAAATAAATAAATAGAATTAAAATCCAACTTATATGTGAAAAT
TCATTGTTAGGACCTAAACTCAATAACGAAAGTAATTCTAGTCATTTATAATACACGACAG
CTAAGACCCAAACTGGGATTAGATACCCCACTATGCTTAGCCATAAACCTAAATAATTAAA
TTTAACAAAACTATTTGCCAGAGAACTACTAGCCATAGCTTAAAACTCAAAGGACTTGGCG
GTACTTTATATCCATCTAGAGGAGCCTGTTCTATAATCGATAAACCCCGCTCTACCTCACC
ATCTCTTGCTAA 
 
mt-16S ATGCAACACTGTTAGTATGAGTAACAAGAATTCCAATTCTCCAGGCATACGCGTATAACAA
CTCGGATAACCATTGTTAGTTAATCAGACTATAGGCAATAATCACACTATAAATAATCCAC
CTATAACTTCTCTGTTAACCCAACACCGGAATGCCTAAAGGAAAGATCCAAAAAGATAAAA
GGAACTCGGCAAACAAGAACCCCGCCTGTTTACCAAAAACATCACCTCTAGCATTACAAG
TATTAGAGGCACTGCCTGCCCAGTGACTAAAGTTTAACGGCCGCGGTATCCTGACCGTG
CAAAGGTAGCATAATCACTTGTTCCTTAATTAGGGACTAGCATGAACGGCTAAACGAGGG
TCCAACTGTCTCTTATCTTTAATCAGTGAAATTGACCTTTCAGTGAAGAGGCTGAAATATA
ATAATAAGACGAGAAGACCCTATGGAG 
 
mt-Co1 GTTCATTATTTTTGGTTGGTTGTCTTGGGTTAGCATTAAAGCCTTCACCTATTTATGGAGG
TTTAGGTTTAATTGTTAGTGGGTTTGTTGGTTGTTTAATGGTTTTAGGGTTTGGTGGATCG
TTTTTAGGTTTAATAGTTTTTTTAATTTATTTAGGGGGGATGTTGGTTGTGTTTGGATATAC
GACTGCTATAGCTACTGAGGAATATCCAGAGACTTGGGGATCTAACTGATTAATTTTGGG
TTTTTTAGTATTGGGGGTGATTATAGAGGTTTTTTTAATTTGTGTGCTTAATTATTATGATG
AAGTTGGAGTAATTAATCTTGATGGTTTGGGAGATTGGTTGATGTATGAGGTTGATGATGT
TGGAGTTATGTTGGAAGGAGGGATTGGGGTAGCGGCAATATATAGTTGTGCTACTTGAAT
GATGGTAGTAGCTGGGTGATCTTTGTTTGCGGGTATTTTTATT 
 
mt-Co2 GGTCTACAAGACGCCACATCCCCTATTATAGAAGAGCTAATAAATTTCCATGATCACACAC
TAATAATTGTTTTCCTAATTAGCTCCTTAGTCCTCTATATCATCTCGCTAATATTAACAACA
AAACTAACACATACAAGCACAATAGATGCACAAGAAGTTGAAACCATTTGAACTATTCTAC
CAGCTGTAATCCTTATCATAATTGCTCTCCCCTCTCTACGCATTCTATATATAATAGACGAA
ATCAACAACCCCGTATTAACCGTTAAAACCATAGGGCACCAATGATACTGAAGCTACGAA
TATACTGACTATGAAGACCTATGCTTTGATTCATATATAATCCCAACAAACGACCTAAAAC
CTGGTGAACTACGACTGCTAGAAGTTGATAACCGAGTCGTTCTGCCAA 
 127 
Probe Sequence  
mt-Cytb AGTAGACAAAGCCACCTTGACCCGATTCTTCGCTTTCCACTTCATCTTACCATTTATTATC
GCGGCCCTAGCAATCGTTCACCTCCTCTTCCTCCACGAAACAGGATCAAACAACCCAACA
GGATTAAACTCAGATGCAGATAAAATTCCATTTCACCCCTACTATACAATCAAAGATATCC
TAGGTATCCTAATCATATTCTTAATTCTCATAACCCTAGTATTATTTTTCCCAGACATACTA
GGAGACCCAGACAACTACATACCAGCTAATCCACTAAACACCCCACCCCATATTAAACCC
GAATGATATTTCCTATTTGCATACGCCATTCTACGCTCAATCCCCAATAAACTAGGAGGTG
TCCTAGCCTTAATCTTATCTATCCTAATTTTAGCCCTAATACCTTTCCTTCATACCTCAAAG
CAACGAAGCCTAATATTCCGCCCAATCACACAAATTTTGTACTGAATCCTAGTAGCCAACC
TACTTATCTTAACCTGAATTGGGGGCCAACCAGTAGAACACCCATTT 
 
mt-Nd1 ACGCAAAATCTTAGGGTACATACAACTACGAAAAGGCCCTAACATTGTTGGTCCATACGG
CATTTTACAACCATTTGCAGACGCCATAAAATTATTTATAAAAGAACCAATACGCCCTTTAA
CAACCTCTATATCCTTATTTATTATTGCACCTACCCTATCACTCACACTAGCATTAAGTCTA
TGAGTTCCCCTACCAATACCACACCCATTAATTAATTTAAACCTAGGGATTTTATTTATTTT
AGCAACATCTAGCCTATCAGTTTACTCCATTCTATGATCAGGATGAGCCTCAAACTCCAAA
TACTCACTATTCGGAGCTTTACGAGCCGTAGCCCAAACAATTTCATATGAAGTAACCATAG
CTATTATCCTTTTATCAGTTCTATTAATAAATGGATCCTACTCTCTACAAACACTTATTACAA
CCCAAGAACACATATGATTACTTCTGCCAGCCTGACCCATAGCCATAATATGATTTATCTC
AACCCTAGCAGAAACAAAC 
 
mt-Nd5 ACAAGACATCCGAAAAATAGGAAACATCACAAAAATCATACCATTCACATCATCATGCCTA
GTAATCGGAAGCCTCGCCCTCACAGGAATACCATTCCTAACAGGGTTCTACTCAAAAGAC
CTAATTATTGAAGCAATTAATACCTGCAACACCAACGCCTGAGCCCTACTAATTACACTAA
TCGCCACTTCTATAACAGCTATGTACAGCATACGAATCATTTACTTCGTAACAATAACAAA
ACCGCGTTTTCCCCCCCTAATCTCCATTAACGAAAATGACCCAGACCTCATAAACCCAAT
CAAACGCCTAGCATTCGGAAGCATCTTTGCAGGATTTGTCATCTCATATAATATTCCACCA
ACCAGCATTCCAGTCCTCACAATACCATGATTTTTAAAAACCACAGCCCTAATTATTTCAG
TATTAGGATTCCTAATCGCACTAGAACTAAACAACCTAACCATAAAACTATCAATAAATAAA
GCAAATCCATATTCATCCTTCTCAACTTTACTGGGGTTTTTCCCATCTATTATTCACCGCAT
TACACC 
 
mt-Nd6 GTTCATTATTTTTGGTTGGTTGTCTTGGGTTAGCATTAAAGCCTTCACCTATTTATGGAGG
TTTAGGTTTAATTGTTAGTGGGTTTGTTGGTTGTTTAATGGTTTTAGGGTTTGGTGGATCG
TTTTTAGGTTTAATAGTTTTTTTAATTTATTTAGGGGGGATGTTGGTTGTGTTTGGATATAC
GACTGCTATAGCTACTGAGGAATATCCAGAGACTTGGGGATCTAACTGATTAATTTTGGG
TTTTTTAGTATTGGGGGTGATTATAGAGGTTTTTTTAATTTGTGTGCTTAATTATTATGATG
AAGTTGGAGTAATTAATCTTGATGGTTTGGGAGATTGGTTGATGTATGAGGTTGATGATGT
TGGAGTTATGTTGGAAGGAGGGATTGGGGTAGCGGCAATATATAGTTGTGCTACTTGAAT
GATGGTAGTAGCTGGGTGATCTTTGTTTGCGGGTATTTTTATT 
 
mt-Ta 5’ GACTTCATCCTACATCTATTG 
mt-Tc 5’ TCTCTACACCTTCGAATTTG 
mt-Te 5 ‘AACTGCGACCAATGACATGAAAAATC 
mt-Tf 5’ CATTTTCAGTGCTTTGCTTTGTTATTA 
mt-Tk TCACTATGGAGATTTTAAGGTC 
mt-Tl1 AAGTCTTACGCAATTTCCTGGCTCTG 
mt-Tl2 GGTTTTTGGTTCCTAAGAC 
mt-Tm CCCGATAGCTTAATTAGCTGACCTTAC 
mt-Tn TACCCTATTACTGGCTTCAA 
mt-Tp TCAAGAAGAAGGAGCTACT 
mt-Tq TTCAAAATTCTCCGTGCTACCTAAACA 
mt-Ts2 GCATGAATTAGCAGTTCTTGCAATC 
mt-Tt AAGATCTTCATTTCAGGTTTACAA 
mt-Tv GTGTAGGCCAGATGCTTTAAT 
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Probe Sequence  
Polrmt E2 – E4 AATTCGCCCTTGTGGGGCCATGCTGAACTGCTGGAAGTGCTGGAGGCTCGGGTGCGGC
AGCTCCGGGCAGAGGGCACACCTGAGATGAGGGTGAAGAAGGTGCAGGTGGACCGGC
CTCCACAGGGCCACAGCAGCCGCTGGGCGCAAAAGCTAGAGGCTGAGAAAAGGGTGAA
GCAGAGGCGCCAAAAGGAAGTTGACCAGCAGAAGCAAGCCCTCACACAGGAGTTCTGG
ACCCTTCACAAGGAGCCCAAGATCTGGAACAAGAAGCTGGCTGGCTACCTGCAGCCAAG
CAAGAAGGGAACACCCACGAACTCAGAGGAAAAGCAGCTGGCCCAGGCCCTTCAGGCT
GCTCTGGGGAGGCTCAGCTCCCGTGAGGCAGAGGCCCTGGCCAGGAAGAAAGCCAAGG
CGGTGGAGGCGCAGATCCTGGTCCTCCAGCAGAAGTTCCTGGCTTTCTTTGAGTGCTGC
GTCTGCACTGGCCAAGTGCCCCTCGCTCACCACGTGCTGGTCACTCACCATAACAACGG
AGACAGACAGCAGGTGCTCACACTGCACATGTACAACACCGTGATGCTTGGCTGGGCCC
GCAAGGGCTCCTTCAGAGAGCTGGTCTATGTGAAGGGCG 
*All the probes and oligonucleotides were previously generated in the laboratory except Porlmt E2 – E4 
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Table S4: List of Taqman assays 
 
Taqman Assay Catalog Number 
Human 18S rRNA Hs99999901_s1 
Mouse Acta1 Mm00808218_g1 
Mouse Actc1 Mm01333821_m1 
Mouse Actg1 Mm01963702_s1 
Mouse Actg2 Mm00656102_m1 
Mouse Adck3 Mm00469737_m1 
Mouse Adck4 Mm00505363_m1 
Mouse Atf4 Mm00515325_m1 
Mouse Coq2 Mm01203260_g1 
Mouse Coq4 Mm00618552_m1 
Mouse Coq5 Mm00518239_m1 
Mouse Coq7 Mm00501587_m1 
Mouse Fdps Mm00836315_g1 
Mouse Gabpa Mm00484598_m1 
Mouse Hmgcs1 Mm01304569_m1 
Mouse Hmgcr Mm01282499_m1 
Mouse Lrpprc Mm00511512_m1 
Mouse mt-Atp6 Mm03649417-g1 
Mouse mt-Co1 Mm04225243_g1 
Mouse mt-Cytb Mm04225271_g1 
Mouse mt-Nd1 Mm04225274_s1 
Mouse mt-Nd5 Custom-made AIHSNT9 
Mouse mt-Rnr2 (mt-16S) Mm04260181_s1 
Mouse Mterf2 Mm01233053_m1 
Mouse Mterf3 Mm00481557_m1 
Mouse Mterf4 Mm00508298_m1 
Mouse Myc Mm00487804_m1 
Mouse Nrf1 Mm00447996_m1 
Mouse Pdss1 Mm00450958_m1 
Mouse Pdss2 Mm01190168_m1 
Mouse Ppargc1(Pgc1a) Mm00447183_m1 
Mouse Polrmt Mm00553272_m1 
Mouse Polga Mm00450527_m1  
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Taqman Assay Catalog Number 
Mouse Serca2 Mm01201431_m1 
Mouse Ssbp1 Mm01131763_g1 
Mouse Tbp Mm00446973_m1 
Mouse Tefm Mm01304209_m1 
Mouse Tfam Mm00627275_m1 
Mouse Tfb2m Mm01620397_s1 
Mouse Peo1/Twnk Mm00467928_m1 
Mouse Pcyox1 Mm00482162_m1 
Mouse Zbtb1 Mm01281881_m1 
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Table S5: List of primary antibodies 
 
Antibody Source Catalog Number 
 
ALDH18A1 
 
Thermofisher Scientific 
 
PA5-19392  
CLPP Sigma-Aldrich WH0008192M1 
COX4 Cell Signaling 4850 
CS Abcam ab129095 
ELAC2 Proteintech 10071-1-AP 
FDPS Abcam ab189874 
FLAG M2 Sigma-Aldrich F1804 
GFP Millipore MAB3580 
GLS Abcam ab93434 
GRSF1 Sigma-Aldrich HPA036985 
HISTONE H3 Sigma-Aldrich H0164 
HMGCS1 Abcam ab194971 
HSPA9/mtHSP70/Grp75 Abcam ab82591 
LONP1 Abcam or Lu et al. 2013 ab103809 or self-made 
polyclonal antisera  
LRPPRC mouse N.-G. Larsson; Ruzzenente et 
al. 2012  
Self-made 
MRPL12 Sigma-Aldrich HPA022853 
MRPL37 Sigma-Aldrich HPA025826 
MRLP44 Proteintech 16394-1-AP 
MRPS35 Proteintech 16457-1-AP 
Mt-CO2 N.-G Larsson; Larsson et al. 
1998 
 
Self-made polyclonal antisera 
 
MTHFD1 Abcam ab103698 
MTHFD2 Abcam ab37840 
NDUFA9 Abcam ab14713 
POLRMT mouse N.-G. Larsson; Kühl et al. 2014 Self-made purified antibody 
POLRMT human Abcam ab32988 
 
POLgA Abcam ab128899 
PYCR1 Proteintech 13108-1-AP 
SDHA Thermofisher Scientific 459200 
SHMT2 Sigma-Aldrich HPA020543 
SLIRP15C4; rat IgG2a N.-G Larsson; Lagouge et al. 
2015 
 
Self-made polyclonal antisera 
 
Antibody Source Catalog Number 
SSBP1 Sigma-Aldrich HPA002866 
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SDHA Thermofisher Scientific 459200 
 
SHMT2 
 
Sigma-Aldrich 
 
HPA020543 
 
TFAM Abcam ab131607 
TEFM Sigma-Aldrich HPA023788 
TFB2M N.-G. Larsson, Harmel et al. 
2013 
 
Self-made purified antibody 
Total OXPHOS Rodent WB Antibody 
Cocktail 
Abcam ab110413 
Tubulin Cell Signaling 2125 
TWINKLE mouse N.-G. Larsson, Milenkovic et al. 
2013  
Self-made purified antibody 
UQCRFS1 Abcam ab131152 
VDAC1 Millipore MABN504 
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8.5. Abbreviations 
 
1C    One carbon 
AARE   Amino acid response element 
ACTA1  Actin, alpha skeletal muscle 
ACTC1  Actin, alpha cardiac muscle 1 
ACTG1  Actin, cytoplasmic 2 
ADP   Adenosine diphosphate 
AFG3L2  AFG3-like protein 2 
ALDH18A1  Delta-1-pyrroline-5-carboxylate synthase 
ALDH4A1  Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 
AMP    Adenosine monophosphate 
AMPK   AMP-activated protein kinase 
ATF   Cyclic AMP-dependent transcription factor 
ATFS-1  Stress activated transcription factor atfs-1 
ATP   Adenosine triphosphate 
ATP5A1  ATP synthase subunit alpha, mitochondrial  
ATP5B   ATP synthase subunit beta, mitochondrial 
ATP5C1  ATP synthase subunit gamma, mitochondrial 
ATP5D  ATP synthase subunit delta, mitochondrial 
ATP5E   ATP synthase subunit epsilon, mitochondrial 
AUC   Area under the cumulative recovery curve (iRegulon) 
B2M   Beta-2-microglobulin 
BAC   Bacterial artificial chromosome 
BAX   Apoptosis regulator BAX 
BID   BH3-interacting domain death agonist 
BN-PAGE  Blue-native polyacrylamide gel electrophoresis 
C/EBPb  CCAAT enhancer binding protein beta 
cDNA   Complementary DNA 
ChIP-Seq  Chromatin immunoprecipitation sequencing 
CI   OXPHOS complex I - NADH:Q oxidoreductase 
CII   OXPHOS complex II - succinate dehydrogenase 
CIII   OXPHOS complex III - ubiquinol:cytochrome c oxidoreductase 
CIV   OXPHOS complex IV - cytochrome c oxidase 
CV   OXPHOS complex V - ATP synthase 
Ckmm   Creatinine kinase, muscle 
CLPP   ATP-dependent Clp protease proteolytic subunit, mitochondrial 
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CoA   Coenzyme A 
COQ10A  Coenzyme Q-binding protein COQ10 homolog A, mitochondrial 
COQ2   4-hydroxybenzoate polyprenyltransferase, mitochondrial 
COQ3   Q biosynthesis O-methyltransferase, mitochondrial 
COQ4   Q biosynthesis protein COQ4 homolog, mitochondrial 
COQ5   2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrial 
COQ6   Q biosynthesis monooxygenase COQ6, mitochondrial 
COQ8A  Atypical kinase COQ8A, mitochondrial 
COQ8B  Atypical kinase COQ8B, mitochondrial 
COQ9   Q biosynthesis protein COQ9, mitochondrial 
COX15  Cytochrome c oxidase assembly protein COX15 homolog 
COX19  Cytochrome c oxidase assembly protein COX19 
CSB    Conserved sequence block 
CTD   C-terminal domain 
DAP-Seq  DNA affinity purification sequencing 
D-loop   Displacement loop 
DARS2  Aspartate-tRNA ligase, mitochondrial 
DDIT3/CHOP  DNA damage-inducible transcript 3 protein 
DNAJA3  DnaJ homolog subfamily A member 3, mitochondrial 
dsDNA   Double-stranded DNA 
EGFP   Enhanced green fluorescent protein 
eIF2   Eukaryotic translation initiation factor 2 
ELAC2   Zinc phosphodiesterase ELAC protein 2 
ENDOG  Endonuclease G 
ERAL1   Era G-protein like 1 
ERR   Estrogen-related receptors 
FAD+   Flavin adenine dinucleotide, oxidized 
FADH2  Flavin adenine dinucleotide, reduced 
FAO   Fatty acid oxidation  
FASTKD1-5  FASTK-domain containing proteins 1-5  
FASTK  Fas-activated serine/threonine kinase 
FDPS   Farnesyl pyrophosphate synthase 
FDR   False discovery rate 
FeS   Iron sulfur 
FGF21   Fibroblast growth factor 21 
GABPA  GA-binding protein alpha chain  
GDF15  Growth differentiation factor 15 
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gDNA   genomic DNA 
GRSF1  G-rich sequence factor 1 
H   Heavy 
HMGCR  3-hydroxy-3-methylglutaryl-CoA reductase 
HMGCS1  HMG-CoA synthase 
HSP   Heavy-strand promoter 
HSPA9/mtHSP70 Stress-70 protein, mitochondrial -  
HSPD1/mtHSP60 60 kDa heat shock protein, mitochondrial 
HSPE1  10 kDa heat shock protein, mitochondrial 
IC   Initiation complex 
IMM   Inner mitochondrial membrane 
IMS   Inter membrane space 
ISR   Integrated stress response 
L   Light 
LFQ   Label-free quantification 
LIG3   DNA ligase 3 
LONP1  AAA+ LON P protease 
LRPPRC  Leucin-rich PPR motif-containing protein 
LSP   Light-strand promoter 
m/z   mass/charge ratio 
MAOA   Monoamine oxidase A 
MEF   Mouse embryonic fibroblast 
MGME1  Mitochondrial genome maintenance exonuclease - 1 
Mitoproteome  Mitochondrial proteome 
MM   Mitochondrial matrix 
MRM1-3  mitochondrial rRNA methyl transferases 
MRPL   Mitochondrial 39S ribosomal protein 
MRPP1-3   Mitochondrial RNAse P protein 1-3 
MRPS   Mitochondrial 28S ribosomal protein 
mtDNA  Mitochondrial DNA 
mt-mRNA  Mitochondrial messenger RNA 
mt-RNA  Mitochondrial RNA 
mt-rRNA  Mitochondrial ribosomal RNA 
mt-tRNA  Mitochondrial transfer RNA 
MTERF1-4  Mitochondrial transcription termination factor 1-4 
MTG1   Mitochondrial ribosome associated GTPase 1 
MTHFD1  C-1 THF synthase, cytosolic 
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MTHFD2 bi-functional methyleneTHF dehydrogenase/cyclohydrolase, 
mitochondrial 
MTIF3   Mitochondrial translation inititation factor 3 
mTOR   Mechanistic target of rapamycin 
mTORC1  mTOR complex 1 
MTS   Mitochondrial targeting sequence 
mtUPR  Mitochondrial unfolded protein response 
MURE 1/2  Mitochondrial unfolded protein response elements 
MYC   Myc proto-oncogene protein 
NAD+   Nicotinamide adenine dinucleotide, oxidized 
NADH   Nicotinamide adenine dinucleotide, reduced 
NADP+   Nicotinamide adenine phosphate dinucleotide, oxidized 
NADPH  Nicotinamide adenine phosphate dinucleotide, reduced 
NCR   Non-coding control region 
NES   Normalized enrichment score (iRegulon) 
NGRN   Neugrin 
NRF1   Nuclear respiratory factor 1 
NSUN4  5-methylcytosine rRNA methyl transferase NSUN4 
NTD   N-terminal domain 
NTE   N-terminal extention 
OH   H-strand origin of replication 
OL   L-strand origin of replication 
OMM   Outer mitochondrial membrane 
OXPHOS  Oxidative phosphorylation 
PCK2   Phosho-enol pyruvate carboxykinase 
PCYOX1  Prenylcysteine oxidase gene 
PDSS1  Decaprenyl-diphosphate synthase subunit 1 
PDSS2  Decaprenyl-diphosphate synthase subunit 1 
PGC1   Peroxisome proliferated-activated receptors 
PHGDH  D-3-phosphoglycerate dehydrogenase 
pI   Isoelectric point 
PNPT1  Polyribonucleotide nucleotidyltransferase 1, mitochondrial 
POLg   DNA polymerase gamma 
PPAR   Peroxisome proliferated-activated receptors 
PPR   Pentatricopeptide repeat 
PPRC1  Peroxisome proliferator-activated receptor gamma coactivator-related 
protein 1 
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PRIMPOL  DNA-directed primase/polymerase protein 
PRODH  Proline dehydrogenase 1 
PSAT1   Phosphoserine aminotransferase 
PTCD2  PPR-containing protein 2 
PYCR1  Pyrroline-5-carboxylate reductase 1, mitochondrial 
PYCR2  Pyrroline-5-carboxylate reductase 2 
Q   Ubiquinone, Coenzyme Q 
qRT-PCR  Quantitative real-time PCR 
R-loop   RNA loop 
RCC1L/WBSCR16 RCC1-like G exchanging factor-like protein 
Redox   Oxido reduction 
RNA-Seq  RNA sequencing 
RNASEH1  RNase H1 
RPUSD3-4  Mitochondrial mRNA pseudouridine synthase RPUSD3-4 
RT-PCR  Reverse-transcriptase PCR 
SCO2   Protein SCO2 homolog, mitochondrial 
siRNA   Small interfering RNA 
SLIRP   SRA stem-loop-interacting RNA-binding protein, mitochondrial 
spRNAP-IV  Single-polypeptide RNA polymerase IV 
SSBP1  Single-stranded binding protein 1 
SUPV3L1  ATP-dependent RNA helicase, mitochondrial 
T7-RNAP  T7 RNA polymerase 
TACO1  Translational activator of cytochrome c oxidase 1 
TAS   Termination associated sequences 
TBP   TATA binding protein 
TCA   Tricarboxylic acid cycle 
TEFM   Mitochondrial transcription elongation factor 
TFAM   Mitochondrial transcription factor A 
TFB1M  Mitochondrial transcription factor B1 
TFB2M  Mitochondrial transcription factor B2 
THF   Tetrahydrofolate 
TOP1MT  DNA topoisomerase I, mitochondrial 
TRAP1  Heat shock protein 75 kDa, mitochondrial 
TRUB2  Mitochondrial mRNA pseudouridine synthase TRUB2 
TSS Transcription start site 
Twnk/TWINKLE Mitochondrial DNA helicase TWINKLE  
UTR   Untranslated region 
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VDAC   Voltage-dependent anion-selective channel 
YME1L1  ATP-dependent zinc metalloprotease YME1L1 
ZBTB1   Zinc-finger BTB domain-containing protein 1 
 
 
Abbreviations one-letter code of amino acids 
 
A   Alanine 
R   Arginine 
N   Asparagine 
D   Aspartic acid 
C   Cysteine 
E   Glutamic acid 
Q   Glutamine 
G   Glycine 
H   Histidine 
I    Isoleucine 
L   Leucine 
K   Lysine 
M   Methionine 
F   Phenylalanine 
P   Proline 
S    Serine 
T   Threonine 
W   Tryptophan 
Y    Tyrosine 
V   Valine 
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